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1. Introduction 
1.1 Neurotrophic Factors  
1.1.1 Discovery, Expression and Function of Neurotrophic factors  
Neurotrophins were originally defined as soluble factors which influence neuronal cell 
survival, death, growth, plasticity and differentiation.  The first neurotrophic factor was 
described by the Italian scientist, Rita Levi-Montalcini at Washington University in 1952.  The 
unknown factor was observed to induce survival of motor neurones shortly removed from 
developing limb buds in chick embryos (Levi-Montalcini and Angeletti 1968) (Cohen and 
Levi-Montalcini 1956).  Collaborations with Stanley Cohen enabled the production of a 
bioassay for the soluble factor’s ability to induce neurite outgrowth in neuronal cells 
extracted from the sensory ganglion from a chick embryo. This neurotrophic factor was 
defined as Nerve Growth Factor (NGF) (Thoenen, Bandtlow et al. 1987) 
In order to have a better understanding of this growth factor, animal models were used to 
knockdown NGF gene expression.  Mice models revealed a severely impaired Peripheral 
Nervous System (PNS), however the Central Nervous System (CNS) neuronal structures and 
functions remained normal.  Inhibiting NGF function by chronic administration of NGF 
antiserum resulted in adult mice lacking sympathetic ganglion.  Interestingly, new born 
rodents injected with NGF develop enlarged sympathetic ganglia. These observations reveal 
that NGF is involved in the survival and development of some sensory neurones and the 
sympathetic nervous system. 
In 1978 Yves-Alain Barde came across a neurotrophic factor released by brain derived 
embryonic glioma cells which also induced survival and growth of sensory neurones (Barde, 
Lindsay et al. 1978).  This unknown factor was purified and added to spinal sensory 
neurones from chick embryos (Barde, Edgar et al. 1982)  Survival and neuronal growth was 
observed.  Importantly, the addition of NGF antiserum did not block the action of this 
neurotrophin; also the addition of the trophic factor in question does not induce survival in 
chick sympathetic neurones.  The novel neurotrophic factor is now referred to as Brain 
Derived Neurotrophic Factor (BDNF) expressed within the hippocampus, cerebral cortex, 
and synapses of the basal forebrain (Hofer, Pagliusi et al. 1990).  
NGF and BDNF gene sequences were compared for similarities (Maisonpierre, Belluscio et 
al. 1990) (Hohn, Leibrock et al. 1990).  From these sequence analysis, the third mammalian 
neurotrophic factor derived from the brain was identified.  Neurotrophic factor-3 (NT-3) is 
also known as Hippocampus-derived neurotrophic factor.   Soluble factors from rat 
hippocampus tissues, were observed to target medial septal neurons and induced neurite 
outgrowth and cholinergic responses in neurones, specific to this neurotrophin (Ojika and 
Appel 1984).  Transgenic mice lacking NT-3 suffer from server sensory and sympathetic 
peripheral neuron impairment (Farinas, Jones et al. 1994) (Snider 1994), and also display 
lack of movement due to deformity of the limbs (Ernfors, Lee et al. 1994). 
Further DNA sequence analysis of the neurotrophins enabled the discovery of a fourth 
neurotrophic factor.  High levels of Neurotrophic factor-4 (NT-4) were observed within the 
ovaries of xenopus (aquatic frogs) and viper (snakes) which is now know to be involved in 
embryonic chick dorsal root ganglion growth and development (Hallbook, Ibanez et al. 
1991).  NT-4 DNA sequences were then used to identify the factor within human and rat 
genomic DNA which have similar survival effects in dorsal root ganglion survival as the 
xenopus counterpart (Ip, Ibanez et al. 1992; Ibanez, Ernfors et al. 1993) (Hallbook, Ibanez et 
al. 1991).  Mice lacking the NT-4 gene suffer from server memory loss, indicating the 
importance of NT-4 for hippocampal dependent memory function (Xie, Sayah et al. 2000). 
Collectively known as the mammalian neurotrophic factors, NGF, BDNF, NT-3 and NT-4 are 
50 to 60% homologous in their amino acid sequences.  In the late 1980’s molecular biology 
techniques were used to sequence DNA for better understanding of the target gene and the 
protein constructed from it.  The most studied neurotrophic factor, NGF was sequenced 
from mice, revealing a 45kb gene with small 5’ exons where four NGF mRNA transcripts are 
produce by alternative slicing (Selby, Edwards et al. 1987).  In mammalian tissue, the NGF 
complex sedimentation value is 7S.  Also known as 7S NGF, the complex is composed of 
three polypeptides, alpha, beta and gamma (Varon, Nomura et al. 1967) (Smith, Varon et al. 
1968).  The beta peptide is the biologically active subunit comprised of 241 amino acids 
(Greene, Shooter et al. 1969), (Dracopoli, Rose et al. 1988).   
Once the mRNA has been spliced, a mature NGF dimer is processed thorough a constitutive 
pathway or secreted as an unprocessed dimer via a regulated pathway.   As shown in 
Illustration 1.1, an 18aa signalling peptide at the amino-terminal is present to for direct 
modified protein to membranes for sorting then secretion.  Within the rough endoplasmic 
reticulum, the prodomain binds to a sortilin receptor enabling folding of the mature 
peptide.  Non covalent links form between two mature NGF peptides forming a dimer which 
is then secreted.  Unprocessed NGF, also known as ProNGF, can be intracellularly cleavage 
by endoproteases such as Furin or prohormone convertase 1 (PC1), or extracellularly 
cleaved by matrix metalloproteinase (MMP) plasmin enzymes, forming mature NGF 
peptides (Edwards, Selby et al. 1988), (Seidah, Benjannet et al. 1996), (Mowla, Pareek et al. 
1999).   
1.1.2 Neurotrophic Factor Receptors   
All four mammalian neurotrophins act as secreted ligands that cause target receptor 
dimerisation  It is now known that mammalian neurotrophic factors exert their actions by 
specifically binding the Tyrosine receptor kinases (Trks). During the late 80s, it was 
discovered that Trks expressed at varying locations in the body, bind to hormones such as 
insulin, Epidermal growth factors and platelet-derived growth factor (Carpenter 1987), 
(Ebina, Ellis et al. 1985), (Yarden, Escobedo et al. 1986).  In 1986, Martin-Zanca D., et al 
identified a novel tyrosine receptor oncogene, structurally related to the tropomyosin gene, 
within a colon carcinoma biopsy (Martin-Zanca, Hughes et al. 1986).     Also known as 
Tropomyosin related kinases, the novel surface receptor was isolated for nucleotide 
sequencing and biochemical characterisation, which is now known as Tyrosine receptor 
kinase A (TrkA) (Martin-Zanca, Oskam et al. 1989), (Klein, Parada et al. 1989). 
TrkA is one of three receptor types, TrkB and TrkC were later identified as neurotrophin 
receptors, having varying binding affinities between the neurotrophins.  TrkB, discovered in 
1989, shares 57% amino acid sequence homology with TrkA in the extracellular region, and 
88% homology with the intracellular catalytic region (Soppet, Escandon et al. 1991).   
TrkA preferentially binds NGF however TrkB binds either BDNF or NT-4 with similar affinities 
and cannot elicit signalling via NGF (Berkemeier, Winslow et al. 1991; Fan, Egles et al. 2000).  
It was later discovered that NT-3 is the preferential growth factor ligand for TrkC (Lamballe, 
Klein et al. 1991).  On the other hand, NT-3, often referred to as a promiscuous Trk ligand, is 
able to bind TrkA and TrkB but with lower affinity than their cognate ligands (Benedetti, Levi 
et al. 1993; Clary and Reichardt 1994).  These receptor-ligand interactions are displayed 
within Illustration 1.2.  
cDNA analysis of Trks has revealed several common receptor protein domains (Middlemas, 
Lindberg et al. 1991). Trk receptor structure is demonstrated within Illustration 1.3.  Trk 
receptors consists of a, 32aa N-terminal signalling sequence which can be cleaved by 
peptidases (Kreil 1981). The next extracellular domains are involved in cell signalling.  Two 
cystein rich domains (CRD) flanking three leucine rich motifs (LRM) are present to assist 
neurotrophic ligand binding which occurs at the second immunoglobulin like domain (ILD).   
The extracellular domain consists of 11 N-glycosylayion sites.  A transmembrane domain 
was identified, leading onto an intracellular juxtamembrane domain that includes a Shc 
binding site.  The catalytic tyrosine kinase domain, involved in cell signalling, is followed by a 
region containing a PLC-gamma binding site (Klein, Parada et al. 1989; Martin-Zanca, Oskam 
et al. 1989; Ninkina, Grashchuck et al. 1997).   
Mammalian neurotrophic factors also bind to p75 Neurotrophin Receptors (p75NTR).  This 
receptor is structurally homogous to TNF receptors such as CD40-L and Fas which is 
composed of four cysteine-rich repeating units in the extracellular region.  The intracellular 
region contains a death domain which signals via varying adapter proteins (Radeke, Misko et 
al. 1987).  Due to the lack of enzymatic cytoplasmic activity in the intracellular domain, this 
receptor is multifaceted, contributing to a variety of biological pathways depending on 
which ligand it is bound to.  Experiments carried out by Herrup K. and Shooter E. M., 
discovered p75NTR as a potential NGF receptor in sensory ganglia (Herrup and Shooter 1973).  
Proir to this finding p75NTR was known to bind peptide hormone such as insulin and 
glucagon (Cuatrecasas 1971).   Considering proinsulin and NGF evolved from a common 
gene, ineffect producing proteins with similar homologies, NGF was discovered to act as 
another p75NTR ligand.      
 
1.1.3 Neurotrophic Factor Receptor Dimerization And Downstream Signalling.  
The differences between Trk receptors and p75NTR have to be considered regarding 
neurotrophin signalling.  Proteolytically cleaved neurotrophins, also known as mature 
neurotrophins, form dimers which bind to two Trk receptors at the cell surface, that inturn, 
initiate prosurvival downstream signalling via the catalytic tyrosine kinase domain (Ibanez, 
Ilag et al. 1993).  It is now also known that receptor complexes between p75NTR and Trk can 
occur, binding to one mature neurotrophin dimer which in turn can provide prosurvival 
signals (Longo, Manthorpe et al. 1997), (He and Garcia 2004).  p75NTR on the other hand is 
also able to bind mature neurotrophin dimers as a single receptor or as a dimerised receptor 
(He and Garcia 2004).  In the absence of TrkA, p75NTR preferentially binds to 
proneurotrophins causing cell death (Barrett and Bartlett 1994; Casaccia-Bonnefil, Carter et 
al. 1996).  Please refer to illustration 1.4.   
Upon binding of mature NGF homodimers, two TrkA receptors are brought together 
enabling phosphorylation of the intracellular catalytic domain.  Trk receptors contain 10 
evolutionarily conserved tyrosines in their cytoplasmic domains forming an autoregulatory 
loop of the tyrosine kinase domain.  NGF binding to TrkA induces phosphorylation of three 
tyrosine residues, involving adaptor proteins such as Phosphoinositide 3-kinase and PLC, 
Src homology and collagen domain protein-1 (SHC).  These phosphotyrosine binding 
domains initiate downstream signalling through Ras/ Mitogen-activated protein (MAP) 
kinases, inositol phosphate and/or protein kinase C (PKC) which activate various 
transcription factors promoting cell survival, proliferation and/or differentiation, as 
reviewed by (Huang and Reichardt 2003; Reichardt 2006; Skaper 2008).   
Signalling via TrkA can be further enhanced within the cell when p75NTR is coexpressed 
(Berg, Sternberg et al. 1991; Hempstead, Martin-Zanca et al. 1991). However 
proneurotrophins are associated with p75 dependent cell death via c -Jun N-terminal 
kinases signalling pathways, in the absence of Trk receptors (Lee, Kermani et al. 2001). On 
the p75NTR receptor structure, ligands bind and signal at the third and fourth cysteine-rich 
repeats (Yan and Chao 1991).  Cell death can also be induced by p75NTR receptors coupling 
with other receptor types such as sortilin (Nykjaer, Lee et al. 2004).  Sortilin is a trans-golgi 
protein adaptor, transmembrane protein with multi-ligand receptor binding capability 
(Bronfman and Fainzilber 2004).  Intracellular sortilin is involved in the folding and 
modification of newly synthesised neurotrophin peptides.  Whereas sortilin surface 
receptors can dimerise with p75NTR initiating cell death upon proneurotrophin binding.  
Whether the neurotrophin signalling outcome provides cell death or survival is dependent 
on various factors such as neurotrophin cleavage and receptor expression patterns.  The 
cell’s location is also an influential factor on it’s survival during neuronal development.   
 
 
 
 
1.1.4 The Expression Of  Neurotrophic Factors 
Since neurotrophic factors were initially observed, defined and characterised within the CNS 
and PNS neuronal populations, they were considered to be trophic factors within these 
neuronal populations.  However as laboratory techniques improved, wider screening 
methods analysing expression patterns also advanced.  In 1992 Ip N.Y. et al, document on 
NT-4 expression patterns with the use of Northern blotting methods (Ip, Ibanez et al. 1992).  
Human RNA from various tissues of the body were hybridized with probes specific for NT-4.  
Surprisingly little to no levels of NT-4 transcripts were detected in the brain, however 
prostate, thymus, placental and skeletal muscle tissues expressed NT-4 RNA.  Work by Blar 
et al, revel the co-expression of TrkC and TrkB genes in several non-neural tissues, including 
the tongue, the whisker pad, mesenchyme by in-situ hybridisation experiments in mice 
(Tessarollo, Tsoulfas et al. 1993). 
Prior to these findings there had been evidence for the expression of neurotrophins linked 
to the immune system.  NGF was observed to induce shape changes in platelets, enhance 
vascular permeability in rat skin and degranulation of mast cells from rats  (Bruni, Bigon et 
al. 1982; Otten, Baumann et al. 1984).  Importantly, functional TrkA receptors were 
documented by Ehrhard  P.A et al, where they observe monocyte cytotoxcicity upon NGF 
administration (Ehrhard, Ganter et al. 1993).  Functional TrkA receptors were also found to 
assist progenitor hematopoetic granulocytes when treated with NGF, inducing proliferation 
and differentiation (Chevalier, Praloran et al. 1994).      
Neurotrophin signalling has also been observed in B lymphocyte development.  An 
important research paper by Torcia M. et al, reveals the dependence of NGF in Memory B 
cell survival (Torcia, Bracci-Laudiero et al. 1996).  NGF has also been shown to induce 
proliferation and differentiation in B lymphocytes (Otten, Ehrhard et al. 1989).  BDNF on the 
other hand has been documented to participate in B cell development.  BDNF deficient mice 
have reduced numbers of B cells in the blood, spleen and bone marrow (Schuhmann, 
Dietrich et al. 2005).  This novel neuro-immuno link will be the main focus for this thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1.5 Communication Between The Immune And Nervous System  
In 1984 Hugo Besedovsky and Edwin Blaclock proposed that “the immune system functions 
as a diffuse sense organ informing the brain about events related to infection and injury” 
(Blalock 1984).  This bi-directional communication is initiated when the immune system 
detects a sign of infection then relays signals to the brain via neuronal and/ or humoral 
routes of transmission.  Although controversial, there are suggestions that sensory neurones 
within the vagus nerve are in direct contact with secondary lymphoid tissues such as lymph 
nodes, where signals are sent to the brain inducing a “stress response”.  
Houmoral routes include various cytokines such as TNF, IL-6 and IL-1 where they are 
released into the blood vessles following infection.  These cytokines are then transported to 
areas such as the circumventricular organs where the blood brain barrier is weaker or 
absent.  By binding to receptors, signals such as prostaglandins are diffused to the brain 
parenchyma.  In effect, the brain is thought to alter behaviour within the animal due to 
these signals for infection.  As initially documented by Benjamin L. Hart in 1988 from his 
work on “biological basis of the behaviour of sick animals”, animals respond to sickness by 
altering sleep and eating patterns and displaying depression symptoms.  Hart believed this 
was an evolved and organised way of fighting infection by letting the body conserve energy 
(Hart 1988).   
Neurotransmitters are then relayed from the brain to blood vessles and lymphoid tissues via 
the hypothalamic-pituitary-adrenal (HPA) axis or the sympathetic Nervous System (SNS).  
The HPA axis is a major part of the neuroendocrine connection between the hypothalamus, 
adrenal glands and the pituitary gland.  During the stress response monoamines can be 
released from adrenal glands into the blood.  The SNS is also activated where 
neurotransmitters such as dopamine and serotonin are diffused from nerve endings within 
lymphoid tissues.   
B cells can encounter neurotransmitters within lymphoid organs at all stages during their 
differentiation.  The activation of the HPA axis and SNS induce release of dopamine and 
serotonin which act upon B lymphocytes expressing their receptors and transporters 
(McKenna, McLaughlin et al. 2002).  It is also known that dopamine and serotonin can 
induce either proliferation or apoptosis in B lymphocytes, depending on concentration 
(Bergquist, Josefsson et al. 1997).         
 
 
 
 
 
 
 
 
 
 
 
1.2 B Lymphocyte Development and Maintenance 
1.2.1 The Immune System 
The immune system of invertebrates is used to defend the body against foreign pathogenic 
organisms, chemicals or molecules.  The immune system is also used to identify and protect 
against internal defects in the development and functioning of cellular tissue.  Innate and 
adaptive immunity are the two branches of defence used for the body’s protection.  Innate 
is non-specific “natural” immunity which utilizes anatomical barriers, phagocytic and 
inflammatory responses to provide a rapid non-specific protection against intruders.  
Adaptive immunity on the other hand is long lived specific immunity acts via a humoral or a 
cell mediated response.  Cell mediated defence involves two major groups of cells from the 
hematopoietic system; cytotoxic T lymphocytes and T helper lymphocytes that target 
epitopes on the cell surface presented by major histocompatibility complex.  The humoral 
response on the other hand, is maintained by B cells which secrete antibodies that target 
epitopes found on the cell surface.   
B and T lymphocytes arise within the bone marrow; B cells mature in the bone whereas T 
cells migrate to the thymus.   
 
 
 
 
 1.2.2 B-cell Development 
There are three stages in B cell development; generation of innate B cells from stem cells, 
their encounter with antigen and finally, differentiation into memory B cells or plasma B 
cells.  Pluripotent hematopoietic stem cells within the bone marrow produce progenitor B 
cells which express CD45R and CD43.  During early B cell maturation, rearrangement of 
immunoglobulin DNA occurs.  By binding to and secreting IL-7, stromal cells enable the 
differentiation of progenitor B cells into precursor B cells that contain immunoglobulin 
heavy chain gene rearrangements. 
For a Pre-B cell to continue in development, productive light chain rearrangements need to 
occur.  Due to allelic exclusion one light chain isotope is expressed on each B cell 
membrane.  This B cell will then be committed to have particular antigenic specificity 
determined by the heavy chain (VDJ) sequence and the light chain (VJ) sequence.     
These Pre-B cells then differentiate into mature immunocompetent B cells which express 
CD45R, IgM, low levels of IgD and the BCR on its surface.  Cells are then transferred to 
secondary lymphoid organs such as the spleen or lymph node for antigen recognition within 
germinal centres. 
The constituents of a germinal centre include activated B cells, T cells, macrophages (also 
known as tingible body macrophages) and follicular dentritic cells (FDCs) (Butcher, Rouse et 
al. 1982; Rouse, Ledbetter et al. 1982; Stein, Gerdes et al. 1982).     
The germinal centre dark zone is the site where rapidly proliferating mature B cells known 
as centroblasts, undergo somatic hypermutation of the immunoglobulin variable regions.  
Here, variations occur in the form of single base substitutions, insertions and deletions 
within hyper variable regions.  These are the sites that correspond to antigen recognition 
which specify the type of antigen recognised by the effector B cell via the immunoglobulin 
receptors.  By class switch recombination, cells generate a variety of immunoglobulin classes 
specific for a variety of antigens.    
Centroblasts are then transported into the light zone, rich in dense networks of FDCs, T-
Helper cells and tingible body macrophages (TMs), which are scavengers for apoptotic 
lymphocytes (MacLennan and Gray 1986; Gray 1988).  Here the centroblasts are converted 
into non-dividing centrocytes that intimately interact with the various cells within the 
germinal centre microenvironment (Gray and Leanderson 1990).   
FDCs present native antigen to B cells in order to select high affinity B cells.  Low affinity B 
cells die by apoptosis, therefore a survival function is mediated though B-cell binding to 
FDCs.  Fc epsilon RII, also known as CD23, is expressed by FDCs which induces an anti-
apoptotic signal via the BCR-CD21-CD19 complex (Bonnefoy et al., 1993).  The adhesion 
receptors, VCAM, ICAM and CD44 as well as, IL-15 receptor which is known to activate B-cell 
proliferation, are expressed by the FDCs (Freedman, Munro et al. 1990; Lindhout, Mevissen 
et al. 1993).  As shown by Hase et al, BAFF is able to initiate the production CD19 by 
activating a B-cell specific transcription factor which in turn enhances proliferation, IgG 
production, and reactivity to CD154 (CD40 ligand binding to CD40 on TH cells) by BCR/CD19 
co-ligation and interleukin-15 (IL-15) (Hase et al., 2004).  
Centrocytes then form two types of effector B cells, small memory B cells and large 
plasmablasts (Coico, Bhogal et al. 1983).  Plasmablasts subsequently develop into plasma 
cells that secrete antibodies, whereas B cells either remain in the GC or circulate peripheral 
vessels.      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.3 B-Cell Signalling Within The Germinal Centre 
Antigen presenting cells such as macrophages and dendritic cells present antigen via MHCII 
to T-cell receptors on CD8 positive T helper cells.  Activated T helper cells then proliferate 
and secrete cytokines, such as interferon gamma, which in turn activate varying cells within 
the germinal centre including B cells and FDCs.   
B cell activation by soluble antigen requires T helper cell signalling.  Initially, antigen binds to 
surface immunoglobulin receptors on B cells, signals via the B cell receptor and is 
internalized by endocytosis and processed within the endocytic pathway.  Signalling via the 
B cell receptor initiates the upregulation of surface receptors such as MHC II and its co-
stimulatory ligand B7.  The B cell then behaves as an antigen presenting cell to T helper cells 
by expressing the processed antigen present on an MHC II receptor which binds to a T cell 
receptor.  Activated T helper cells then expresses CD40 ligand that binds to CD40 receptor 
present on B cells, stimulating B cell proliferation and survival via protein tyrosine kinases 
such as Syk and Lyn, Phospholipase C and transcription factors such as NFB.  B7 receptor 
then binds CD28 and the release of cytokines such as IL-2, IL-4 and IL-5 bind to cytokine 
receptors expressed by B cells (Gordon et al., 1989; Liu et al., 1989). 
Since most of the B-cell lymphomas originate from germinal centres, their transformation 
occurs in close association with FDCs in the early stage of tumorigenesis (Li, Yoon et al. 
2004). 
It is known that FDCs may be involved in lymphomagenesis by providing signalling molecules 
such as 8D6 and 4G10/CD44.  These molecules have been shown to promote 
lymphomagenesis within L3055 cells, a human B cell line co-cultured with HK cells, an FDC 
line. 
HK cells also promote L3055 cell line and germinal centre B cell proliferation (Choe, Li et al. 
2000; Li, Zhang et al. 2000). 
Based on this literature the aims of the investigation were drawn for the study into possible 
neurotrophic factor signalling in Burkitt’s lymphoma B cells and normal germinal centre B 
cells.  Looking further into neurotrophic factor signalling within a germinal centre possible 
NGF signalling within this germinal centre microenvironment were also questioned by 
studying possible FDC-B-cell interactions.  
 
 
 
 
 
 
 
 
 
 
1.3 Burkitt’s Lymphoma And Epstein Barr Virus 
1.3.1 Discovery Of Burkitt’s Lymphoma 
In 1958, Dennis Burkitt submitted a report on a recently discovered Lymphoma sarcoma in 
two to fourteen year old children within equatorial parts of Africa (Burkitt 1958; Burkitt 
1962).  Cancerous growths were observed within the kidneys, adreanal glands, liver, thyroid, 
heart stomach, ovaries, salivary glands and jaw causing facial disfigurement (Renovanz 
1960).   These growths were defined as malignant lymphoma in the early 60s by J.N.P. Davis 
and G.T. O’Conner in Uganda (Burkitt and O'Conor 1961). Without treatment, the children 
died within four months.   
Geographical distribution and race did not influence the prevalence of the lymphoma, 
suggesting a possible environmental factor.  The possible influence of a viral factor was 
suggested by Professor Davis in 1961 where there were initial speculations on a possible 
arthropod vector.  However, it is now known, the epidemiology of the lymphoma is 
associated with malaria which weakens the immune system rendering the patient 
susceptible to viral infection (Old, Boyse et al. 1966). 
 
 
 
 
 
1.3.2 The Characteristics And Pathogenesis Of Endemic Burkitt’s Lymphoma 
Histological Burkitt’s lymphoma tumour sections obtained from the jaw had been stained in 
Giemsa and Leishman.  Images were described as “a uniform pattern of sheets of immature 
lymphoid cells interspersed with non-malignant histiocytes which often assume a clear or 
vacuolated form giving the tumour a characteristic “Starry sky” appearance” (O'Conor and 
Davies 1960).   Due to the high levels of lymphoblast proliferation and apoptosis, tingible-
body macrophages ladened with apoptosed tumour cells are observed (Clift, Wright et al. 
1963).    
A common characteristic of Endemic Burkitt’s lymphoma also includes the translocation of 
c-myc, a protooncogene located on chromosome 8 with the immunoglobulin heavy-chain 
(chromosome 14) or light-chain genes (chromosomes 2 or 22) (Manolov and Manolova 
1972; Zech, Haglund et al. 1976; Taub, Kirsch et al. 1982).  This translocation is what causes 
neoplasia in B cells due to the constitutive activation of a c-myc oncogene (Erikson, ar-
Rushdi et al. 1983).  Later it was discovered that a virus drives this translocation.    
Epstein M.A. and Barr Y.M. cultivated Burkitt’s lymphoma cells from biopsies flown to 
London from Uganda.  The biopsy material was shipped within 50% guinea pig serum in 
Hanks B.S.S.  On arrival cells were fed every three to four days in Eagle’s basal medium with 
10% human serum and incubated at 37oC.  After ten months of continuous culture cells 
continued to grow as free floating cells that were described having an altered lymphoblast 
morphology (Epstein and Barr 1965).  Some cells in culture had a pear shaped contour 
however most appeared round under phase contrast microscopy analysis.    Larger cells 
were also observed containing multiple nuclei with basophilic cytoplasms and numerous 
cytoplasmic vacuoles.   Single round cells had a tendency to form doublets and clumps of 
five to ten cells.  The successful cultivation of Burkitt’s lymphoma cell lines were and are still 
considered a useful tool for investigating the in vitro interactions between B cells and EBV.  
In 1964 M.A. Epstein and Y.M. Barr collaborated with D. Burkitt, where they obtained biopsy 
tissue from a maxillary lymphoma excised from a child.  These tissues were placed in guinea 
pig serum and shipped to London from Uganda.  The suspending fluid appeared dense 
containing single round cells shaken from the biopsy.  These cells were split in Eagle’s basal 
media containing 5% human serum.  Long term cell cultures were achieved enabling further 
characterisation of the B cells.  Within the same year, M.A. Epstein and Y.M. Barr observed 
small particles within the cytoplasm that resembled Herpes viruses.   Further electron 
microscopy on cell lines obtained from Burkitt’s patients verify the virus to be within the 
Herpes family due to its ability to bud into two viral partials through the plasma membrane 
and the presence of an outer envelope and a viral capsid (Epstein, Henle et al. 1965).         
Burkitts’s lymphoma B cells have also been observed to show phenotypic characteristics 
resembling germinal centre B cells.  Klein, U. et al, have documented on the presence of 
somatically hyper-mutated variable regions within Burkitt’s lymphoma cell lines (Klein et al., 
1995).    
 
 
 
 
 
1.3.3 Epstein Barr Virus And B Lymphocytes 
From 1964, Epstein T., Barr Y. and Achong B. discovered a herpesvirus which infected 
cultured cells from African endemic Burkitt’s patient tissue samples (Epstein, Achong et al. 
1964).  EBV is a gammaherpesvirinae virus within the herpesviridae family (Duncan, 2001).  
It consists of a 173kbp double stranded DNA sequence that multiplies within the nucleus of 
its host cell.  EBV differs from other herpesviridae viruses due to their pathogenicity and are 
associated with several B-cell lymphomas including Post-transplant lymphoproliferative 
diseases and Hodgkin’s lymphoma.  Burkitt’s lymphoma is also an EBV associated disease 
which occurs due to mass proliferation of latently infected B cells at a level which the failure 
the host’s immune system, namely cytotoxic T cells, are unable to control.  
EBV viral particles are transmitted orally within saliva (Hoagland, 1955).  These particles 
enter within the nasopharynx through the epithelium lining composed of crypts, underlined 
by lymphoid tissue (lymphoepithelium) causing pharyngitis (Perry, 1994, Sitki-Green et al., 
2003).  EBV is speculated to infect, replicate and release viral particles within the stratified 
squamous epithelium, commonly associated with Infectious Mononucleosis (Henle G., Henle 
W. Seroepidemiology of the virus Epstein M. A. Achong B. G. eds.  The Epstein-Barr Virus, 
pp. 297-320, Springer-Verlag Berlin 1979).  B lymphocytes within the oropharyngeal 
lymphoid organs are then presumed to be latently infected, initiating the growth of Burkitt’s 
lymphoma cancerous tissues (Greenspan et al., 1985, Babcock et al., 1998) (Rickinson, A. B., 
and E. Kieff. 1996. Epstein-Barr virus, p. 2397-2446. In B. N. Fields, D. M. Knipe, P. M. 
Howley, R. Chanock, J. Melnick, T. Monath, B. Roizman, and S. Straus (ed.), Fields virology. 
Lippincott-Raven, New York, N.Y).   
EBV is endocytosed through non-dividing B lymphocyte membranes via a viral membrane 
glycoprotein binding to the type-two complement receptor, (CR2) also known as CD21 
(Fingeroth, Weis et al. 1984).  Once uncoated within the cytoplasm, the virus enters the 
nucleus establishing a state of viral latency.  These latently infected B cells undergo 
proliferation, virus encoded regulatory proteins then prohibit cell death progression by 
silencing Retinoblastoma and p53 functions (Zhang, Gutsch et al. 1994; Zacny, Wilson et al. 
1998).  Like many other successful viruses, EBV is also able to manipulate its host’s 
machinery such as cellular proteins involved in apoptosis prevention.  For example, the pro-
apoptotic protein, Bim, a member of the Bcl-2 family, is down regulated in human B cells 
infected with EBV (Clybouw et al., 2005).  EBV is able to modulate caspase-8 and FLICE-
inhibitory protein by preventing Fas-mediated apoptosis (Tepper and Seldin 1999). In vitro, 
EBV efficiently induces latent infections in B cells that transform to a lymphoblastoid 
phenotype dependent on constitutively active autonomous signals maintain the latent 
infection.  A small proportion of latently infected B cells can be primed by BZLF1 to induce a 
lytic EBV infection (Flemington and Speck 1990).  Immediate-early transcription activation 
genes, BRLF1 and BZLF1 orchestrate the production of de novo viral particles by inducing 
early and late EBV gene expression (Farrell, Rowe et al. 1989; Flemington and Speck 1990).  
In vitro, latently infected B cells are immortalized by the regulation of EBV latency 
associated genes which control cell proliferation and survival.  Of which includes, six EBV 
Nuclear Antigens (EBNA) (EBNA-1, 2, -3A, -3B, -3C and -LP), three Latent Membrane Proteins 
(LMP) (LMP-1, -2A, -2B), BamHI-A rightward transcripts (BARTs) and Epstein-Barr encoded 
small RNAs (EBERs).  Depending on which genes are expressed at one time, alternative 
latency phenotypes are observed which can be influenced by cytokines such as IL-6 and IL-
10 (Brennan, 2001, Kis et al., 2006b).  Table 1.1 is a summary of EBV genes observed within 
lymphoblastoid cell lines (LCLs) and their functions.  
Table 1.1:     Summary of EBV gene expression within lymphoblastoid cell lines  
EBV Genes Main Functions 
EBNA-1  Required for the replication of viral episomes within latently 
infected memory B cells cells. 
 Can bind to BamHI Q promoters, therefore regulate its own 
expression (Elizabeth R. Leight 2000). 
EBNA-2  Similar to NOTCH, enhances and protects against apoptosis (Hsieh, 
Nofziger et al. 1997). 
 Controls Lymphocyte with EBV transformation (Cohen and Levi-
Montalcini 1956).  
EBNA-3A   Can bind to the cellular repressor binding protein RBP-Jk (CBF-1), a 
component of the Notch signalling pathway (Cludts and Farrell, 
1998, Waltzer et al., 1996) 
EBNA-3B aka EBNA-4  Can recruit Histone Deacetylase. 
EBNA-3C aka EBNA-6  Activates the LMP1 promoter in the presence of EBNA2 (Zhao and 
Sample 2000). 
EBNA-LP aka EBNA-5   Binds to the tumour suppressor proteins Retinoblastoma and p53 
for survival against death (Szekely, Selivanova et al. 1993). 
LMP-1  Upgregulate anti-apoptosis factors (Bcl-2, A20, Mcl-2) (Izumi 2001). 
 Mimics a constitutively active CD40-Receptor (Kis, Takahara et al. 
2006).   
 Activates NFkB which inturn switches on survival factors (BAFF, Bcl-
XL, Bcl-2) (Elizabeth R. Leight 2000). 
LMP-2A  Controls viral lytic phase by inhibiting surface immunoglobulin 
cross linking within lymphoblastoid cells (Miller, Lee et al. 1994). 
 Mimics BCR signalling and is involved in B-cell survival (Caldwell, 
Wilson et al. 1998). 
LMP-2B  Regulates viral and cellular gene expression by modulating NFkB 
(Stewart, Dawson et al. 2004). 
EBERs  Induce IL10 transcription for growth within BL (Kitagawa, Goto et 
al. 2000) 
 Form complexes with bouble-stranded RNA activated protein 
kinase, inhibiting the interferon  (Meurs, Chong et al. 1990; 
Clarke, Schwemmle et al. 1991). 
BARTs  Unknown functions. 
NOTE: It is worth noting there is difficulty in allocating specific functions for each EBV gene.  Through evolution 
EBV has developed more than one way of enabling proliferation and survival.  A vast network of external 
signals and genes are required at different stages during an infection involving the activation and silencing of 
various genes.   Key: 
Genes essential for primary growth transformation (Rickinson, Young et al. 1987; Izumi 2001).  
 Genes essential for B-cell immortalization (Tomkinson, Robertson et al. 1993). 
Genes that can interact with complexes of cellular proteins involved in transcription regulation (Young 
and Rickinson 2004; Gorzer, Niesters et al. 2006). 
During an EBV infection cells can exhibit all types of latency stages depending on the cells location and 
external survival signals which in turn can alter viral gene expression for survival and proliferation 
(Thorley-Lawson, 2001).    
 
 
  
  
 
 
 
 
 
 
 
 
Aims of the investigation 
The main focus for this investigation is to question the expression and signalling outcomes of the 
four mammalian neurotrophic factors and their high and low affinity receptors in Burkitt’s 
lymphoma B cells lines displaying varying EBV latency phenotypes – to be utilised as specific 
therapeutic targets for treatment of Burkitt’s lymphoma.   
 
The following questions were investigated and analysed within the indicated results chapters 
Chapter 3  
Do Burkitt’s lymphoma B cells displaying varying EBV latency phenotypes express neurotrophic 
factor mRNA transcripts? 
Chapter 4  
 Do Burkitt’s lymphoma B cells displaying varying EBV latency phenotypes express TrkB, 
p75NTR, BDNF and NT-4 protein? 
 To question  possible autocrine signalling via TrkB and p75NTR receptors and their ligands NT-
4 and BDNF for cell survival and proliferation in Mutu latency III clone J8 Burkitt’s lymphoma 
B cell lines. 
Chapter 5  
 Do germinal centre B cells, extracted from human tonsils, express neurotrophic factors and 
receptor mRNA transcripts? 
 To question possible paracrine signalling via NGF, secreted by FDCs to signal to B cells via 
TrkA and P75 receptors to rescue cells  from apoptosis, induce proliferation and cell 
migration in Mutu negative clone 3 Burkitt’s lymphoma B cell lines. 
 Autocrine signalling via TrkA and P75 receptors and their ligand NGF for cell survival and 
proliferation in Mutu latency III clone J8 Burkitt’s lymphoma B cell lines.  
Chapter 6 
 Do germinal centre FDC cells, in human tonsils, express NGF protein? 
 To question TrkA and p75NTR receptors on germinal centre B cells, signalling in a paracrine 
manner, with NGF producing FDCs. 
2.  Materials and Methods 
2.1 Cell Culture and Reagents 
2.1.1 Cell Culture Media 
Cell Culture Media  
500mls  RPMI 1640 
10%  Foetal Calf Serum 
2mM  L-Glutamine 
100g/ml Penicillin Streptomycin   
 
 
Cells were grown in Sarstedt cell culture flasks and stored within a 5% CO2, 37
oC incubator.  Cells 
were maintained in RPMI (Roswell Park Memorial Institute) 1640 media (Gibco) containing various 
amino acids such as L-Serine, required for the production of phosholipids for cellular membranes. 
RPMI 1640 also contains vitamins, inorganic salts such as Sodium Chloride and Potassium Chloride, 
for osmotic balance, and other compounds such as Glucose for Adenosine Triphosphate.  Phenol Red 
is an important addictive within media which is used as a pH indicator.  Two days after feeding cells, 
media turns from red to yellow due to the acidic products from cellular metabolism (Moore, Gerner 
et al. 1967). 
   
Before RPMI 1640 could be used in cell culture, other essential addictives were added.  An extra 1% 
L-Glutamine was added to RPMI 1640 media.  As described by Eagle, et al, L-Glutamine (Gibco BRL 
25030-024) was essential for the survival and growth of mammalian cells and is highly utilized by 
lymphocytes and other cells within the immune system (Eagle, Oyama et al. 1956; Newsholme, Curi 
et al. 1999).   1% Penicillin Streptomycin (Gibco BRL 15140-122) was added to prevent microbial 
contamination.  10% FCS-1621 (first link UK Ltd) was also added and is essential for cell growth.  
For long term storage 106 cells were pelleted and resuspened per 1 ml of sterile filtered neat FCS 
containing 5% DMSO.  Cells were left in a “Mr Frosty” NALGENE cryo 1o freezing container containing 
Isopropanol.  Mr Frosty was placed in a -80oC freezer over night to ensure cells were frozen at a rate 
of 1oC per minute; cells were then placed in liquid nitrogen.   
 
 
2.1.2 Burkitt’s lymphoma cell lines 
Within Burkitt’s lymphoma endemic areas, this B-cell malignancy is found to harbour EBV genes 
within infected B cells.  However within the western world such as North America, the Burkitt’s 
lymphoma cells are usually negative for the EBV genome (Cohen and Levi-Montalcini 1956).    
The following Burkitt’s lymphoma cell lines were established at the International Agency for 
Research on Cancer in Lyon, France; BL41, BL41 with EBV and IARC-171.  BL41 is an EBV negative B-
Lymphoma cell line with c-myc translocations and p53 point mutations (Cohen and Levi-Montalcini 
1956; Farrell, Allan et al. 1991).   
Two sets of cell lines, BL41 and the MUTU series, displaying varying latency groups were used to 
compare EBV gene patterns to investigate the expression of varying survival factors.  A summary of 
the cell lines used in this investigation is illustrated below within table 2. 
 
  
 
 
 
Table 2.1:     Burkitt’s lymphoma cell lines used within the project 
 
Cell lines Latency stage Cellular morphology 
BL41 Latency I Single small cells in suspension with 
no clumps and a “shiny” 
appearance under microscope  
Fast growth observed 
BL41 + EBV Latency III Bigger size cells in suspension 
within clumps when compared to 
BL41 alone. 
IARC 171 Latency III Two morphologies: 
 Adherent cells are 
irregular in shape and 
have a granular 
appearance. 
 Cells in suspension form 
huge “cotton wool” like 
clumps with very few 
single floating cells. 
 
These cells grow slower than the 
other Burkitt’s lines analysed. 
MUTU Neg. Clone 1 N/A Similar to BL41 and Mutu Lat I cells 
in appearance, single small cells in 
suspension. MUTU Neg. Clone 3 N/A 
MUTU Neg. Clone 4 N/A Sensitive to apoptosis. 
MUTU Lat I Clone 59 Latency I 
 
Similar to Mutu negatives in 
appearance, single small cells in 
suspension. 
Slightly less sensitive to apoptosis 
than Mutu negatives. 
MUTU Lat I Clone 179 Latency I 
MUTU Lat III Clone K5 Latency III 
 
Morphology similar to LCL cell line 
IARC-171, however the adherent 
cells were round. 
These cells also grow as slow as 
IARC-171 cells. 
MUTU Lat III Clone J8 Latency III 
 
 
 
 
 
 
 
 
 
2.1.3 Neurotrophic factor expression positive control cell lines 
 
When this investigation was started, there were limited accessible lines transfected with either 
neurotrophic factors or their receptors.  Therefore to optimise all the reagents and methods used 
within this project, cell lines published to express neurotrophic factors and/ or the receptors were 
obtained and utilised as positive controls.   
 
Table 2.2:     Neurotrophic factor positive control cell lines 
Cell line NT expression Info. Source/ Reference Media 
NT-2 NGF NTera-2/D1 is a human 
teratocarcinoma, neural precursor cell 
line. 
Shiao Chan's group (IBR, UK) DMEM 
10% FCS 
2mM L-glut 
100 U/ml penicillin 
100ug/ml streptavidin 
KMS-11 BDNF and TrKB Multiple myeloma cell line. (Pearse, Swendeman et al. 
2005) 
RPMI 
10% FCS 
2mM L-glut 
100 U/ml penicillin 
100ug/ml streptavidin 
Kelly TrkA, TrkB and 
p75
NTR
 
Kelly (ACC 355),) is a human 
neuroblastoma cell line that is 
predominantly neuroblastic (i.e. does 
not express a nonneuronal phenotype). 
(Martens, Kirschner et al. 
2007) 
RPMI 
10% FCS 
2mM L-glut 
100 U/ml penicillin 
100ug/ml streptavidin 
Colo-357 NT-3 and NT-4 Human pancreatic cancer cell line 
established from a celiac lymph node 
metastasis of well-differentiated, 
mucin-containing pancreatic cancer 
cells 
Knut Ketterer  
 
(Morgan, Woods et al. 1980) 
DMEM 
7.5% FCS 
2mM L-glut 
100 U/ml penicillin 
100ug/ml streptavidin 
HMC-1 TrkC Human mast cell leukaemia cell line.   (Tam, Tsai et al. 1997) RPMI-1640 
10% FCS 
2mM L-glut 
Penstrep. 
 
2.1.4 Reagents used within the investigation 
 
The antibodies, inhibitors, recombinant proteins used within this investigation are illustrated within 
table 2.3.   
Add table 2.3 here 
2.2 Measurement of gene expression by Semi-Quantitative 
Polymerase Chain Reaction 
 
Invitrogen Ltd, Paisley, Scotland: 
Oligo(dT) 12-18 Primers (18418-012) 
10mM dNTPs Mix (18427-013) 
Superscript II reverse transcriptase (18064-014) 
100bp DNA ladder (15628-019) 
RNase OUT ribonuclease inhibitor (10777-019) 
DNAse I reagent (18068-015) 
And TRIzol reagent (15596-026) 
 
Qiagen Ltd, West Sussex, UK: 
RNeasy mini kit (74104) 
 
Applera, UK: 
Amplitaq Gold (N808-0241) 
 
Sigma: 
Chloroform (C2432) 
Ethanol (E7023) 
-mercaptoethanol (M7154) 
Isopropyl alcohol (I9516) 
TRIS Base  
Boric Acid (B6768) 
Injection water (W4502-1L) 
Jump start Taq DNA Polymerase (D 4184) 
 
Bioline: 
Agarose (BIO-41025) 
 
Fisher Scientific, UK, Ltd: 
EDTA (BPE-152-1) 
 
 
 
  
 
 
2.2.1 RNA extraction and purification 
 
107 Cells were seeded during log phase 24hrs post feeding.  Using TRIzol (Invitrogen) the RNA 
extraction procedure was followed according to the manufacturer’s instructions.  RNA pellets were 
re-dissolved in nuclease free DEPC- treated water (Ambion).  RNA was then purified using an RNeasy 
Mini kit (Qiagen) according to the manufacturer’s instructions.  For the RNA concentration 
calculation, RNA was dissolved in DEPC water, measured using a UV/Vis Spectrophotometer 
(Jenway).   
 
 
 
 
2.2.2 RT-PCR to obtain cDNA 
 
Reverse Transcription - Polymerase Chain Reaction (RT-PCR) of purified RNA (2g) was carried out 
using Invitrogen reagents in a 20μl reaction mix.  10l of cell sample RNA diluted in injection water 
was added to 1l Oligo(dT) 12-18 Primers and 1l dNTPs.  The reaction was heated for 5 minutes at 
65oC.  7l of RT-PCR mix was added.  (RT-PCR Mix contains 5X PCR buffer, DTT OUT (0.1M), RNase 
OUT and injection water).  This reaction was heated for 5 minutes at 50oC.  2l of superscript was 
added to the RT-positive samples, whereas 2l of injection water was added to the RT-negative 
samples. The reaction was left to amplify cDNA at 50oC for 50 minutes and then 70oC for 15 minutes.  
30l of water was added to obtain 50l of cDNA.  This cDNA was aliquoted and stored at -80oC.    
 
2.2.3 RT-PCR experiments 
 
Using specific primers of interest, RT-PCR was used to isolate and amplify known DNA sequences 
from cellular RNA samples.  For each primer analysed the reaction mix was made up according to the 
concentration of Magnesium Chloride required.  Within a 20μl PCR reaction mix, 2μl of cDNA was 
analysed for each MWG Biotech primer, the primers used are shown in table 2.4.  AmpliTaq Gold 
DNA polymerase (5 units/ul), Magnesium Chloride solution (25mM) and 10x PCR Buffer II reagents 
were used to analyse all the primers of interest (Applied biosystems).  AmpliTaq Gold is derived from 
a recombinant thermostable DNA polymerase encoded by the Thermus aquaticus DNA polymerase 
gene inserted within an Escherichia coli host (Lawyer, Stoffel et al. 1989).  However the amplification 
efficiency (amplicon within an agarose gel) for the p75NTR primers were not efficient when using 
AmpliTaq Gold DNA polymerase, therefore JumpStart Taq DNA polymerase (2.5 units/ul) was used 
to analyse p75NTR primers.  JumpStart Taq DNA polymerase is an antibody inactivated hot start 
enzyme that prevents non-specific amplification and increases target DNA yield (Sigma).  
 
The following Hot start PCR reaction conditions were used; 95oC for 10 minutes for the initial 
initiation step, used to denature the DNA template and primers.  The initiation step is used to 
activate AmpliTaq Gold DNA polymerase which is provided in an inactive form.  For the annealing 
step, various temperatures were used for each set of primers; these differences are due to different 
melting points.  Primers are able to attach to single stranded DNA sequences at the annealing 
temperature.  The temperature is then increased for the extension step to enable DNA synthesis of 
DNA strands complementary to the primer templates.  As shown in table 2.4, the various extension 
times are due to different lengths of target DNA strands.  The annealing and extension steps are 
then repeated depending on cycle numbers for each primer, followed by the final elongation step 
which ensures any remaining single stranded DNA is fully extended.  The elongation step is the same 
for all the primers used reaction mixes were left at 72 oC for 10 minutes.   
 
Add table 2.4 here 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
2.2.4 PCR product examination  
 
PCR products were run on 1.5% agarose gels containing 0.6g/ml ethidium bromide within 24 hours 
from the PCR amplification reaction.  Gels were exposed under UV light using a SynGene Bio imaging 
system (Cambridge, UK).  Gels were labelled and printed using Gene Snap software from SynGene, 
then saved as JPEG files. 
 
 
2.3 Measurement of gene expression by Real Time 
Polymerase Chain Reaction 
 
The same cDNA used for RT-PCR experiments was used within quantitative real time PCR (qRT-PCR).  
5l of cDNA was added within a 50l PCR reaction containing taqman 30 ml tube PCR master Mix 
(Applied Biosystems) and optimised “house keeping” gene, 2-Microglobulin (2M) primers and 
probes, together with TrkB primers and probes in multiplex RT-PCR experiment.  Triplicate reactions 
for each cell line were conducted within 96 well optical reaction plates (Applied Biosystems).  FAM 
and VIC fluorescence was measured using an ABI prism detection 7900HT SDS machine.   
Raw fluorescence values were obtained using the SDS v2.2 software.  Once the base line was set for 
each experiment, relative TrkB fluorescence values were calculated from 2M fluorescence for each 
cell line using excel spread sheets.  This calculation was obtained by subtracting the 2M levels from 
the TrkB fluorescence values.  Positive increases in fluorescence were then plotted for each line. 
 
 
 
 
2.4 Measurement of protein expression by Western blots 
2.4.1 Whole cell extracts 
Urea Buffer 
9M  Urea 
50mM   Tris pH 7.5 
 
107 cells in log phase (24 hours post addition of fresh media to ensure cells are at log growth phase) 
were pelleted at 13,000g (8400 rpm) for 5 minutes.  Pellets were resuspended and washed twice in 
10mls of room temperature, sterile phosphate buffered saline (PBS).  A final wash was completed 
within eppendorfs containing 1ml of room temperature PBS, spun at 13,000g.  Pellets were flicked to 
resuspend, 100l of 9M Urea buffer was added to each pellet.  Cells were vortexed, to mix and then 
placed on ice.         
 
Each pellet was sonicated for 20 seconds, well sonicated pellets frothed at the top and were easily 
taken up into a p200 yellow Gilson pipette tip to ensure minimum viscosity.  If pellets were larger, 
they were resonicated for a further 20 seconds with a 1 minute interval.  
 
 
 
 
 
 
 
 
2.4.2 Quantifying protein concentration  
Protein concentrations were measured using the Bio-Rad, Bradford assay (catalogue number 500-
0006) (Bradford 1976).  The acidic dye (Coomassie Brilliant blue G-250) binds to solubilised protein, 
the colour of the dye intensifies depending on the concentration of protein present.  The samples 
were then measured at a wavelength of 595nm using a spectrophotometer. 
When comparing this protein determination procedure with the Lowry method, variations in protein 
concentrations are observed.  As seen below in table 3 the concentration of Bovine serum albumin 
(BSA) using the Bio-Rad method is double compared to the Lowry method.  This information was 
obtained from the manufacturer’s manual (Bio-Rad 2006).  
 
Table 2.4 : Comparison of varying protein determination methods 
 
BSA is of interest from this table since it was used to make up the protein concentration standards.  
Concentrations of 0.2, 0.4, 0.6, 0.8 and 1.0 mg/ml were made up in distilled water and frozen at -
20oC.   
 
For each protein determination assay, distilled water was used a blank control to calibrate the 
spectrophotometer.  The BSA standards were defrosted and measured in duplicates within 
disposable, 10mm Fisherbrand cuvettes to obtain a standard curve.  The linear regression line and 
the R-squared (line of best fit) value was then calculated.  Once duplicate values of the samples 
measured were entered onto an excel spread sheet the concentration of protein was then calculated 
using the example shown Illustration 2.1.  
 
These calculations shown in Illustration 2.1 were used to work out amount of cell lysate protein and 
the amount in microliteres required to add to gel sample buffer, used for western blot analysis. 
 
 
Illustration 2.1 goes here 
 
 
 
 
 
 
 
2.4.3 Protein sample preparation  
 
Gel sample buffer (2X) 
0.4M   Sodium 2-mercaptoethanesulfonate (MESNA) 
125 mM  Tris-HCl pH 6.8 
20%   Glycerol 
4%   SDS 
0.004%  Bromophenol blue 
 
The protein determination example shown in Illustration 2.1 shows an example calculation for BL41.  
The lysate was diluted 1 in 20 using distilled water.  980l of the Bio-Rad dye reagent concentrate 
(diluted 1 in 5 using distilled water) was added to a 1 ml cuvette, this was completed in duplicate for 
more accurate readings.    20l of diluted cell lysate/BSA standard was added and mixed using a 
pipette tip; the reaction was left for 15 minutes.  The spectrophotometer was calibrated at 595nm 
using the blank sample (980l of diluted Bio-Rad dye reagent with 20l of distilled water).  The BSA 
standard’s optical density (OD) were measured in duplicate and used to plot the standard curve on 
an Excel spreadsheet.  Both sets of the sample lysate (Abs 1 and 2) were measured and applied into 
the spreadsheet calculation shown in Illustration 2.1.   
 
The mean value and protein concentration was calculated as shown in the red and orange boxes.   
For the protein concentration calculation the mean absorbance was divided by the value of the Y 
axis taken from the standard curve (Y=1.1043) multiplied by the dilution factor (20).  (The X axis 
value was not taken into consideration since the value was very low). 
 
Since BSA standards were used for the standard plot the protein concentration was divided in two 
due to the difference in the Bio-Rad assay and the Lowry assay as shown in table 2.4.  This 
calculation is displayed within the yellow box. 
 
To calculate the number of microlitres required to obtain 100g of protein, 100 was divided by the 
protein calculation, as shown within the green box.  Illustration 2.1 shows that 17.8l of the BL41 
cell lysate will contain 100g of protein. 
 
Therefore in order to dilute the lysate with gel sample buffer, 100g of cell lysate is diluted to give a 
final volume of 50l, an equal volume of gel sample buffer (2X stock) is then added.  Glycerol is 
present within the sample buffer to help the protein sink to the bottom of the well within the 
staking gel.  Bromophenol blue is the tracking dye added to follow the electrophoresis run.  Gel 
sample buffer also contains MESNA which breaks down disulphide bonds and helps preserve the 
protein sample, ready to load into a western blot gel. MESNA is a non-smelly equivalent to Beta-2-
mercaptanol.  The final concentration of the lysate ready to load was 100g in 100l or 1g in 1l.  
20l of ready to load samples were used to load the NuPAGE Noxex gels.  The loading samples were 
then stored at -20oC.  
 
 
 
 
 
  
2.4.4 Western blot analysis  
Running buffers 
TrisBase running buffer 
MOPS buffer 
 
Blotting Buffer 
25 mM  Tris-base 
192 mM  Glycine 
20%   Methanol 
 
 
I-Block with Tween buffer (IBT blocking buffer) 
0.4%   Casein in PBS 
0.05%   Tween-20 
0.02%   NaN3 
 
The Invitrogen NuPAGE gel electrophoresis western blot technique was used within this project.  
Depending on the aims for each experiment different types of gels were used.  NuPAGE Novex Bis-
Tris gels, at 10% and gradient gels (4-12%) (MOPS) were used to analyse 50kDa to 10kDa protein, 
whereas 7%  NuPAGE Novex Tris-Acetate gels were used to analyse 50kDa to 200kDa protein.   
 The gel electrophoresis apparatus was set up using an XCell SureLock Mini-Cell apparatus.  To ensure 
an even distribution of volts thorough out the apparatus, running buffers containing SDS and glycine 
were used. Tris-Acetate SDS running buffer from InVitrogen was diluted 1 in 20 and used for Tris-
Acetate gels, whereas MOPS SDS running buffer 1x was used for Bis-Tris gels.  Ready to load lysate 
samples within gel sample buffer were heated at 100oC for 5 minutes on a heat block. (Subsequent 
use of these lysates required heating at 80oC after they are thawed from -20oC to re-solubilise 
protein.)  SDS within the sample buffer and the application of heat ensures di-sulphide bonds are 
broken down, disrupting secondary and tertiary peptide structures by applying a negative charge to 
the amino acids (Laemmli 1970). 
 
As soon as the samples were heated and cooled for 5 minutes, 20l of loading sample lysate was 
carefully pipetted into each well.  Within either the first or last well, 20l (diluted 15 to 25) of 
SeeBlue Plus2 Pre-Stained Standard molecular weights were added as markers to determine protein 
size.  Table 2.5 shows the molecular weight markers for both types of gels used. 
 
Table 2.5 : Chart indicating size for molecular weight markers on the gels used   
         
 
 
 
This chart was used to mark the correct molecular weight  sizes in kDa for each western blot 
(Invitrogen 2002). 
 
Bis-Tris gels were run at 200Volts for 50 minutes whereas Tris-Acetate gels were run 160Volts for 1 
hour.       
 
One Invitrogen polyvinylidene difluoride PVDF membrane was pre-soaked in methanol for 10 
seconds; this step was required since PVDF membranes are hydrophobic. Membranes were then 
 
 
soaked in blotting buffer together with two filter paper sheets for at least 5 minutes to ensure the 
complete surface was wet for the transfer step.  Protein was then transferred from the gel to the 
PVDF membrane by applying 30Volts (250 milliamps) for 1 hour 20 minutes when using a Bis-Tris gel, 
and 35Volts (250 milliamps) for 1 hour 30 minutes when using a Tris-Actetate gel.  In each case the 
voltage remained constant throughout the transfer therefore the milliamps were set higher than the 
amount required.  The blots were aligned to ensure protein within the gel moved from the 
negatively charged cathode core towards the positively charged anode onto the PVDF membrane.  
To ensure efficient transfer, blotting pads were also soaked in blotting buffer to ensure a steady 
current is able to move through the gel (Towbin, Staehelin et al. 1979).    
 
Once the transfer was completed, blots were labelled and soaked in I-Block (Applied Biosystems Inc) 
with Tween (IBT) buffer for 1 hour at room temperature or at 4oC overnight to block excess binding 
sites on the PVDF membrane. 
 
 
2.4.5 Primary and secondary antibodies 
 
Phosphate buffered saline with Tween (PBST) 
58mM Na2HPO4 
17mM NaH2PO4.H2O  Pre-mixed tablets 
68mM NaCl 
 
0.1% Tween-20 
 
Primary antibodies were diluted at varying concentrations (see experimental reagents table 2.3) 
within in IBT and stored at 2oC.  The number of times each diluted antibody mix was used to probe a 
PVDF membrane was recorded then discarded once it had been used 10 times.    
 
 
Membranes were probed for 2 to 4 hours at room temperature or at 4oC over night.  The primary 
antibody was replaced within the 30 ml tube to be re-used and the blots were washed with 
Phosphate buffered saline with Tween (PBS-T) to remove excess primary antibodies from the 
membrane for 30 minutes.  The appropriate secondary antibody was selected to match the host 
species of the primary antibody.  Table 2.6 lists the alkaline phosphatase secondary antibodies used 
and their dilutions. 
 
 
 
 
 
 
Table 2.6 : Working concentrations of alkaline phosphatase conjugated secondary  
 antibodies used for western blotting 
 
Secondary Antibodies in 
IBT 
Source and Catalogue number Final working dilution 
AP-anti-mouse IgG   BioRad 170-6520 1/10,000 
AP-anti-rabbit IgG BioRad 170-6518 1/10,000 
AP-anti-goat IgG Sigma A4062 1/40,000 
 
10ml of secondary antibody was made up and probed for 30 minutes at room temperature, then 
discarded after first use. 
 
 
 
2.4.6 Exposure of bands on film 
Alkaline Phosphatase assay buffer (10X) 
0.1M   Diethanolamine pH 9.5 
1mM   MgCl2 
 
To ensure excess secondary antibodies were efficiently washed off the membranes, blots were 
washed for at least an hour with five PBS-T changes.  The container with which the membrane was 
being washed in was changed after the first wash cycle to ensure a complete removal of secondary 
antibodies off the membrane.  The blot was then soaked in 10mls of 1x Alkaline Phosphatase assay 
buffer for 2 minutes twice.  800l CDP-star chemiluminescent substrate was left to soak on the 
membrane for 15 minutes within a plastic sleeve.  The developer was spread across the membrane 
to ensure and even layer of developer across the surface of the blot.  
 
Excess developer was squeezed out from the plastic sleeve and dried to prevent drops of developer 
reacting with the film (Amersham chemiluminescence film).  Each blot was taped onto the cassette 
which was wiped with tissue to ensure a completely dry surface.  Initially blots were exposed for 2 
minutes.  Depending on the strength of the antibody and how long the membrane was probed for, 
film exposure times were either increased or decreased to produce clear bands on the film within 
the expected molecular weight.  The blots showing the best exposure times were scanned and saved 
for analysis. 
 
Once the films were scanned and the results were obtained, excess CDP-star chemiluminescent 
substrate was washed off the blot twice, using 30mls of PBS-T.  10mls of PBS-T was then added to a 
plastic sleeve containing the blot; this was then sealed and stored at 4oC.  
2.4.7 Stripping Blots for reprobing 
Sodium Dodecyl Sulfate (SDS) wash buffer 
62.5 mM  Tris-HCl pH 6.8 
2%   SDS 
 
Stripping buffer 
50 mM  sodium 2-mercaptoethasulfonate (MESNA) 
62.5 mM  Tris-HCl pH 6.8 
2%   SDS 
  
Once a membrane had been probed with a primary and secondary antibody, it was either stored at 
4oC within 10mls of PBS-T or stripped to re-probe with other primary antibodies.  The advantage of 
this method allows direct comparison of varying antibodies corresponding to different epitopes of 
different molecular weights within one blot.  
 
Blots were removed from the PBS-T wash and placed in a fresh plastic sleeve.  15mls of pre-heated 
stripping buffer was added to the blot which was sealed and added within a water bath set at 55oC.  
Blots were heated for 15 minutes; then temporarily removed and shaken to ensure an even 
distribution of stripping buffer over the entire membrane surface.  Blots were then quickly returned 
to the 55oC water bath and left for another 15 minutes.  
 
MESNA was washed off the blots with 30mls of SDS wash buffer (NB; MESNA is a non-smelly and 
more stable alternative to -mercaptoethanol).  Blots were then washed three times in 30mls of 
PBS-T for 10 minutes each.  The blot was blocked with IBT blocking buffer for one hour at room 
temperature or over night at 4oC.  The blot was then ready to be re-probed with a primary antibody.  
It is worth noting that this method is an efficient process and will produce clear blots, however the 
blots become less clear if stripped and re-probed 5 times or more. 
 
 
2.5 Measurement of protein expression by Flow cytometry 
FACS buffer 
500ml  PBS 
25ml  Goat Serum Donor Herd  
5 ml  10% Sodium Azide 
 
Fix Buffer- 2% Paraformaldehyde 
500l  Paraformaldehyde (37 wt. % in solution) 
9.5ml  Distilled water 
 
Permeabilization buffer 
0.01g  Saponin 
10mls  PBS 
 
Flow cytometry is a method used to measure the size, shape of cells and to identify specific surface 
or intracellular molecules from a suspension of live cells travelling though a laser.  Within this 
investigation FACSCalibur, a Becton Dickinson Immunocytometry Systems modular bench top flow 
cytometry was used to analyse live cells stained for specific surface markers.   
 
For each FACS experiment each cell line used was analysed using three different variables.  Each cell 
line was divided into three FACS tubes for analysis.  Cells within the “Cells Alone” tube were treated 
with 50l of FACS buffer alone, used as a negative staining control to draw a dot plot of viable cells 
(no antibodies present).  Cells within the “Negative antibody (irrelevant antibody) and secondary 
antibody” tubes are cells treated with an appropriate negative control antibody depending on the 
immunoblobulin class of the primary antibody.  And finally cells within the “Primary and secondary 
antibody” tubes contain the target antibody which will bind to the surface protein being studied; the 
appropriate secondary antibody will then allow fluorescence of this surface protein.  Table 2.7 is a 
summary illustrating these experimental variables. 
 
 
 
 
 
 
 
 
Table 2.7: Experimental set up for FACS analysis 
Experimental 
variables 
Staining stage 1 
(50l) 
Staining stage 
2 (50l) 
Expected 
results 
“Cells alone” FACS Buffer FACS Buffer Negative 
“Negative antibody 
with secondary 
antibody” 
Negative antibody 
diluted in FACS 
Buffer  
Secondary 
antibody 
diluted in FACS 
Buffer 
Negative 
“Primary antibody 
and secondary 
antibody” 
Primary antibody 
diluted in FACS 
Buffer  
Secondary 
antibody 
diluted in FACS 
Buffer 
Positive 
 
  
 
2.5.1 Flow cytometry – Surface staining 
24 hours post feeding, the number of mls required to obtain 2.5 million cells was calculated for each 
cell line.  Cells were spun down at 13,000g (8400 RPM) for 5 minutes and washed twice in 10ml of 
PBS to remove excess FCS protein.  3 mls of FACS buffer was added to the pelleted to resuspend the 
cells.  1 ml of each cell line was aliquoted into three labelled FACS tubes (5ml polystyrene round 
bottom falcon tubes).  A p1000 Gilson pipette was used to accurately aliquot 1ml, containing 
500,000 cells into each tube.  These tubes were then spun to pellet the cells enabling them to stick 
to the tube surface; excess FACS buffer was then aspirated.   
Within the first stage of the staining method, antibodies were diluted in FACS buffer; 50l was then 
aliquoted to the correctly labelled tubes.  As shown in table 2.7 one set of cells were used as a “cells 
alone” negative control, 50l of FACS buffer alone was added to these cells.  The appropriate 
antibodies (negative control and primary antibodies being tested) were applied to the other tubes 
within the experiment. Cells were then left on ice for 45 minutes; cells were then washed within 
4mls of FACS buffer.   
 
For the second staining stage, cells were incubated in 50l of FACS buffer with FITC conjugated 
secondary antibody; no secondary antibody was added to the cells alone control.  The secondary 
antibody was left to react with the cells on ice whilst covered in foil to remove external light during 
the 45 minute incubation time.  Cells were then washed in 4mls of FACS buffer and fixed using 500l 
of FACS FIX buffer to fix the cell membranes. FACS tubes were then stored at 4oC wrapped in foil.  
Although cells could have been kept and measured seven days post staining, all the FACS analysis 
experiments results were recorded 24hrs (at the most) post staining.   
 
 
2.5.2 Flow cytometry – Intracellular staining 
24 hours post feeding, the number of mls required to obtain 1.5 million cells was calculated for each 
cell line.  Cells were spun down at 13,000g (8400 RPM) for 5 minutes and washed twice in 10ml of 
PBS to remove excess FCS protein.  Within the 30 ml tube, cells were then treated with 150l of 2% 
paraformaldehyde for 5 minutes, to fix the cellular plasma membrane.  Cells were then washed in 
cold PBS, and treated on ice for 5 minutes with 750l of 0.1% saponin which form pores on their 
plasma membranes.  After a wash step in 10mls of 0.1% saponin cells were then left on ice for 5 
minutes in 150l of neat FCS (the same serum used in cell culture “L3 serum”).  Serum was washed 
off the cells with another 10ml 0.1% saponin wash.  3 mls of 0.1 saponin was added to each 30 ml 
tube.  1 ml of each cell line was aliquoted into three labelled FACS tubes.  A p1000 Gilson pipette 
was used to accurately aliquot 1ml, containing 500,000 cells into each tube.  These tubes were then 
spun to pellet the cells enabling them to stick to the tube surface.   
 
For the first stage of the staining method, negative control and antibodies of interest were diluted in 
0.1% saponin; no antibody was added in the cells alone negative control.  50l was then aliquoted to 
the appropriate labelled tubes which were then left on ice for 45 minutes. Cells were then washed 
within 4mls of 0.1% saponin.   
 
As for the second staining stage, cells were incubated in 50l of 0.1% saponin with FITC conjugated 
secondary antibody; no secondary antibody was added to the cells alone control.  Cells were treated 
on ice whilst covered in foil to remove external light during the 45 minute incubation time.  For the 
final wash step cells were then washed in 4mls of FACS buffer, the new goats serum within FACS 
buffer is used to re-seal the cellular plasma membranes.  These cells were then fixed using 500l of 
FACS FIX buffer to fix the cell membranes. 
 
2.5.3 Flow cytometry Results Analysis - FlowJo 
Staining results was analysed using the FACSCalibur flow cytometer.  Dot plots of side scatter and 
forward scatter light emissions were recorded using Cell Quest Pro software.  Green fluorescence 
(FITC-1 staining) was recorded for each variable within each cell line and saved for analysis. 
FlowJo software (Version 6.3.2) was used to analyse dot plots for each experimental variable.  Viable 
cells within the cells alone dot plot were gated and used to directly compare and analyse the various 
antibody combinations.  Histograms were drawn to observe any possible shifts in fluorescence to 
compare appropriate negative control with the primary antibodies.   
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.6 Measurement of protein expression by Confocal 
Microscopy 
 
DABCO 
90% Glycerol 
10% PBS 
2.5g/100ml DABCO (Sigma D2522)  
 
Confocal microscopy was used to view fixed and fluorescently stained protein in cells.  Cells were 
mounted on glass slides, their images were viewed and captured by a Zeiss Axiovert 100M 
microscope.  The LSM 510 software was used to analyse the fluorescent images. 
 
106 cells at log growth phase and at a viable count of 80% or more were counted and washed in PBS 
at room temperature.  Pelleted cells were then fixed in 100l of 2% Paraformaldehybe for 10 min on 
ice. Once washed in cold PBS, cells were incubated in 1ml 0.1% saponin at room temperature for 5 
min, and then washed in 10ml 0.1% saponin.  Next, cells were either stained for target protein or F-
actin. 
 
To stain for target protein, permeabilized cells were then incubated with primary antibody diluted in 
cold 50l 0.1% saponin within FACS tubes for 1hr on ice.  Cells were then washed twice in 2mls of 
cold 0.1% saponin and incubated with the isotype specific fluorescently conjugated secondary 
antibody diluted in 50 l cold 0.1% saponin for 30 minutes on ice.  At this step, cells were incubated 
within a dark container to maintain the fluorescence of the light sensitive secondary conjugates.  The 
secondary antibodies applied for confocal analyses are illustrated within the table below. 
 
 
Table 2.8: Working concentrations of secondary antibodies used for confocal analysis 
Secondary Antibodies in IBT Source and Catalogue number Working Conc. 
Donkey anti-Goat IgG FITC   Santa Cruz – SC2024 5g/ml 
Goat anti-Mouse IgG (H&L) TRITC   SouthernBiotech -  1031-03 1g/ml 
Goat anti-Mouse IgG2a TRITC   SouthernBiotech - 1080-03 1g/ml 
Goat anti-Mouse IgG1 FITC SouthernBiotech - 1072-02 5g/ml 
Alexa Fluor 633 Goat anti-Mouse IgM  Invitrogen -  A-21046 g/ml 
Alexa Fluor® 488 Goat anti-Rabbit IgG (H&L) Invitrogen -  A-11008 5g/ml 
Alexa Fluor 488Goat anti-Mouse IgG (H&L) Invitrogen -  A-11001 2.5g/ml 
 
   
Cells were then washed in cold 0.1% saponin.  To stain for F-actin re-arrangement cells were stained 
with 250ng/ml phalloidin conjugated with TRITC (Sigma - 77418) for 30 minutes on ice and within a 
dark container.  Cells were then washed in cold 0.1% saponin.  
 
For nuclear staining, cells were incubated with 10g/ml DAPI diluted in 50L of cold 0.1% saponin at 
room temperature for 5 minutes.  
Multispot glass slides were washed initially in 500l of 100% ethanol and rinsed four times in 20mls 
of distilled water.  Slides were air dried before use. 
To seal membranes, cells were washed in cold PBS and resuspended in 2mls PBS.  100ul of cells were 
added per spot, then left to air dry in the dark.  Once dry, 20l of DABCO was added per spot to 
prevent fluorophores fading.  Cover slips were added on top and sealed with clear nail polish at the 
edges of the slide. 
Prior to viewing slides were kept wrapped in foil at 4oC.  All slides were viewed and captured within 
24 hours of staining using a Zeiss Axiovert 100M microscope.      
 
 
 
2.7 Enzyme-linked immunosorbent assay 
 
Two Enzyme-linked immunosorbent assay (ELISA) kits were used within this investigation.  One kit 
was used to measure BDNF protein and was obtained from Chemicon (Cat. Number CYT306).  The 
second kit, used to measure NGF protein was obtained from Signosis (Cat. Number EA0406). 
 
2.7.1 Intracellular and extracellular BDNF ELISA kit – Sample preparation and 
incubation 
 
Homogenization buffer 
100mM Tris HCl, pH7 
2% BSA 
1M NaCl 
4mM EDTA.Na2 
2% Triton X-100 
0.1% Sodium Azide 
5g/ml Aproptinin 
157g/ml Benzamide 
17g/ml PMSF- Calpain inhibitor 
 
To prepare test samples, 106 cells were pelleted from media.  Supernatant was used to analysed 
extracellular BDNF whereas cell pellets was lysed in 100ul of pre chilled homogenisation buffer to 
analyse intracellular BDNF protein.  Cells were pippeted to break their membranes and left at 4oC for 
30 minutes.  Cells were then centrifuged for 30 minutes at 40C.  This supernatant was used to assess 
intracellular BDNF protein.     
To prepare BDNF standards, manufactures’ instructions were followed.  Serial dilutions of Human 
recombinant BDNF standard controls were performed, producing the following concentrations, 
0pg/ml (diluent alone), 7.82pg/ml, 15.63pg/ml, 31.25pg/ml, 62.5pg/ml, 125pg/ml, 250pg/ml and 
500pg/ml. 
100l of duplicate BDNF standard controls were added to the 96 well immunoplate pre-coated with 
rabbit anti-human BDNF polyclonal antibody.  100l of duplicate cell lysate samples were also added 
to the pre-coated 96 well plate and left to incubate overnight at 4oC.   
The wells were then washed and incubated with 100l biotinylated mouse anti-BDNF monoclonal 
antibody for 3 hours at room temperature.  Wells were washed then treated with streptavidin-HRP 
conjugate solution at room temperature for 1 hour within a dark container.  Once washed 100l of 
TMB/E substrate was added (producing a blue colour) to incubate for 15 minutes within a dark 
container.  The reaction was stopped by adding 100l of stop solution (producing a yellow colour). 
  
2.7.2 Intracellular and extracellular NGF ELISA kit – Sample preparation and 
incubation 
 
Like the BDNF cell lysate sample preparation, 106 cells were pelleted from media.  Cell culture 
supernatant was used to analyse extracellular NGF and 100l of homogenized cell lysates were used 
to analyse intracellular NGF protein. 
 
To prepare NGF standards, manufactures’ instructions were followed.  Serial dilutions of Human 
recombinant NGF standard controls were performed, producing the following concentrations, 
0pg/ml (diluent alone), 15.63pg/ml, 31.25pg/ml, 62.5pg/ml, 125pg/ml, 250pg/ml, 500pg/ml and 
1000pg/ml. 
 
100l of duplicate NGF standard controls were added to the 96 well immunoplate pre-coated with 
rabbit anti-human NGF antibody.  100l of duplicate cell lysate samples were also added to the pre-
coated 96 well plate and at room temperature for 1 hour.   
 
The wells were then washed and incubated with 100l biotinylated rabbit anti-NGF antibody for 1 
hour at room temperature.  Wells were washed then treated with streptavidin-HRP conjugate 
solution at room temperature for 45 minutes within a dark container.  Once washed 100l of TMB 
substrate was added (producing a blue colour) to incubate for 30 minutes within a dark container.  
The reaction was stopped by adding 50l of stop solution (producing a yellow colour). 
  
2.7.3   Optical density readings for ELISA plates 
ELISA plates were read using a Molecular devises E-Max precision micropate reader at a wavelength 
of 450nM (“1 only” settings).  Soft MaxPro v311 was the software used to analyse the readings, 
which were then transferred to Microsoft excel for further analysis.   
 
 
 
 
 
 
 
 
2.8 Assessment of DNA synthesis by thymidine 
incorporation 
 
The rate of cell division was obtained by treating cells with varying reagents then exposed to 
thymidine ([3H]Thy) (Amersham International).  [3H]Thy is incorporated by proliferating cells during 
S-phase DNA synthesis.  96 well flat bottomed microculture (Nunc) plates were used to culture 200l 
of quadruplet cell samples at densities and for varying periods of time.  Burkitt’s lymphoma B cells 
were then pulsed with 50l of [3H]Thy during the last 4 hours of culture, whereas germinal centre B 
cells were pulsed during the last 12 hours of culture. 
Cells were then harvest onto filter mats (Cox Scientific) using a Skatron cell harvester model 11051 
(Helis Bio Ltd, Newmarket, UK).  Radioactivity, per well, was measured samples using a liquid 
scintillaton counter (Betaplate) over 60 seconds.  Mean counts per minutes were calculated for 
quadruplicate wells and results expressed as mean thymidine incorporation counts per cell sample.    
 
 
 
 
 
 
 
 
 
 
2.9 Assessment of lymphocyte cell division using CFSE dye 
 
Carboxyfluorescein succinimidyl ester (CFSE) is a membrane permeable, fluorescently labelled dye 
used to stain live cells in order to track proliferation rate which diminishes over time due to the 
progressive halving of CFSE fluorescence within daughter cells following each cell division (Lyons and 
Parish 1994). 
 
107 cells were washed twice in 10mls PBS and the pellet resuspended in 1ml 5M CFSE.  Cells were 
then incubated for 10 minutes at room temperature on a gentle shaker.  1ml of culture media with 
10% FCS was added to quench the labelling reaction.  Cells were then washed twice in 20mls PBS 
and resuspended in culture media.  100l per well of 2x105 cells/ ml cells were then treated with 
varying reagents diluted in 10% Culture media on 96 well plates for 48 hours. 
 
The total volume (200l) of cells was then added to polystyrene FACS tubes containing 100l of PBS.  
10,000 cells were acquired and the CFSE fluorescence levels were measured using a FACSCalibur 
flow cytometer.  CFSE levels were analysed for each treatment and compared to control treated cells 
using FlowJo software. 
 
 
 
 
 
 
2.10  Assessment of cell viability by propidium iodide stain 
 Propidium Iodide (PI) is a fluorescent compound that binds to non-viable cells.  Upon treatment with 
varying reagents and for varying time points, quadruplicate cell samples cultured within 96 well 
plates (2x105 cells/ ml), were pooled into polystyrene FACS tubes and washed in 2mls of PBS at room 
temperature.  Cells were then kept on ice until use.  4l of 100g/ml PI was added per FACS tube 
then immediately analysed using a flow cytometry Becton Dickinson FACScalibur for intensity in PI 
staining using FL-2 lasers.  10,000 cells were measured for each sample and analysed using FlowJo 
software v2.2.   
 
2.11  Assessment of cell viability by propidium iodide co-
stained with Phiphilux  
 
To measure viable, early apoptotic, late apoptotic and necrotic cells treated with varying reagents, 
quadruplicate cell samples cultured within 96 well plates (2x105 cells/ ml), were pooled into 
polystyrene FACS tubes and washed in 2mls of PBS at room temperature.  30l of the caspase 
substrate Phiphilux-G1D2 (OncoImmunin, Inc. – A304RIG) was added per cell pellet (PhiPhilux 
fluorescence intensity increases when it is cleaved by active caspases).  Centrifugation speeds and 
times were followed from according to the manufactures instructions.  Tubes were incubated within 
a dark 37oC tissue culture incubator for 1 hour.  Once washed in 2mls of cold PBS cells were gently 
resuspended in 350l of flow cytometry buffer (provided within the kit) and kept on ice, wrapped in 
foil.  Immediately before running each sample, 4l of 100g/ml PI was added per FACS tube and 
analysed using the flow cytometry Becton Dickinson FACScalibur.  10,000 cells were collected to 
measure the intensity of Phiphilux fluorescence using FL-1 lasers, and PI fluorescence using FL-3 
lasers.     
This dual staining is then analysed using FlowJo software.  Cells populations were distributed into PI 
low/ Caspase low (viable), PI low/ Caspase high (early apoptotic), PI high/ Caspase high (late 
apoptotic) and PI high/ Caspase low (necrotic) populations.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
2.12 Human tonsil sections and Germinal centre B cell 
isolation 
 
 
2.12.1 Human tonsil tissue section preparation and staining 
 
Human tonsil, obtained from a young adult at routine tonsillectomy was sliced into 5mm thick 
sections.  These sections were then wrapped in aluminium foil, snap-frozen in liquid Nitrogen, and 
stored at –70°C in grip-sealed polythene bags until use. The frozen tonsil sections were embedded in 
OCT compound (Miles, Inc., Elkhart, IN) and 5µm cryostat sections were mounted onto 4-spot glass 
slides. These were air dried for 1 h, then fixed in acetone at 4°C for 20minutes, dried, and stored in 
sealed polythene bags at –80°C. 
When used for staining, sections were left to thaw at room temperature for 15 minutes, then 
washed in a gently stirred PBS bath for 10 minutes.  Sections were then stained with 100l of diluted 
primary antibody, over night at 4oC within a damp sealed container. 
Excess primary antibody was then carefully tipped off the sections which were washed for 10 
minutes in a PBS bath.  Secondary antibodies used for confocal staining are illustrated below. 
100l of diluted secondary antibodies were added per tissue section at left in a dark, damp sealed 
container for 3 minutes at room temperature.  Excess secondary antibody was then carefully tipped 
off the sections that were washed for 10 minutes in a PBS bath protected from light to preserve the 
conjugated fluorescence. 
Immunofluorescencent images were viewed using a Zeiss Axiovert 100M microscope.  Images were 
then analysed using LSM v510 software.       
 
2.12.2 Isolation of germinal centre cells 
 
Human tonsils, obtained from young adults at routine tonsillectomy were finely minced in RPMI 
1640 media without any additional supplements.  The cell suspension was subjected to two rounds 
of T cell depletion using 2% 2-aminoethyl-isothiouronium bromide-treated sheep red blood cells 
(TCS Microbiology, Botolph Claydon, UK– SB068). B cells were then isolated by centrifugation 
through a 60% Percoll gradient (Pharmacia, Uppsala, Sweden).  Cells were then incubated with four 
primary mouse antibodies, 2.5g/ml anti-IgD polyclonal mouse monoclonal antibody (Sigma – HJ9), 
10g/ml anti-CD39 (AC2), 1/100 anti CD14 (61D3) and anti 10g/ml anti-CD3 antibody (OKT3) for 30 
minutes at 4oC.  Once washed twice in RPMI 1640 media cells were resuspended in 1ml PDS 
containing 1% BSA.  Sheep anti Mouse IgG dynabeads were added to bind to the four primary mouse 
antibodies, for 30 minutes at 4oC.  A 4 to 1 ratio of beads to total cell numbers were added to ensure 
high purity levels of germinal centre B cells depletion.  Germinal centre B cells (IgD-ve, CD39-ve, 
CD3-ve and CD14-ve) were isolated from five rounds of magnetic separation and kept on ice prior to 
use.  
 
2.12.3  Phenotyping tonsillar germinal centre B cells 
 Cell surface staining was competed to phenotype freshly isolated germinal centre B cells.  105 cells 
were added to polystyrene FACS tubes and washed in 2ml cold PBS.  Cells were gently resuspened in 
50l and dual-stained for 7g/ml RPE conjugated anti-CD3 (Dako – R0810) and 4g/ml FITC 
conjugated anti-CD19 (Dako – F0768) as well as 4g/ml PE conjugated anti-CD38 (Phamigen - 31015) 
and 1g/ml FITC conjugated anti-IgD (Dako – F0059).  Cells were stained for 30 minutes on ice then 
washed in 2mls of cold PBS.  Cells were resuspeded in 350l of FACS buffer.  10,000 cells were 
collected to measure the intensity of FITC fluorescence using FL-1 lasers, and RPE or PE fluorescence 
using FL-3 lasers.  Data was analysed using FlowJo software.      
 
 
 
 
  
3. Results 
Characterisation of Burkitt’s lymphoma B cells and 
their expression of neurotrophic factor mRNA 
transcripts 
 
3.1 Introduction 
Nearly all African Burkitt’s lymphoma patient tumours are EBV positive.  Increasing evidence 
for the involvement of EBV in Burkitt’s lymphoma pathogenesis has been provided, 
questioning how the virus controls its host via the expression of latency genes.  In order to 
efficiently investigate these viral-cellular interactions model Burkitt’s lymohoma cell lines 
have been established to yield clues to the understanding of EBV.  Two main patterns of EBV 
gene expression are observed.  Freshly isolated and cultured Burkitt’s lymphoma cells from 
tumour display only one EBV latent gene, EBNA1 (Rowe, Rowe et al. 1987).  This EBV gene 
expression phenotype is described to have latency I characteristic.  However, in vitro 
infection of primary resting B cells with EBV produces an EBV transformed lymphoblastoid 
cell line (LCL) which displayed all six EBNA latent proteins and three Latent membrane 
proteins.  These LCLs are described to have a latency III phenotype.  LCLs are a good model 
for the study of uncontrolled proliferation as that observed in Burkitt’s lymphoma tissues 
and other EBV associated malignancies, particularly in immunosupresed patients with post-
transplant proliferative diseases. 
Considering c-myc translocations coincide with cell death, it is possible that the main 
function for EBV gene expression is to oppose these apoptotic effects enabling Burkitt’s 
lymphoma pathogenesis.  Examples of this include EBV proteins such as EBNA and BARF1 
which are known to prevent cell apoptosis (Kennedy, Komano et al. 2003; Sheng, Decaussin 
et al. 2003).  EBERs also promote cell survival via the up regulation of IL10 (Kitagawa, Goto 
et al. 2000).     
To further investigate the involvement of EBV latency gene expression Burkitt’s lymphoma 
pathogenesis, model cell lines displaying varying latency phenotypes were analysed within 
the investigation.   
As mentioned before, the use of cells displaying latency I phenotype is a good model for 
Burkitt’s lymphoma which behave like original Burkitt’s tumours.          
Work by Gregory C.D. et al., in 1990 document on the establishment of varying Burkitt’s 
lymphoma clones from a tumour biopsy (Gregory, Rowe et al. 1990).  At the period of time 
in culture, when EBV latency phenotype altered, morphologically distinct cell populations 
were separated and characterised.  LCL-like cells which grew in clumps and contained 
cytoplasmic projections were fractioned from small, round, free floating single cells.  These 
cell lines were named as the Mutu Burkitt’s lymphoma line.  Clones of single round cells 
were described to have a group I phenotype based on morphological and surface antigen 
expression.  Consequently, LCL clones were known to display a group III morphological 
phenotype.  Once characterised for the expression of EBV latency proteins, group I cells 
were shown to express only EBNA1, which in turn displays a latency I EBV gene expression 
phenotype.  Group III cells on the other hand expressed all five EBNA proteins, LMP and lytic 
cycle antigens, displaying a latency III phenotype.      
Cell lines have also been established from rare non-EBV associated sporadic Burkitt’s 
lymphoma cases.  These EBV negative cell lines include BL41, which was first established at 
the International Agency for Research on Cancer (IARC) in Lyon, France.  Experimental 
infection of cell lines such as BL41 with the transforming EBV strain, B95.8 resembled the 
phenotype and EBV gene expression patterns observed within in vitro infected normal B 
cells (Calender, Billaud et al. 1987).    
The initial aim within this investigation was to question the expression patterns of 
neurotrophic factors and receptors within Burkitt’s lymphoma cell lines displaying varying 
EBV latency phenotypes.  Additional research using Burkitt’s lymphoma model lines by 
questioning EBV gene patterns and the control of the cellular proteins, neurotrophic factors 
and receptors could provide further insights to viral-cellular communication in Burkitt’s 
lymphoma.  The involvement of neurotrophic factor signalling in B cells has previously been 
documented by several laboratories.   
In 1987 Thorpe L.W. and Perez-Polo J.R. discovered that rat spleen B and T lymphocytes 
express NGF-receptor which can induce cell proliferation upon NGF treatment (Thorpe and 
Perez-Polo 1987).  Subsequently, Otten U. et al., document on the expression of NGF 
receptors within human spleen and lymph node tissues.  Importantly they also discovered 
that NGF induced proliferation and differentiation in human B lymphocyte (Otten, Ehrhard 
et al. 1989).  Further research by Edling A.E., et al., show the expression of NT-4, BDNF and 
their receptor TrkB as well as NGF expression in human B cells (Edling, Nanavati et al. 2004). 
Neurotrophic factor expression and signalling can also be associated with haematological 
malignancies.  Hodgkin Reed Sternberg cells obtained from Hodgkin lymphoma, express 
TrkA and TrkB receptors which can be phosphorylated upon ligand binding (Renne, 
Willenbrock et al. 2005).  The B cell neoplasm, Multiple myeloma tumour cells also express 
BDNF and its receptor TrkB.  In this case, BDNF acts as a potent growth factor, inhibits 
apoptosis induced by dexamethasone, enhances cell survival and acts as a chemoattractant 
(Pearse, Swendeman et al. 2005; Hu, Sun et al. 2006).        
This increase in evidence on the involvement of neurotrophic factor signalling in cancers of 
the immune system has lead to the main focus for this section of the investigation.  Here the 
aim is to explore neurotrophic factor mRNA expression patterns in characterised Burkitt’s 
lymphoma B cells.    
 
 
 
 
 
 
 
 
 
 
 
  
3.2 Results 
3.2.1 Morphological characteristics of a series of model Burkitt’s lymphoma 
lines  
 
Two sets of Burkitt’s lymphoma B cell lines were provided displaying varying EBV latency 
and cellular phenotypes.  The first set from an EBV negative Burkitt’s lymphoma patient, 
comprise the EBV tumour line BL41; an EBV convertant of this line, BL41+EBV strain B95.8, 
established by in vitro infection of the original tumor line and IARC-171, an EBV transformed 
lymphopblastoid line generated by in vitro infection of normal B cells from the blood of this 
patient.  The second set are subclones of the Mutu- Burkitt’s lymphoma line, two EBV 
negative clones, two latency I and two latency III clones (Gregory, Rowe et al. 1990).  Figure 
3.1 shows the differences in cell morphology between EBV negative/ latency I cells 
compared to those expressing EBV latency III genes.  EBV negative cells appear as free 
floating, small circular single cells in suspension (figure 3.1a), while Latency III cells appear in 
clumps with some single cells in suspension (figure 3.1b).      
 
 
 
 
  
3.2.2 Verification of EBV gene expression patterns in the model Burkitt’s 
lymphoma lines 
 
Burkitt’s lymphoma lines were screened using antibodies specific to each EBV latency 
protein.  Protein lysates were obtained from each line 24 hours post feeding to ensure the 
cells were at growth phase.  The first set of whole cell extracts were prepared and ran on 7% 
polyacrylamide with SDS gels (Tris-Acetate buffer) under reducing conditions.  Samples were 
then screened for EBNA1, EBNA2, EBNA3a, EBNA3b, EBNA3c, LMP1 and LMP2a (figure 3.2a).   
The lymphoblastoid cell line, IARC-171 expressed all latent proteins analysed.  BL41+EBV 
strain B95.8 shows weaker expression of EBNA3c and LMP1, with undetectable EBNA3b and 
LMP2a expression.  Mutu latency III clone J8 show similar expression patterns to BL41+EBV, 
whereas Mutu latency III clone K5 is probably a micture if ENB loss and latency III cells.   
Since EBNA-LP is composed of proteins with multiple molecular weights, a 4 to 12% 
polyacrylamide with SDS gradient gel (Bis-Tris buffer) under reducing conditions, was used 
to display a larger range in molecular weight proteins (figure 3.2b).  BL41+EBV lines show 
strong protein expression at ~20kDa and ~30kDa.  IARC-171 on the other hand shows 
weaker levels of proteins running at a wide range of molecular weights.  All Mutu lines were 
negative for EBNA-LP with the use of this antibody.        
 
  
 
3.2.3 Analysis of mRNA expression of Neurotrophic factors and their receptors 
in Burkitt’s lymphoma cell lines 
 
 To examine the expression of neurotrophic factors and their receptors, RNA was extracted 
from all Burkitt’s lymphoma cell lines and analysed by semi-quantitive RT-PCR.  Following 
amplification of target sequences, samples were run on agarose gels containing 0.6g/ml 
ethidium bromide and visualised under UV light.  -actin primers were used to monitor the 
presence of equal cDNA levels within RT positive samples (figure 3.3.1).  All PCR results are 
representatives of three independent RNA extractions and PCR experiments. 
NGF specifically binds to TrkA.  Although expression of the receptor, TrkA was observed 
within all Burkitt’s lymphoma B cell lines, transcript expression of its NGF ligand was 
undetectable across the set of lines analysed (figure 3.3.2).    
The expression levels of NT-4, BDNF and their specific receptor TrkB, were also examined. 
Both BDNF and NT-4 primers lie within one exon and can therefore pick up non-specific 
genomic DNA, therefore RT negative cDNA was compared to RT positive cell samples (figure 
3.3.3).  BDNF PCR products were present within all RT positive Burkitt’s lymphoma cell lines 
and absent within the RT negative controls.  Weak expression of NT-4 PCR products were 
observed within all cell lines, however non-specific genomic DNA was also amplified within 
all the RT negative sample.   
Two primer sets were used to examine TrkB expression.  The first primer sets recognize all 
TrkB variants and are named “Pan TrkB primers”.  The second set on the other hand only 
recognizes the two full length TrkB variants A and C; this set is named “variants A & C TrkB 
primers”.  All EBV negative cell lines, and the Mutu latency I clone 59 lacked detectable 
transcripts specific for all TrkB variants.  BL41+EBV and Mutu latency I clone 179 only 
expressed Pan-TrkB transcripts where as IARC-171 and both Mutu clones expressed all TrkB 
transcript variants.  
Which specific variants are upregulated by the latency III phenotype however, remains 
unknown.  For these experiments to be repeated, it would be worth knowing which specific 
variants are upregulated by designing semi-quantitative RT-PCR primers specific for unique 
regions on each TrkB variant.   
NT-3 specifically binds to TrkC receptor.  The NT-3 primers used also lie within one exon 
therefore RT positive PCR products were compared to RT negative samples to ensure 
specificity of transcript detection.  Expression of NT-3 transcripts was observed within all cell 
lines; however it was remarkable that these expression levels seemed to decrease with 
acquisition of a latency III phenotype (figure 3.3.4).  Based on the concluding remarks for 
latency characteristics of Mutu latency III clone K5; where a heterogeneous population may 
be present, the few latency III cells within the culture may influence the lower expression 
levels of NT-3 transcripts observed.  All EBV negative and Mutu latency I lines show strong 
transcript levels whereas latency III lines show weaker NT-3 levels.  The RT-negative control 
samples for NT-3 expression did not pick up any genomic DNA rendering the NT-3 results a 
true positive.   
In contrast to the reproducible results obtained for other neurotrophic factors and receptor 
transcript assays, variation of TrkC expression between RNA extractions within the lines 
analysed therefore, three independent results for TrkC mRNA expression are shown.  These 
results were inconclusive but suggest that very low levels of transcripts may be present in 
most of the cell lines, but with no obvious correlation to latency phenotype. 
RT-PCR experiments were conducted to question p75NTR expression levels.  NGF, BDNF, NT-3 
and NT-4 bind to p75NTR receptor with lower affinity than their cognate Trk receptors.  Most 
Burkitt’s lymphoma B cell lines analysed express p75NTR transcripts regardless of EBV latency 
phenotype with the exception of Mutu latency I clone 179.   
 
3.2.4   Quantitative analysis of TrkB mRNA   
Using real time PCR methods, Pan-TrkB primers were used to quantify TrkB transcripts 
within characterised Burkitt’s lymphoma lines.  VIC labelled Beta-2 Microglobulin (B2M) 
primers and FAM labelled TrkB primers were designed and optimised to be used in a duplex 
RT-PCR detection system.  mRNA levels of TrkB were calculated relative to B2M levels for 
each Burkitt’s lymphoma cell line (figure 3.4).  Consistent with RT-PCR data shown within 
figure 3.3.3, latency III cells expressed detectable levels of TrkB transcripts compared to 
their EBV negative or latency I counterparts.  The multiple myeloma cell line, KMS-11 was 
used as the positive control.       
A summary of the data analysing expression of EBV latency proteins, neurotrophic factors 
and their receptors in the model Burkitt’s lymphoma B cell lines is illustrated within Table 
3.1.   
  
 
 
 
 
 
 
 
 
 
 
  
 
 
3.3  Discussion 
Freshly isolated Burkitt’s lymphoma cell lines can change in EBV latency phenotype when 
cultured.  Over time, these cells can shed viral episomes changing their phenotype from 
latency III to an EBV latency I/ negative line.  To ensure the cell lines provided for the 
investigation were true to their EBV latency phenotypes morphologies were closely 
examined and recorded whilst in culture.  This was important for interpreting data produced 
from future neurotrophic factor signalling experiments.  As shown within figure 3.1, latency 
three cells form clumps in culture, differences in cell morphologies between Mutu latency III 
clone J8 and K5 were observed.  Clone J8 cells retained their characteristic clumping 
morphology, whereas clone K5 cells appeared to have much smaller clumps with a very high 
proportion of free floating single cells in suspension.  Further evidence of viral episome 
shedding was observed when screening the cells for EBV latency proteins.  Comparing Mutu 
latency III clones, J8 cells expressed stronger levels of EBNA1, EBNA2, EBNA3a and EBNA3c.  
K5 cells on the other hand lacked LMP1 and EBNA3b proteins expressed within J8 clones.  
BL41 lines infected with EBV also lacked EBNA3b proteins, however it is worth noting, the 
antibody used to probe for EBNA3b is relatively weak and may not have been sensitive 
enough to detect expression within EBV infected BL41 lines and Mutu latency III K5.  
Differences in molecular weight for EBNA2 protein between BL41+EBV and IARC 171 
indicating possible variation in EBV virus strain however this is unlikely since both lines were 
in vitro infected with EBV stain B95.8.  Immunoprecipitation and mass spectrometry analysis 
would be a useful experiment to further analyse whether the proteins detected are true 
EBNA2 proteins. 
LMP2a expression however was only observed within the LCL line, IARC-171.  This result is 
either due to antibody sensitivity or a true representation of LMP2a expression within the 
two Mutu latancy III lines.  LMP2a is a mimic for BCR signalling in EBV infected B cells, these 
signalling events, together with LMP1 are essential for survival and growth are essential in 
maintaining the latency III phenotype.  Taking this into consideration it would be beneficial 
to question LMP2a expression using an alternative antibody and to also examine gene 
expression within the two Mutu latency III lines.            
 
The expression pattern for EBNA-LP is consistent with previous EBNA-LP expression as 
documented by Finke J. et al,.  Here, they investigated on EBV infected BL41 cells where two 
EBNA-LP proteins, one at approximately 30kDa and the other at roughly 20kDa are observed 
(Finke et al., 1987).  The RT-PCR results shown in figure 3.2b for BL41+EBV cells are 
consistent with these results.  Although IARC 171 was not included as one of the LCLs 
analysed within Finke, J. et al’s study, proteins observed within IARC 171 ranging from 
20kDa to 65kDa lysates resemble EBV infected B cells illustrated within the publication.   
However, EBNA-LP expression was not observed within any of the Mutu clones.  The reason 
for this is due to the antibody used, JF186, which recognises specific sites of the EBNA-LP 
antigen present within BL41+EBV and IARC 171 cell lines, however this antigen is not 
present in Mutu lines (communication with Professor Rowe.)    
Prior to each RT-PCR experiment, amplicons from positive control cell lines such as Kelly and 
KMS-11 were run out on a 1.5% agarose gel.  Extracted DNA was obtained using a Qiagen 
gel extraction kit and sent to MWG Biotech Ltd (Covent Garden, London) for sequence 
verification.  Primers specific for each neurotrophic factor and receptor were then used 
within a series of RT-PCR experiments.   
Three independent RNA extractions were performed for all Burkitt’s lymphoma lines to be         
screened for the expression of neurotrohic factors and receptor mRNA transcripts.  For each 
RNA extraction, a -Actin RT-PCR test was completed to ensure cDNA was successfully 
obtained for each cell sample (figure 3.3.1).   
All Burkitt’s lymphoma lines expressed TrkA transcripts regardless of EBV latency 
phenotype, however the lack of its ligand, NGF was observed (figure 3.3.2).    This lack in 
NGF mRNA expression was unexpected considering previous publications show NGF 
expression in B cells.  As shown by Torcia M. et al., NGF is synthesised and signals in an 
autocrine manner through its receptor TrkA and p75NTR within memory B cells (Torcia, 
Bracci-Laudiero et al. 1996).   Further evidence on NGF expression in B cells was 
documented by Coppola V. et al., and Bracci-Laudiero L. et a.l. (Coppola, Barrick et al. 2004; 
Bracci-Laudiero, Aloe et al. 2005).  However based on the RT-PCR experiments, the lack of 
NGF expression is observed in all Burkitt’s lymphoma B cells and possibilities of paracrine 
signalling with NGF expressing cells will later be question within the investigation. 
Transcripts for TrkB ligands on the other hand, are expressed within all Burkitt’s lymphoma 
lines.  Publications have been submitted showing bioactive BDNF secretion from B cells can 
support neuronal survival in vitro (Kerschensteiner, Gallmeier et al. 1999).  As for NT-4 
expression in B cells, there is currently limited literature on this neurotrphic factor however 
NT-4 mRNA expression has been documented in murine lymphocytes (Barouch, Appel et al. 
2000).  The expression of NT-4 transcripts was observed within all Burkitt’s lymphoma lines.  
Their cognate receptor, TrkB is formed of varying isoforms therefore two primer sets were 
used to screen for TrkB expression.  Using the Pan-TrkB primers, expression was only 
observed within latency I and latency III cell lines, excluding Mutu latency I clone 59 
(figure3.3.3).  This expression pattern is possibly due the presence of EBNA1 within this set 
of Burkitt’s lymphoma lines.  TrkB primers recognising variants A and C on the other hand 
only detected transcripts within IARC-171 and both Mutu latency III clones.  The initial 
postulations from these results may indicate the co-expression of TrkB and LMP1 within 
these lines, except Mutu latency III clone K5.  The lack of full length TrkB variants A and C in 
EBV negative and latency I lines revel a possibility in the up regulation of TrkB in latency III 
tumour cells.  The up regulation of TrkB for tumour survival and progression has been 
indicated for a number of neuronal and nonneuronal solid tumours (Ricci, Greco et al. 2001; 
Sakamoto, Kitajima et al. 2001).  Like Multiple myeloma, Burkitt’s lymphoma latency III cells 
express TrkB and may respond to BDNF promoting tumour growth (Pearse, Swendeman et 
al. 2005).   
As for NT-3 expression, all lines reguardless of EBV phenotype express NT-3 transcripts, 
however the level of expression seemed to correlate with EBV phenotype.  With increasing 
EBV phenotype from EBV negative to latency III, cells seem to have a decrease in NT-3 
expression levels.  As of yet, there are no publications investigating the changes in 
neurotrophic factor expression levels between EBV latency groups, however there is 
evidence for changes in expression levels between activated and non-activated 
lymphocytes.  Stimulating B cells obtained from PBMCs with heat-inactivated 
Staphylococcus aureus increases their expression of soluble BDNF (Kerschensteiner, 
Gallmeier et al. 1999).  It is a possibility that normal B cells have high levels of NT-3 mRNA 
which decrease upon EBV infection.  Although NT-3 binds with its cognate receptor TrkC, it 
is the most promiscuous of the mammalian neurotrophic factors which can also signal via 
TrkA and TrkB at a lower affinity together with the low affinity receptor p75NTR but (Ibanez 
1994; Ibanez 1998).   
The need for stronger NT-3 levels in EBV negative lines may be linked to the lack of full 
length TrkB within these cells as discussed above.  The expression of TrkC however was not 
clear from the RT-PCR experiments completed.  Varying transcript levels were detected 
between Burkitt’s lymphoma RNA extractions (figure 3.3.4).  Overall, TrkC expression was 
only observed within EBV negative BL41 line, Mutu negative clones and Mutu latency III 
clones therefore the expression of this receptor was conclude to not be EBV latency specific.   
BDNF, NT-3 and NT-4 expressed by Burkitt’s lymphoma B cells could signal through their 
cognate receptors and the low affinity receptor p75NTR in Burkitt’s lymphoma B cells.  The 
expression of p75NTR transcripts were observed within all Burkitt’s lymphoma lines excluding 
Mutu latency I clone 179 (figure 3.3.5).  Mature EBV negative B cell lines have been 
previously show to have increased membrane expression of p75NTR and TrkB when deprived 
of serum for 24 to 72 hours (Fauchais, Lalloue et al. 2008).  p75NTR signalling for proliferation 
can occur in B cells obtained from patients with chronic lymphocytic leukaemia (Waage, 
Liabakk et al. 1992), and the activation of mantel zone B cells with anti-immunoglobulin and 
IL-4 or IL-2, increases receptor expression of p75NTR (Zola, Flego et al. 1993).   
4. Results 
Expression and autocrine signalling of TrkB and p75NTR 
receptors and their ligands BDNF and NT-4 
 4.1 Introduction 
The conclusions drawn based on TrkB and p75NTR expression, from the previous chapter, 
illustrate that latency III Burkitt’s lymphoma lines, IARC-171 and Mutu clone J8 show clear, 
detectable mRNA expression for full length TrkB whereas their EBV negative counterparts, 
BL41 and Mutu negative clones and EBV latency I clones lacked detectable full length TrkB 
mRNA.  On the other hand, all Burkitt’s lymphoma lines expressed the high affinity TrkB 
ligands NT-4 and BDNF.  
 
The main focus for this chapter is to explore protein expression of TrkB and p75NTR receptors 
in Burkitt’s lymphoma B cell lines previously characterised.  The expression of their ligands 
NT-4 and BDNF will also be investigated.  Ligand expression confirmation is important since 
possible autocrine signalling may occur in Burkitt’s lymphoma lines.  For this question to be 
answered, downstream signalling effects on cell survival and proliferation within the Mutu 
clone J8 latency III Burkitt’s lymphoma line will be analysed by the use of varying receptor 
and/ or ligand inhibitors. 
 
4.1.1 Alternatively spliced TrkB variants 
The TrkB gene contains 24 exons that are influenced by alternative promoters, splicing, and 
polyadenylation sites.  In effect, the TrkB gene can create at least 100 isoforms that can 
encode around 10 proteins (Klein, Parada et al. 1989).  However by using RT-PCR and 
Northern blot analysis, it is known that three major protein isoforms are generated by the 
TrkB gene (Middlemas, Lindberg et al. 1991).  A TrkB full length receptor, a isoform lacking 
the tyrosine kinase domain (TrkB-T1), and an isoform lacking the tyrosine kinase domain but 
containing an Shc binding site (TrkB T-Shc) (Klein, Conway et al. 1990; Shelton, Sutherland et 
al. 1995).   There are 5 well characterised mammalian TrkB isoforms, displayed within 
illustration 4.1. 
Like the full length TrkB, TrkB-T1 variant can bind and activate to neurotrophins and is 
internalized, but due to the lack of a kinase domain it cannot signal catalytically (Biffo, 
Offenhauser et al. 1995).  However its specific function remains controversial. 
As for TrkB-T-Shc, it is a truncated variant which contains a Shc-binding site in the 
juxtamembrane domain but lacks the kinase domain and has a unique truncated C terminus. 
T-Shc is predominantly expressed in the brain, but its role is so far mostly unknown 
(Haapasalo, Sipola et al. 2002).  TrkB-T-Shc is generated by the use of a new alternative exon 
19. 
 
 
 
4.1.2 TrkB phosphorylation and downstream signalling 
BDNF and or NT-4 ligand binding can result in receptor dimerisation of either two TrkB 
receptor dimers or one TrkB with a p75NTR receptor (Bibel, Hoppe et al. 1999).  This occurs at 
the cell surface resulting in autophosphorylation of intracellular tyrosine residues (Stephens, 
Loeb et al. 1994; Inagaki, Thoenen et al. 1995).   TrkB autophosphorylation occurs on five 
BDNF inducible cytoplasmic tyrosine site: Y484, Y670, Y674, Y675, and Y785 as displayed in 
illustrated 4.2  (Guiton, Gunn-Moore et al. 1994; Middlemas, Meisenhelder et al. 1994).   
As reviewed by Huang E.J. and Reichardt L.F., phosphorylated tyrosines act as docking sites 
for adaptor proteins containing PTB or SH2 domains which in turn activate Ras-Raf-Erk, 
Phosphoinositide 3-kinases (PI3-K), PLC--Ca2+ and NFB pathways (Wooten, Seibenhener et 
al. 1999; Foehr, Lin et al. 2000; Kaplan and Miller 2000; Huang and Reichardt 2003).  The 
tyrosine site, Y484, lies within the intracellular juxtamembrane region of TrkB and is 
predicted to be the binding site for the PTB domain of the SHC adapter protein (Nimnual, 
Yatsula et al. 1998; Xing, Kornhauser et al. 1998).  Shc recruits the Grb2 adaptor protein 
complexed with SOS which is exchanged with Ras.  Activated Ras then stimulates varying 
downstream pathways including PI3-K which produce phosphatidylinositides generated by 
phosphatiyinositde-dependent protein kinase (PDK-1) and PI3-K.  These three 
phosphoinositides activate protein kinase Akt which then phosphorylates sereval proteins 
important in promoting cell survival.   
Substrates of Akt phosphorylation include anti-apoptotic proteins such as Bad, a member of 
the Bcl-2 family which prevents apoptosis when phosphorylated.  It has also been shown 
that NT-3 signalling, involving PI3-K, can orchestrate anti-apoptotic effects on cultured 
cortical neurons (Liot, Gabriel et al. 2004).   
Activated Ras can also stimulate Raf which phosphorylates Erk 1 and Erk 2 by MEK1 or MEK 
2 (English, Pearson et al. 1999).  Rsk are Erk 1 and Erk 2 substrates that activate CREB which 
regulates genes associated with differentiation and survival (Riccio, Ahn et al. 1999).  
Neurotrophin signalling involving Erk activation is shown by the addition of BDNF to intact 
adult hippocampus which allows long lasting synaptic strengthening, acting through Erk-
Mek signalling adaptors.              
TrkB signalling can also regulate cell proliferation in the development of murine embryonic 
central nervous system precursors (Bartkowska, Paquin et al. 2007).  Here, it was noted that 
Erk and not Akt signalling is involved in cell proliferation of cortical precursors in vivo.  Upon 
phosphorylation of the tyrosine kinase residue, Y-484, Shc is phosphorylated then signals via 
adaptor proteins such as Ras, Erk1/2 and c-fos enhancing protein synthesis (McCarty and 
Feinstein 1999).  The three autophosphorylation sites, tyrosine Y670, Y674 and Y675 lie 
within a structurally flexible activation loop, inside the TrkB catalytic domain (illustration 
4.1).  When phosphorylated it is presumed that SH2 and/ or PTB domain-containing proteins 
interact with one or more of the activation loop phosphotyrosines inducing mitogenesis via 
Erk1/2 and c-fos synthesis (McCarty and Feinstein 1998). 
 
Hence, to question whether Burkitt’s lymphoma B cell lines express TrkB and/ or p75NTR 
protein, three anti-p75NTR antibodies and two Anti-TrkB antibodies were used for analysis.  
The regions the antibodies recognise on the TrkB and the p75NTR structures are annotated 
within illustration 4.3 and 4.4.  To question possible autocrine signals via TrkB and/ or 
p75NTR, Burkitt’s lymphoma latency III B cells were exposed to varying TrkB and or/p75NTR 
inhibitors discussed below.     
4.1.3 Inhibitions for TrkB signalling 
The most commonly documented neurotrophic factor receptor signalling inhibitor is K252a, 
an alkaloid-like compound isolated from the Nocardwpsis species of soil fungi 
(1987;142:43).  K252a is a membrane permeable, staurosporine analog and an inhibitor of 
Ca2+/calmodulin-dependent protein kinases, phosphorylase kinases, many tyrosine and 
serine/threonine kinases (Ruegg and Burgess 1989; Elliott, Wilkinson et al. 1990; Chin, 
Murray et al. 1999).   As reported by Smith R.J. et al., K252a was initially discovered as an 
inhibitor of protein kinase C signalling in human polymorphonuclear neutrophils at an IC50 of 
0.58M (Smith, Justen et al. 1988).  Inhibition of degranulation in neutrophils can also be 
observed upon K252a treatment at high IC50 values, 0.1–10 μM.   
The inhibition of NGF signalling by K252a, was first tested in rat pheochromocytoma cells 
(PC12) which revealed an inhibition of NGF induced neurite outgrowth and the 
phosphorylation of various kinases including tyrosine hydroxylase at a concentration of 
100nM (Hashimoto 1988).  After a report by Berg M.M. et al.,  K252a was demonstrated to 
act directly on NGF specific signal transduction in PC12 cells by inhibiting tyrosine 
phosphorylation and kinase activity of TrkA in a does dependent manner (Berg, Sternberg et 
al. 1992). 
K252a is now used to inhibit TrkA, TrkB and TrkC signalling in varying cell types, investigating 
different neurotrophic factor signalling effects.  Some examples of where K252a has been 
used as a Trk inhibitor include investigations on breast cancer cells, which normally express 
high levels of TrkA and are resistant to cell death.  Upon K252a treatment, anoikis resistance 
was diminished (Lagadec, Meignan et al. 2009).  K252a also inhibits NGF induced human 
aortic endothelial cell migration (Dolle, Rezvan et al. 2005), as well as inhibiting TrkB and 
BDNF autocrine signalling, promoting the proliferation of retinoblastoma tissue and 
retinoblastoma cell lines (Stephan, Zakrzewski et al. 2008).       
However, it is worth noting that K252a is regarded as a high-affinity but nonselective kinase 
inhibitor known to disrupt Akt kinase (PKB), protein kinase CR (PKC-R), Ca++/calmodulin 
kinase II (CamKII), and cGMP-dependent protein kinase (PKG) (Hashimoto, Nakayama et al. 
1991).  Since K252a is not a specific inhibitor for Trk signalling, its effects were compared to 
a TrkB receptor analogue.   
TrkB-domain 5 (TrkAd5) was constructed after the discovery of BDNF and NT-4s’ specific 
binding site on the TrkB receptor structure.  This binding site lies within the extracellular 
part of TrkB known as the immunoglobulin-like domain 5 (please refer to Trk receptor 
structure – illustration 1.3) (Holden, Asopa et al. 1997; Watson, Fahey et al. 2006).  The 
TrkBd5 receptor analogue acts by binding to BDNF or NT-4, which in turn out competes with 
any extracellular BDNF and/ or NT-4 ligand.  This 5th domain structure was cloned, purified 
and tested in vitro and in vivo for its inhibitory effects on TrkB signalling.   
TrkBd5 binds with NT-4 and BDNF ligands with no significant binding with NGF (Banfield, 
Naylor et al. 2001; Naylor, Robertson et al. 2002).  Upon nerve injury BDNF induced release 
from microglia is observed causing chronic constriction injury.  TrkBd5 has been shown to 
attenuate the effects of chronic constriction injury (neuropathic pain) of the sciatic nerve 
from 20 day old rats by binding to BDNF (Lu, Biggs et al. 2009).  
 
 
 
4.1.4 p75NTR cleavage and signalling inhibition 
Since the latency III lines characterised in chapter 3 express both high and low affinity 
receptors for BDNF and NT-4, p75NTR signalling will also be of interest within this study.  
Upon phorbol ester treatment within cells expressing p75NTR, a zinc dependent 
metalloprotease cleavage thought to be an -secretase, induces shedding of the 
extracellular domain, leaving a membrane bound carboxy-terminal fragment (CTF) 
(DiStefano, Chelsea et al. 1993; Zampieri, Xu et al. 2005). p75NTR, like the Notch receptor, 
then transmits its signals to the nucleus via an intracellular domain (ICD), cleaved from the 
transmembrane region of a CTF fragment by -secretase (Kanning, Hudson et al. 2003).  A 
study by Kenchappa R. S., et al, using sympathetic neurones from rats, examined p75NTR 
cleavage upon ligand binding (Kenchappa, Zampieri et al. 2006).  After a 2 day culture in 
20ng/ml NGF, cells were treated with the p75NTR high affinity ligand, ProBDNF, it’s low 
affinity receptors, BDNF and NGF as well as PMA for up to 24 hours.  PMA, BDNF and 
ProBDNF ligands induced full length receptor (~75kDa) cleavage, producing a CTF (~30-
24kDa), and an ICD fragment (~25-19kDa), whereas NGF ligand did not induce receptor 
cleavage.  These p75NTR domains were identified by western blotting.  The anti-p75NTR 9992 
antibody used within the publication was provided by Moses Chao at New York University 
School of Medicine, USA.  This antibody is a rabbit polyclonal, raised against the intracellular 
domain of p75NTR which recognises the full length p75NTR protein, the CTF as well as the ICD 
(Kanning, Hudson et al. 2003).  This antibody was used within this study to detect any p75NTR 
protein in the characterised Burkitt’s lymphoma B cell lines and to show possible p75NTR 
signalling by receptor cleavage.    
Previously, it has been shown that ProBDNF or ProNGF can induce cell apoptosis in 
sympathetic neurons via p75NTR by outcompeting their mature equivalent proteins BDNF or 
NGF which promote cell survival, growth, and differentiation (Chun and Patterson 1977; 
Teng, Teng et al. 2005).  The co-expression of TrkA and p75NTR, within these sympathetic 
neurons prevents ProNGF from stimulating p75NTR proteolysis but signalling via the mature 
form, NGF ligand. This is consistent with previous findings that TrkA expression inhibits -
secretase dependent p75NTR cleavage (Kanning, Hudson et al. 2003). 
Upon cleavage, the ICD can bind to varying proteins involved in cell apoptosis.  These 
include, TRAF6, NRIF, NADE, Rac, NRAGE and Necdin.  For apoptosis induction, the C-
terminal domain of TRAF6 (TNF receptor associated factor) directly interacts with the death 
effector domain of pro-caspase 8, and the N-terminal RING domain, which is required for 
activation of caspase 8 (Khursigara, Orlinick et al. 1999; Yeiser, Rutkoski et al. 2004).  NRIF 
(neurotrophin receptor interacting factor) is a ubiquitously expressed zinc finger protein 
which is a selective mediator for p75NTR-dependent JNK activation and apoptosis in 
sympathetic neurones (Casademunt, Carter et al. 1999; Linggi, Burke et al. 2005).  NRAGE 
(Neurotrophin Receptor–interacting MAGE homolog) binds p75NTR in the presence of NGF 
and can block the physical associated between p75NTR and TrkA (Salehi, Roux et al. 2000).  
When overexpressed in sympathetic neuron precursor cells, NRAGE induces NGF dependent 
apoptosis and cell cycle arrest.  Necdin, also a member of the MAGE family, is a growth 
suppressor protein predominantly expressed in post-mitotic neurones.  When p75NTR is over 
expressed in neuroblastoma cells, necdin is translocated to the proximity of the plasma 
membrane, reducing its association with the transcription factor E2F1, and enabling E2F1-
induced death (Kuwako, Taniura et al. 2004).  
The expression of p75NTR protein will be the initial task when investigating p75NTR signalling 
in Mutu latency III clone J8 cells.  Next, the induction of apoptosis by ProBDNF will then be 
explored.  Possible p75NTR autocrine signalling in Mutu latency III clone J8 cells will then be 
addressed with the use of p75NTR antibodies to neutralise signalling.   
These antibodies were obtained from collaboration with Robert A. Rush from Flinders 
University in Australia.  Three functional monoclonal antibodies to human p75NTR were 
raised in knockout mice as illustrated within a publication by Mary-Louise Rogers et al,. 
(Rogers, Atmosukarto et al. 2006).  These three monoclonal antibodies were names MLR1, 
MLR2 and MLR3.  They recognise the ligand binding, extracellular domain region of p75NTR 
and can be used to detect p75NTR protein by western blotting, flow cytometry and 
immunohistochemistry methods.  MLR1, MLR2 and MLR3 are biologically active antibodies 
that can neutralise NGF induced cell death in an NSC-34 mouse cell line which expressed 
p75NTR but lack TrkA (Turner, Murray et al. 2004). 
 
 
 
 
 
 
 
 
  
  
  
 
4.2 Results 
4.2.1   The expression of TrkB protein in Burkitt’s lymphoma B cell lines by 
western blotting methods 
 
To screen the previously characterised Burkitt's lymphoma lines for TrkB protein, two 
antibodies recognising varying TrkB receptor epitopes were applied for protein analysis.  
The first being, TrkB (794) which recognises an epitope corresponding to a peptide at or 
around the 794 amino acid, within the C-terminal cytoplasmic domain for TrkB.  This 
antibody therefore can only recognize full length TrkB isoforms A and C.   
20g of Mutu negative clone 3, Mutu latency I clone 59, Mutu latency III clone J8 and IARC-
171 protein samples were loaded per well.  Once run within a 7% polyacrylamide with SDS 
gradient gel (Tris-Acetate buffer) under reducing conditions, samples were transferred onto 
PVDF membranes.  Samples were probed using the TrkB (794) antibody alone or TrkB (794) 
antibody pre-treated with its specific peptide (figure 4.1.1).  A table was drawn illustrating 
known TrkB isoforms and their core or glycosylated molecular weights.  These molecular 
weights were obtained from the National Center for Biotechnology Information (NCBI), 
protein database linked with PubMed.     
All Burkitt’s lymphoma B cell lines analysed expressed a ~70kda band.  According to the TrkB 
isofrom table shown in figure 4.1.1 this ~70kDa protein does not correspond to any of the 
known TrkB isoforms and is therefore an unknown protein. Mutu latency III clone J8 and 
IARC-171 lines on the other hand, expressed a ~145kda protein which may indicate 
glycosylated full length TrkB protein.  This full length TrkB protein was not detected in EBV 
negative clone 3 and EBV latency I clone 59 lines.   
As expected, the peptide blocker prevented antibody binding to TrkB protein within all 
Burkitt’s lymphoma samples although the unknown ~70kDa band was also diminished 
within all the cell lines analysed.  His led to question wether the 70 kDa protein is a true 
TrkB protein.   
There are publications where a 70kDa TrkB protein had been detected by western blotting 
methods.  For example, a 70kDa protein can be detected in TRK-transformed NIH3T3 cells 
(Mitra, Martin-Zanca et al. 1987; Ohmichi, Decker et al. 1991).  This 70kDa TrkB protein was 
shown to be preferentially located within the cytoplasm and can be phosphorylated in vivo, 
therefore the 70kDa band observed in all Burkitt’s lymphoma lines may represent a genuine 
TrkB protein, however it is unknown which TrkB isoform is detected.  For this to be further 
investigated mass spectronomy would be needed to secuence the unknown peptide for 
verification. 
The second antibody used to probe for TrkB protein was Anti-TrkB (H181) which recognises 
an epitope corresponding to a peptide at or around the 181 amino acid, within the N-
terminal extracellular domain for TrkB.  At this epitope, the antibody is able to recognise full 
length TrkB gp145, truncated TrkB-T1 and truncated TrkB T-Shc isoforms.   
20g of Mutu negative clone 3, Mutu latency I clone 59, Mutu latency III clone J8, IARC-171 
protein samples and 2g of wild type (WT) HEK293 and TrkB transfected HEK293 cell 
samples were loaded per well.  Once run within a 4% to 12% polyacrylamide with SDS 
gradient gel (Bis -Tris buffer) under reducing conditions, samples were transferred onto 
PVDF membranes.  All Burkitt’s lymphoma lines analysed express ~61kDa, ~59kDa and 
~53kDa proteins which may represent unglycosylated TrkB T-Sch (isoforms D), 
unglycosylated TrkB T-Sch (isoforms E) and unglycosylated TrkB T-1 (isoform B), respectively 
(figure 4.1.2).   
Detected proteins running at a kDa range lower than ~51kDa were also observed on the 
western blot, however these proteins do not correspond to any known TrkB isoforms and 
may indicate degraded protein or the antibody may detect unspecific protein.  To repeat 
this experiment I would be useful to initially do an SG substrate blocking step first.  This 
method blocks the secondary antibody from binding directly onto protein transferred onto a 
PVDF which would in turn be detected by alkaline phosphatase chemiluminescent enzyme. 
The same blot is magnified in figure 4.1.3 displaying TrkB isoforms at higher molecular 
weights.  The ~94kDa to ~95kDa protein may represent unglycosylated full length TrkB 
protein which was observed in all Burkitt’s lymphoma lines and TrkB transfected HEK293 
cells.  The ~94kDa band is thought to be full length TrkB core protein since HEK293-TrkB 
cells were transfected with just the full length TrkB protein, hence truncated isoforms would 
not be detected.  Hence, the detection of only unglycosylated full length TrkB protein in 
transfected HEK293 cells is further indication that the ~61kDa to ~53kDa bands detected 
may represent truncated TrkB protein since these bands are absent within the transfected 
line. 
The unglycosylated TrkB core peptide is also registered to migrate at around the 95kDa 
molecular weight, according to the NCBI, protein database.  It is however unknown why 
transfected TrkB protein is not glycosylated within these HEK293s.  This is unexpected since 
previous publications on TrkB transfected HEK293 cells show fully glycosylated full length 
TrkB protein, viewed on western blots (Narisawa-Saito, Iwakura et al. 2002).    
On the other hand, weak expression of the glycosylated ~145kDa, full length TrkB protein 
was observed within Mutu latency III clone J8 and a stronger band within IARC 171 cell 
samples but not the EBV negative or latency I samples.   
To ensure the ~94kDa to ~95kDa bands suspected to be unglycosylated full length TrkB, and 
the ~145kDa bands suspected to be glycosylated full length TrkB protein are genuine 
proteins, all cell lines shown in figure 4.1.3 should ideally be treated in tunicamycine and/ or 
PNGase.  These inhibitors disrupt N-glycosylation sites; therefore the predicted results 
would indicate all Burkitt’s lymphoma lines and TrkB transfected HEK293 lines to express 
the ~94kDa to ~95kDa unglycosylated TrkB protein and the detection of the ~145kDa bands 
detected in latency III lines should be diminished.  This experiment was not competed due 
to time restrictions.       
Also, the expression of TrkB full length protein does not directly correspond to the PCR data 
concluded from the previous chapter, where TrkB isoform variants corresponding to full 
length TrkB mRNA were only detected within latency III Burkitt’s lines.  Within figure 4.1.3, 
the expression of full length TrkB protein is presumed to be expressed within all Burkitt’s 
lymphoma cell lines, nonetheless the protein expressed seemed to migrate at ~94 to 
~95kDa which may represent the unglycosylated, core TrkB protein.  On the other hand, 
protein migrating at ~145kDa which may represent glycosylated full length TrkB protein was 
only detected within latency III lines.   
The lack of detectable full length TrkB mRNA variants and yet the expression of full length 
unglycosylated TrkB protein within EBV negative and latency I lines may be due to the RT-
PCR method which being too insensitive to detect full length TrkB transcripts in EBV 
negative Burkitt’s lymphoma lines that may be present but at lower levels compared to the 
latency III lines.  It is therefore also possible that EBV latency may upregulate full length TrkB 
mRNA transcript levels and this may influence the upregulation of glycosylated full length 
TrkB protein.  
In conclusion, Burkitt’s lymphoma cells lines that express full length TrkB mRNA variants also 
seem to express glycosylated full length TrkB protein as observed with the use of two 
different Anti-TrkB antibodies.  It would however be useful to verify the multiple proteins 
observed by extracting protein from a western blot gel and extracting the peptides running 
at varying molecular weights.  These proteins would then be sequenced to confirm the 
varying TrkB isoforms detected.  Another method for verification could involve transfecting 
Mutu latency III lines with a full length specific TrkB expression silencer such as an siRNA.  It 
would also be of great benefit to compare results from this experiment with the 
transfection of an siRNA that specifically targets truncated TrkB isforms.  Any bands 
diminshed from the samples on a western blot may help also identify the proteins observed.   
 
Add figs 4.1  
 
 
 
  
 
4.2.2   The expression of TrkB protein in Burkitt’s lymphoma B cell lines by 
confocal imaging 
 
The TrkB (H-181) antibody was also used to screen for TrkB proteins using confocal imaging 
analysis.  Burkitt’s lymphoma lines were permeabilized with 0.1% saponin and probed for 
TrkB protein and DAPI nuclear stain (figure 4.2).  A FITC- conjugated secondary antibody was 
used to observe any specific TrkB antibody bound to cells and viewed under confocal 
microscopy.  Any TrkB antibody staining observed was compared to its non-immune isotype 
control.   
The images shown in figure 4.2.1 are representatives of two independent experiments.  
Mutu negative clone 3 and Mutu latency I clone 59 staining were weak but positive (figure 
4.2.1a) compared to Mutu latency III clone J8 and IARC-171 cells which show stronger TrkB 
protein staining (figure 4.2.1b).  It can be noted that the positive TrkB stain is specific due to 
the lack of FITC-conjugated staining within the isotype controls for each cell line analysed. 
To directly compare TrkB staining images between the Burkitt’s lymphoma cell lines, the 
third confocal staining experiment is illustrated in figure 4.2.2 showing just TrkB staining.  
The isotype controls were negative for this set of images (data not shown), however an 
example of the control staining is shown for the positive control cell line KMS-11.  From 
these confocal images and the TrkB western blot results, it can be conclude that higher TrkB 
protein levels were observed with increasing EBV latency phenotype. 
 
Analysing the western blotting data and the confocal images shows some correlation 
between the two methods for TrkB protein expression. Looking at western blots shown in 
figures 4.1.1 and 4.2.1, total TrkB protein levels seem to increase slightly from cells 
displaying an EBV negative phenotype compared to those with a latency III phenotype due 
to the number of bands detected.   
This correlation of increasing total TrkB protein with increasing EBV latency is more clearly 
defined within the confocal images.  The reason for this may be that the TrkB (H181) 
antibody may have higher affinity for certain TrkB isoforms when applied to PVDF 
membranes for western blotting as opposed to when it is applied to permeablised cells for 
confocal imaging.  Hence more TrkB isoform structures and possibly degraded TrkB protein 
may be detected on a western blot membrane compared to permeablised cells.    
           
So far it can be concluded that all Burkitt’s lymphoma B cell lines analysed express truncated 
TrkB protein whereas those displaying latency III characteristics reveal higher total TrkB 
protein staining and detectable glycosylated full length TrkB protein. 
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4.2.3   The expression of p75NTR protein in Burkitt’s lymphoma B cell lines  
Here, p75NTR protein expression levels were analysed within the same Burkitt’s lymphoma 
lines.   A p75NTR specific antibody (p75NTR 9992) provided by M.V. Chao, was applied for 
expression analysis by western blotting methods.  This antibody recognises the entire 
cytoplasmic domain of the human p75NTR structure.  20g of protein samples were run 
within a 4 to 12% polyacrylamide with SDS gradient gel (Bis-Tris buffer) under reducing 
conditions and transferred onto PVDF.  Samples were then probed for p75NTR protein (figure 
4.3).   
The human neuroblastoma cell line, Kelly was used as a positive control for p75NTR protein 
expression.  Several immunoreactive protein species were detected within the positive 
control, as well as all Burkitt’s lymphoma lines.  As well as the full length p75NTR ~75kda 
band, various bands with molecular weights ranging from ~35kDa to ~65kDa were also 
observed on the membrane within all cell lines analysed.  These bands possibly represent 
degraded protein or immature nascent protein that is not fully glycosylated.    
As shown in chapter 3, all Burkitt’s lymphoma B cells express p75NTR mRNA with the 
exception of Mutu negative clone 4 and Mutu latency I clone 179 (figure 3.3.5).  However 
p75NTR protein levels in Mutu latency I clone 179 lines were detected, although weaker 
compared to other Burkitt’s samples (figure 4.3).  A discrepancy between Protein and RT-
PCR expression was also observed in the expression of p75NTR protein in Mutu negative 
clone 4 line.  This may be due to the sensitivity of the RT-PCR method in its lack of detecting 
low levels of p75NTR transcripts, particularly in Mutu negative clone 4 and Mutu latency I 
clone 179. On the other hand, the correlations between p75NTR mRNA and protein 
expression levels are similar within all other Burkitt’s lymphoma lines analysed.  
Next, p75NTR protein expression was analysed in the Burkitt’s lymphoma cell lines by flow 
cytometry.  Two p75NTR specific antibodies (MLR2 and MLR3), obtained from a collaboration 
with Robert A. Rush, were compared (Rogers, Atmosukarto et al. 2006). 
Initially, to optimise antibody concentrations, Kelly cell line was used as a control.  
Intracellular as well as extracellular expression was detected from both p75NTR antibodies 
MLR2 and MLR3 (Figure 4.4.1).  Higher levels of p75NTR protein were detected when Kelly 
cells were permablised compared to the live cell staining.  Intercellular p75NTR expression 
levels were then analysed in Burkitt’s lymphoma B cells using both MLR2 (figure 4.4.2) and 
MLR3 (figure 4.4.3). 
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As shown in figure 4.4.2 and 4.4.3, detectable p75NTR protein was observed in all Burkitt’s 
lymphoma lines.   
However, EBV negative Mutu clone 3 lines expressed lower levels of p75NTR protein 
compared to all other EBV positive lines analysed.   This is true for both MLR2 and MLR3 
p75NTR antibodies tested by flow cytometry, however these p75NTR protein levels do not 
correlate with data obtained from p75NTR mRNA expression by RT-PCR (figure 3.3.5) or 
p75NTR expression by western blotting (figure 4.3).  The differences in protein correlation 
levels maybe due to different antibody specificities between the anti-p75NTR MLR antibodies 
and that obtained from M.V. Chao.   
As discussed by L. He and M.H. Fox, the differences in flow cytometry and western blotting 
methods include the accessibility of protein binding for the monoclonal antibodies.  Cell 
lysate proteins separated by electrophoresis and transferred to membrane are more 
accessible compared to protein within intact, permeablised cells (He and Fox 1996). 
Differences in flow cytometry and western blotting detection levels may also be altered 
depending on how the cells are permeablised for confocal staining.  Burkitt’s lymphoma 
lines shown in figure 4.2.2 were fixed in 2% paraformaldehyde then permeablised in 0.1% 
saponin, this may have altered the epitope on the cell surface, affecting antibody specificity 
and binding.   
 
However, it can be concluded that all Burkitt’s lymphoma cell lines characterised, express 
p75NTR protein, regardless of their EBV latency phenotype. 
 
4.2.4   The expression of BDNF and NT-4 protein in Burkitt’s lymphoma B cell 
lines  
 
Since Burkitt’s lymphoma cell lines express TrkB and p75NTR receptor proteins, it was worth 
questioning protein expression of the receptor ligands, BDNF and NT-4.  This was completed 
using specific antibodies for expression analysis by western blotting methods.  20g of 
protein samples were run within a 4 to 12% polyacrylamide with SDS gradient gel (Bis-Tris 
buffer) under reducing conditions and transferred onto PVDF.  Initially, samples were 
probed using an Anti-NT-4 primary antibody (figure 4.5.1).   
All cell lines expressed a ~14kDa NT-4 specific protein, as compared to human recombinant 
NT-4 control (figure 4.5.1).  The ~28kDa band observed within the recombinant protein 
sample may correspond to a mature NT-4 dimer but was not observed within any of the cell 
samples analysed, however this maybe due to the concentration of lysate added to the well, 
hence it would be useful to compare NT-4 protein expression in higher Burkitt’s lymphoma 
cell lysate concentrations.   
To compare the data obtained from the NT-4 western blot, NT-4 protein expression was 
analysed by flow cytometry.  Burkitt’s lymphoma cell lines together with the NT-4 positive 
control line (Colo-369) were permeabilized in 0.1% saponin and stained for NT-4 (figure 
4.5.2).  Gated cells are shown within the dot plots.  These gates were then used to acquire 
10,000 permeabilized and stained cells, measuring NT-4 expression levels using FL-1 laser 
settings.  Histograms were used to display FL-1 levels for each cell line comparing secondary 
antibody alone stained cells, isotype control with secondary antibody stained cells and 
primary antibody with secondary antibody stained cells.  Add figs 4.5  
The flow cytometry data reveals expressed of NT-4 protein in all Burkitt’s lymphoma lines 
analysed supporting the results obtained from NT-4 the western blots.   
Next BDNF protein expression was analysed by western blotting methods (figure 4.6.1).  This 
BDNF blot revealed many bands of various sizes.  Mature BDNF is presumed to run at 
~14kDa, as compared to the human recombinant BDNF control.  All Burkitt’s lymphoma B 
cell lines expressed this ~14kDa band.  As for the BDNF homodimer which is alleged to run 
at ~27kDa, was detected only within the Mutu latency III clone J8 cell line.      
Unprocessed, Pro-BDNF is presumed to run at ~35kDa, whereas its dimer is possibly what is 
observed at ~55kDa, ~57kDa and/ or ~60kDa.  The multiple bands detected may also 
correspond to the multiple BDNF variants illustrated in table 4.1, which may be post-
translationally modified.  These BDNF variants are further discussed within this chapter’s 
discussion section.  Calregulin was used as the loading control.  
On the other hand, although the levels are low, BDNF protein was detected within all 
Burkitt’s lymphoma lines using flow cytometry analysis (figure 4.6.2).  These protein levels 
show some correlation with the multiple bands detected by western blotting methods.   
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Looking at the ~52 to ~60kDa ProBDNF bands in figure 4.6.2, stronger levels of protein are 
observed in IARC-171, latency I and III Mutu lines.  As for the EBV negative line, the ~60kDa 
band is absent and shows lower levels of the ProBDNF protein presumed to run at ~55kDa 
and ~57kDa.  Hence these ProBDNF bands may be readily detected by flow cytometry 
analysis. 
In all, like NT-4, BDNF protein can be detected in all Burkitt’s lymphoma B cell lines analysed. 
However both NT-4 and BDNF are secreted proteins, hence the best protein expression 
analysis method is by using an ELISA and comparing intracellular and extracellular protein.  
Research funds were only available to purchase one ELISA kit, which detected BDNF protein. 
 
Upon secretion into the cellular environment, BDNF can bind and signal via extracellular 
TrkB and/ or p75NTR receptor domains.  Therefore, intracellular and extracellular BDNF 
protein was measured for each Burkitt’s lymphoma B cell line by ELISA (figure 4.7).  When 
cells from culture were centrifuged, pellets were used as intracellular samples, whereas 
supernatant was used as extracellular samples.  For intracellular samples, 106 cells were 
lysed using the ELISA homogenisation buffer (review ELISA materials section within the 
materials and methods chapter for details).  Specifically bound BDNF protein was detected 
by horseradish peroxidase enzyme, colour detection.  OD values (read at 450nM) were 
collected for standard BDNF protein and for each cell line.  BDNF concentrations for each 
cell line sample were then calculated using the linear regression equation from the standard 
curve graph (y = 0.001x + 0.0782).  Kelly and KMS-11 cell lines were used as positive controls 
for the expression of BDNF protein.  Add figs 4.7  
In conclusion all Burkitt’s lymphoma B cell lines expressed intracellular BDNF protein.  Mutu 
cell lines expressed between 48.3 to 52.3 pg/ml intracellular BDNF protein.  IARC 171 on the 
other hand expressed 110.3 pg/ml intracellular BDNF protein.  Secreted BDNF obtained 
from cell culture supernatant was observed in all Burkitt’s lines excluding Mutu negative 
clone 3.   
Importantly, it is worth noting that the levels of intracellular and extracellular BDNF in 
MUTU latency I clone 59 and MUTU latency III clone J8 have very similar intracellular and 
extracellular BDNF concentrations, although IARC 171 cell line expressed the highest level of 
extracellular BDNF protein within all lines analysed.  As for the control lines, Kelly and KMS-
11, the highest levels of intracellular BDNF protein were recorded however, very low to 
undetectable levels of extracellular BDNF protein were observed.  
BDNF protein was not detected in the media cells were grown in or the background control 
used to dilute the BDNF standards.  Hence, all BDNF protein detected was obtained solely 
from the cells.  Burkitt’s lymphoma cells lines displaying varying EBV latency phenotypes can 
therefore secrete detectable BDNF protein within the cellular environment.      
 
 
 
 
 
 
4.2.5 The effects on cell survival upon TrkB:p75NTR autocrine signalling 
inhibition in Mutu latency III clone J8 Burkitt’s lymphoma B cell line 
 
So far, it can be presumed that glycosylated full length TrkB receptors may dimerise with 
themselves and/ or with p75NTR and induce autocrine signalling upon NT-4 or/ and secreted 
BDNF binding in Burkitt’s lymphoma cell lines displaying a latency III phenotype.   
 
To question whether TrkB:p75NTR signalling is implicated in cell survival, a dose response to 
their inhibitors were utilized to assess the levels of live, early, late and necrotic cells 24 
hours post treatment.  Cells were then stained with a membrane permeable fluorochrome-
labelled dye, PhiPhiLux which enables the measurement of caspase 3 activities, 
distinguishing early and late apoptotic cells.  The fluorochrome generated by proteolytic 
cleavage of the caspase 3 substrate is proportional to the concentration of activated 
caspase 3 within the cell sample.  Prior to sample measurement by flow cytometry, 
propidium iodide (PI) was added to each cell sample to distinguish live cells from necrotic 
cells.    
TrkB signalling was initially inhibited by treating cells with TrkBd5 which inhibits the fifth 
domain on the TrkB receptor (figure 4.8.1).  A dose range from 1M to 50M TrkBd5 
inhibitor concentration was added to Mutu latency III clone J8 cells for 24 hours.  Control 
media (CM) and Tris buffer (TRIS), the vehicle control for TrkBd5 were used as control 
treatments compared to TrkBd5 treated cells.  Mutu latency III clone J8 cells treated with 
1M TrkBd5 enabled cells survival and increased the number of live cells compared the 
control treated cells.      At a concentration of 5M and 10M TrkBd5, reduced levels of live 
cells were observed, with higher early, late apoptotic and necrotic Mutu latency III cells.  
However 45.7% cells were early apoptotic at a concentration of 25M whereas 71.1% of 
cells were late apoptotic at a concentration of 50M.  Therefore by inhibiting TrkB signalling 
in Mutu latency III clone J8, cells die from apoptosis. 
 
The effects observed by TrkBd5 inhibition were compared to another Trk inhibitor, K252a.  
Between 50nM and 5M concentrations of K252a live cell numbers decreased, as late 
apoptotic cell numbers increased (figure 4.8.2).  Representative mean cell percentages from 
three independent experiments are displayed together with their standard error bars.  This 
result is similar to that observed by inhibiting TrkB signalling alone, where cells die from 
apoptosis at higher concentrations of inhibitors.  
To question whether p75NTR signalling is also involved in cell survival, increasing 
concentrations of the neutralising antibodies MLR2 and MLR3 were added to Mutu latency 
III clone J8 cells (figure 4.8.3).  Interestingly, inhibiting p75NTR signalling by steric hindrance 
of extracellular p75NTR interactions with the specific antibodies does not inhibit cell survival.  
On the contrary, by adding p75NTR antibody MLR2 at a concentration of 50g/ml and MLR3 
at 10g/ml, the highest level of live cells were observed.  Therefore unlike TrkB, inhibiting 
p75NTR signalling does not induce cell death but may enable cell survival in Mutu latency III 
clone J8 cells. 
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Since downstream TrkB signalling may involve Erk and Akt adapter proteins, the next 
experiment was to inhibit either Erk or Akt signalling and to question their effects on cell 
survival (figure 4.8.4).  Between 1M and 200M Erk and Akt inhibitor concentrations were 
used in a dose response assay.  Inhibiting Akt signalling by adding increasing concentrations 
of LY294002 resulted in a decrease in live cells but a gradual increase in necrotic cells.  As for 
Erk inhibition, PD98059 used between 1M to 50M concentrations seemed to show similar 
live, early, late apoptotic and necrotic levels of cells with some late apoptotic cells and yet 
more necrotic cells compared to those control treated.  Highest levels of late apoptotic cells 
were observed in cell treated in 100M of PD98059, whereas those treated in 200M 
PD98059 show the highest level of necrotic cells.  Hence, inhibiting either Akt or Erk 
signalling by adding their inhibitors at very high concentrations for 24 hours, induces cell 
necrosis in Mutu latency III clone J8 lines.  
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At this point it can be concluded that Mutu latency III clone J8 cells express both TrkB and 
p75NTR receptors and their ligands BDNF and NT-4.  Inhibiting TrkB signalling hinders cell 
survival by inducing apoptosis, while p75NTR inhibition may slightly enhance cell survival.  
However for this question to be looked at in more detail, it would be useful to treat cells in 
the same inhibitors and analysed cell lysates by a western blot probed for Poly (ADP-ribose) 
polymerase and Caspases such as 3, 8 or 9.  Unfortunately due to time constraints and 
available funds these antibodies were not included in the investigation.     
 
From these dose response experiments, the working concentrations of the inhibiters were 
determined.  K252a was used at 0.5M concentration, TrkBd5 used at 4.5M, p75 
neutralising antibodies (MLR2 and MLR3) used at 100g/ml and Akt inhibitor (LY294002) 
and Erk inhibitor (PD98059) used at 50M/ml.  To ensure these inhibitors are targeting TrkB 
signalling, the next step was to question TrkB phosphorylation upon treatment with these 
TrkB inhibitors.    
 
 
 
 
 
 
 
4.2.6 The inhibition of autocrine dependent TrkB phosphorylation in Mutu 
latency III clone J8 Burkitt’s lymphoma B cell line 
 
K252a is the most frequently used tyrosine kinase inhibitor within publications on 
neurotrophic factor signalling pathways.  However K252a is known to inhibit TrkA, TrkB and 
TrkC signalling whereas TrkBd5 is a TrkB receptor specific inhibitor.  TrkBd5 was therefore 
also utilised to question TrkB phosphorylation in MUTU latency III clone J8 cells.  Since 
p75NTR co-localises with TrkB during NT-4 and/ or BDNF dependent signalling, a neutralising 
p75NTR antibody (MLR2) was also used to question autocrine signalling.   
ProBDNF protein has a higher affinity to p75NTR compared to TrkB receptor.  The effects of 
exogenous ProBDNF treatment were also analysed and compared to the inhibition of NT-4 
and BDNF neutralisation as well as TrkB and p75NTR inhibition, with the addition of ProBDNF 
treatment.   
Neutralising antibodies specific for TrkB ligands, NT-4 and BDNF were included in the 
investigation to investigate if TrkB receptor phosphorylation is ligand dependent.  These NT-
4 and BDNF signalling inhibitors were then compared to the effects of the well documented 
K252a inhibitor.   
 
Mutu latency III clone J8 cells were treated with these signalling inhibitors for one hour.  
20g of cell lysate samples were collected and run within 10% polyacrylamide with SDS 
gradient gels (Bis-Tris buffer) under reducing conditions and transferred onto PVDF.  
Samples were probed using a TrkB receptor antibody which recognises phosphorylated 
tyrosine residue Y705 protein (figure 4.9).  These blots were then stripped and re-probed 
with an antibody that recognises full TrkB protein (TrkB H-181).   
Mutu latency III clone J8 cells expressed both NT-4 and BDNF ligands.  Inhibiting NT-4 or 
BDNF individually by steric hindrance of extracellular NT-4 and BDNF interactions with their 
specific antibodies (Anti-NT-4 used at 10g/ml and Anti-BDNF used at 20g/ml), TrkB 
phosphorylation was maintained; therefore NT-4 and BDNF are individually able to 
phosphorylate TrkB.  However when both ligands were inhibited (NT-4 Ab + BDNF Ab) TrkB 
phosphorylation is undetectable. 
Mutu latency III clone J8 cells also express both p75NTR as well as full length TrkB receptors.  
When p75NTR alone was inhibited (Anti-p75NTR used at 100g/ml) TrkB phosphorylation was 
still observed, however, by adding TrkBd5 inhibitor (TrkBd5 used at 4.5M/ml), lower levels 
of TrkB phospho-protein were detected when compared to control treated Mutu J8 cells.  
On the other hand, by inhibiting both TrkB and p75NTR receptors (p75NTR Ab + TrkBd5) 
undetectable levels of TrkB phosphoprotein are observed.    
Treatment with exogenous ProBDNF (ProBDNF used at 50ng/ml), which binds p75NTR was 
able to inhibit TrkB phosphorylation.  Together with the inhibition of TrkB and p75 receptors 
(ProBDNF + p75NTR Ab + TrkBd5) or NT-4 and BDNF ligands (ProBDNF + NT-4 Ab + BDNF Ab), 
ProBDNF treatment resulted in undetectable levels of phospho-TrkB.  
K252a on the other hand inhibits Trk kinase activity which when added alone (at 0.5M/ml) 
inhibited TrkB phosphorylation.  Upon the addition of human recombinant NT-4 and human 
recombinant BDNF exogenous TrkB ligands (both added at 50ng/ml), the levels of inhibition 
by K252a were slightly reduced by the observation of weak TrkB phospho-protein in cells 
treated in K252a plus the two human recombinant TrkB ligands. 
Control cells were treated in either control media, DMSO, vehicle control for K252a or TRIS 
buffer, vehicle control for TrkBd5 for one hour.  TrkB Phosphorylation was observed within 
all control cell samples, showing autocrine signalling via TrkB and p75NTR and their ligands 
NT-4 and BDNF.     
Although the Anti-phospho-TrkB antibody used, recognised the ~95kDa band, protein 
running at ~50kDa to 10kDa were observed.  Initially it was suspected that these unknown 
lower molecular weight bands may correspond to proteolytically degraded TrkB phosphor 
protein, however cell lysate samples were prepared with the appropriate protease 
inhibitors.  Other possible explanations may involve unspecific secondary binding to lower 
molecular weight proteins.  To eliminate this in future experiments it would be of interest to 
use an SG substrate blocker prior to the primary antibody incubation.    
Importantly used as a control, when this blot was stripped and reprobed for TrkB protein 
expression using the Anti-TrkB (H181) antibody, all cell samples treated within the varying 
inhibitors expressed the full length glycosylated (~145kDa) and unglycosylated (~92kda) 
TrkB proteins.  Although, Mutu latency III clone J8 cells treated in Anti-p75NTR antibody, the 
cell lysate concentration is slightly lower compared to the other cell samples on the blot.  
This inaccuracy is due to loading amounts during sample preparation.   
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In conclusion, inhibiting both NT-4 and BDNF ligand signalling or both TrkB and p75NTR 
receptors, inhibits TrkB phosphorylation.  However when either ligand or receptor is 
inhibited individually, TrkB phosphorylation is maintained.  Therefore TrkB phosphorylation 
is dependent on TrkB, p75NTR and both NT-4 and BDNF.  The addition of ProBDNF however, 
hinders this TrkB:p75NTR and NT-4:BDNF signalling pathway.  
Although the results from the western blot are informative of TrkB phosphorylation in Mutu 
latency III clone J8 lines, to confirm that the addition of either Anti-NT-4 and Anti-BDNF 
neutralising antibodies, TrkBd5 and Anti-p75NTR neutralising antibody, ProBDNF protein or 
K252a truly inhibit TrkB phosphorylation, the effects of these inhibitor combinations could 
be compared to control treated in Mutu latency III clone J8 cells treated in Lambda Protein 
Phosphatase.  This enzyme inhibits phosphorylated serine, threonine and tyrosine residues.   
Also, to ensure that Anti-p75NTR antibody specifically targets p75NTR signalling, an Anti-
Phospho-p75NTR antibody should be incorporated in the above experiment.  However, 
during the time these experiments were conducted, this antibody was not commercially 
available. 
 
The next sets of experiments were with taken to ask whether TrkB:p75NTR downstream 
signalling involves the Erk and/or Akt adaptor proteins.  
 
 
 
4.2.7 The effect on cell proliferation upon TrkB:p75NTR autocrine signalling 
inhibition in Mutu latency III clone J8 Burkitt’s lymphoma B cell line 
 
To question the functional outcomes for TrkB:p75NTR signalling in Mutu latency III clone J8 
lines, inhibitors were added in culture to observe any changes in cell proliferation.  Cells 
were stained with CFSE dye then cultured with varying TrkB: p75NTR signalling inhibitors for 
48 hours.  Histograms were plotted showing CFSE levels on day two; control media treated 
cells were compared to varying inhibitors as illustrated in figure 4.10.     
Anti-IgM (2g/ml) and Mitomycin C (40g/ml) were used as positive controls to inhibit cell 
proliferation (figure 4.10.1).  Both Anti-IgM and Mitomycin C slowed cell proliferation in 
Mutu latency III clone J8 cells as expected.  Inhibiting Akt and Erk phosphorylation by 
treatment with their inhibitors LY294002 and PD98059 respectively, also slowed cell growth.  
PD98059, however, inhibited cell proliferation to a lesser extent compared to LY294002. 
Adding the tyrosine kinase inhibitor, K252a inhibits cells proliferation in latency III Mutu 
cells.  To ensure tyrosine kinase signalling was inhibited, exogenous human recombinant 
TrkB ligands BDNF and NT-4 were also added together with the K252a treatment which also 
prevented cell growth.  This is further confirmation that inhibiting K252a inhibits the TrkB 
signalling pathway.  DMSO was used as the vehicle control for K252a, which slowed cell 
growth but to a lesser extent compared to K252a. 
Inhibiting TrkB ligands BDNF or NT-4 individually had no effect on cell proliferation, however 
when both ligands are inhibited within one treatment, cell proliferation was reduced in 
Mutu latency III clone J8 cells (figure 4.10.2). 
The specific inhibitor for TrkB receptor, TrkBd5, also reduced cell proliferation.  This 
inhibitor was compared to its vehicle control Tris buffer which had no effect on cell growth.  
Moreover, inhibiting the low affinity receptor p75NTR in Mutu latency III clone J8 cells had no 
effect on cell proliferation.   
On the other hand, inhibiting both TrkB and p75NTR receptors slowed cell proliferation; 
however this was of a lesser extent compared to inhibiting TrkB signalling alone. 
ProBDNF protein, which has a higher binding affinity for p75NTR, was added to culture (figure 
4.10.3).  ProBDNF alone slows cell proliferation compared to control treated cells.  This 
inhibition was slightly increased by adding neutralising antibodies for BDNF and NT-4, 
together with ProBDNF protein treatment.  Interestingly, inhibiting the TrkB receptor, and 
enabling p75NTR signalling by adding ProBDNF, significantly hinders cell proliferation in Mutu 
latency III clone J8 cells.      
Add figs 4.10  
 
 
 
 
 
 
Taken together, these results indicate that inhibiting TrkB signalling by either inhibiting the 
receptor alone or its ligands BDNF and NT-4, reduces cell proliferation therefore TrkB 
enhances cell growth.  While, inhibiting TrkB receptor and promoting p75NTR signalling by 
adding its high affinity ligand, ProBDNF, p75NTR signalling slows cell proliferation compared 
to control treated cells which signal via both TrkB and p75NTR.  
It would however be useful to compare these CFSE histograms by using another cell 
proliferation assay such as an MTT kit or simply counting live versus apoptotic cells by either 
using a haemocytometer in trypan blue stained cells or by simply staining with PI and 
acquiring cells on a flow cytometer.   
 
 
 
 




  
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 4.3 Discussion 
The main conclusions from this part of the investigation are that Burkitt’s lymphoma B cells 
express the neurotrophins BDNF and NT-4 and their receptors, TrkB and p75NTR and that 
Mutu latency III clone J8 cells express functional full length TrkB and p75NTR receptors which 
signal via their ligands in an autocrine manner for cell survival and proliferation. 
 
4.3.1  BDNF and NT-4 expression and signalling discussion 
The expression of BDNF protein in all Burkitt’s lymphoma B cell lines analysed was observed 
by flow cytometry, western blotting and ELISA methods.  BDNF has been shown to have 
varying functions in B cells such as B cell development.  According to a study by Schuhmann 
B. et al., paracine signalling between bone marrow stromal cells expressing BDNF which 
binds to Pre-BII cells, expressing p75NTR and truncated TrkB, plays a significant role in B cell 
development (Schuhmann, Dietrich et al. 2005).  Mice deficient in BDNF have considerable B 
cell number reductions in Blood, spleen and bone marrow.  
The detection of mature BDNF (~14kDa) and ProBDNF (~35kDa) within all Burkitt’s 
lymphoma B cell lines was observed, however many other BDNF proteins with varying 
molecular weights were also detected.  The human BDNF gene consists of 11 exons which 
respond to 9 promoters producing 17 sliced variants expressing the same protein, encoded 
from exon 8 (Pruunsild, Kazantseva et al. 2007).  When glycosylated, these variants may 
produce multiple BDNF protein corresponding to varying molecular weights, as shown in 
figure 4.9.2.    
Different BDNF spliced variants are expressed within diverse regions of the brain and other 
peripheral organs such as the spleen (Liu, Lu et al. 2006).  The splice variants usage within 
peripheral immune organs are significantly different from those in brain tissue (Kruse, Cetin 
et al. 2007).  In activated T cells for example, an upregulation of certain BDNF splice variants 
were observed, however the specific differences in function between the variants are 
unknown.   
The observation of multiple BDNF protein within the western blot is also likely to represent 
varying BDNF dimmers.  Mature BDNF can form homodimers for binding to TrkB receptor 
homodimers or TrkB:p75NTR heterodimers.  Mature BDNF homodimers are presumed to 
form ~27kDa proteins which were detected within Mutu latency III clone J8 cell, but 
undetected within other latency III lines indicating a possible clonal variant since its 
expression seems to not be latency phenotype specific (Roland, Stefan et al. 1994). 
ProBDNF can also form homodimers for preferential binding to p75NTR coupled with 
receptors such as sortilin.  These ProBDNF homodimers can form biologically active proteins 
ranging from ~50kDa to 60kDa (Roland, Stefan et al. 1994).  Therefore, protein detected at 
~55kDa, ~57kDa and/ or ~60kDa are presumed to be ProBDNF dimmer proteins observed 
within the BDNF western blot for the Burkitt’s lymphoma cell samples.  However it is also 
possible that ProBDNF may activate TrkB.  Work by Fayard B. et al., show that ProBDNF 
induces TrkB tyrosine phosphorylation, activation of Erk pathways, and neurite outgrowth in 
COS-7 cells, hence it is a possibility that ProBDNF maybe secreted and may be involved in 
TrkB autophosphorylaton in Mutu latency III clone J8 cells (Fayard, Loeffler et al. 2005).  
Proteins also detected by the BDNF antibody, running above 64kDa are unknown.  If this 
experiment on BDNF expression was to be repeated, it would be worth pre-incubating the 
PVDF membrane with secondary antibody.  An SG substrate should then be applied to be 
attached to any secondary antibody bound to the PVDF.  Once the blot is washed and 
blocked, the BDNF primary antibody should then be applied as normal.  The secondary 
antibody will then be re-applied to bind primary BDNF antibodies for detected by alkaline 
phosphatase chemiluminescence.    
Pre-incubation with the secondary antibody and the SG substrate ensures any unspecifically 
bound secondary antibody is eliminated.  Another suggestion to be considered if the 
experiment is to be repeated is to compare cells that express BDNF and those that are 
negative for BDNF expression. 
RN46A is a neuronal cell line derived from rat raphe nuclei.  The raphe nucleus is a 
moderate-size cluster of nuclei found in the brain stem which releases serotonin.  These 
cells were used within a study on autocrine BDNF secretion and serotonergic differentiation 
in neuronal cells of the CNS within adult rats (Eaton and Whittemore 1996).  These cells 
were transfected with a plasmid containing the cDNA sequence for rat BDNF.  Wild type 
RN46A cells are negative for BDNF but efficiently express BDNF when transfected.   
Control transfected and BDNF transfected RN64A cell samples could be compared to 
samples from the Burkitt’s lymphoma lines within the same gel to ensure the various BDNF 
bands detected are specific for BDNF, although, a mature BDNF antibody which reacts to 
both human and rat BDNF protein will need to be used.  It would also be informative to 
obtain an antibody which also recognised rat and human ProBDNF proteins detected at 
higher molecular weights.    
Extracellular and intracellular BDNF expression was explored in Burkitt’s lymphoma B cell 
lines by the use of a pre-coated sandwich ELISA kit, however it is worth noting that this 
ELISA kit does not distinguish between mature BDNF and ProBDNF protein.  All Burkitt’s 
lymphoma cell lines expressed detectable levels of intracellular BDNF, whereas only latency 
I and latency III cell lines secreted detectable levels of BDNF within their cell culture 
supernatant (figure 4.11).   
The addition of either NGF or BDNF is able to induce neurite outgrowth in PC12 lines 
transfected with TrkB.  There are suggestions in the literature that BDNF secreted by B cells 
is bioactive (Kerschensteiner, Gallmeier et al. 1999), therefore to test this using latency I and 
latency III Burkitt’s lines, PC12 cells transfected with functional full length TrkB receptors 
were treated with supernatant from latency I and latency III Burkitt’s lymphoma lines for 14 
days (data not shown).   
TrkB transfected PC12 lines produced neurite outgrowth when treated with 50ng/ml of 
human recombinant BDNF protein, whereas supernatant obtained from latency I Burkitt’s 
lymphoma lines did not induce neurite outgrowth.  The lack of neurite outgrowth was 
possibly due to the half life for secreted BDNF protein within culture, therefore in the next 
experiment, TrkB transfected PC12s were treated every 48 hours with fresh supernatant; 
however this experiment was also unsuccessful.  In this case it was proposed that the lack of 
neurite outgrowth in cells treated in culture supernatant may be due the concentration of 
secreted BDNF.  Based on the BDNF ELISA experiment, the highest concentration of BDNF 
detected in culture supernatant was within IARC-171 supernatant containing 75.8 pg/ml 
BDNF compared to unstimulated B cells obtained from PBMCs which secreted 250pg/ml and 
750pg/ml when stimulated, as documented by Kerschensteiner, M. et al, (Kerschensteiner, 
Gallmeier et al. 1999).    
 
All Burkitt’s lymphoma B cells lines analysed possessed detectable levels of NT-4 protein, 
however there is limited literature on NT-4 expression and function in human B 
lymphocytes.  NT-4 mRNA however, has been documented to be expressed at basal levels in 
T and B splenocytes obtained from mice (Barouch, Appel et al. 2000).  Whereas, within 
humans, NT-4 has been detected in alveolar and interstitial macrophages (Hikawa, 
Kobayashi et al. 2002), eosinophil granulocytes (Laurenzi, Beccari et al. 1998) monocyte-
derived macrophages (Samah, Porcheray et al. 2008) and slow- and fast-twitch muscle fibers 
(Walker and Schon 1998).     
 4.3.2  TrkB expression discussion 
Like BDNF, NT-4 binds and signals via TrkB and p75NTR and has been shown to induce neurite 
outgrowth and cell survival in embryonic trigeminal ganglia and trigeminal ganglion neurons 
excised from rat tissue (Ibanez, Ernfors et al. 1993).  As seen in Mutu latency III clone J8 
cells, NT-4 also signals for survival through TrkB but can also induce cell death through 
p75NTR within sensory neurones (Agerman, Baudet et al. 2000). 
Other examples of BDNF and NT-4 signalling via TrkB have also been suggested during 
dendritic cell maturation which corresponds to an increase in the expression of HLA-DR and 
CD80, markers for antigen presentation (Bratke, Maruschke et al. 2007).  TrkB expression 
was observed to be increased within maturing, human monocyte-derived dendritic cells and 
is linked to cell survival.     
The expression of glycosylated full length TrkB protein (145kDa) was detected within the 
latency III lines, Mutu clone J8 and IARC-171 (figure 4.4), whereas glycosylated TrkB-T1 
(95Kda)was detected in latency I, III and EBV negative Burkitt’s lymphoma lines.  
Importantly, unglycosylated TrkB-T1 protein was only observed within EBV negative and 
latency I lines.   
During embryogenesis BDNF and full length TrkB are highly expressed in neurones of the 
central nervous system.  At later stages in postnatal development, truncated TrkB-T1 
variants become more abundant (Allendoerfer, Cabelli et al. 1994; Armanini, McMahon et 
al. 1995; Biffo, Offenhauser et al. 1995).  Screening adult rat cerebellar cDNA libraries 
reveals TrkB-T1 contains the TrkB extracellular domain, as well the transmembrane region, 
but lacks the kinase domain (Middlemas, Lindberg et al. 1991).   
TrkB.T1 is a functional receptor which when overexpressed, can increase the proliferation of 
neural progenitors (Tervonen, Ajamian et al. 2006).  TrkB-T1 can internalise and store BDNF 
in biologically active forms and release it depending on the BDNF concentration within the 
cellular environment; this inturn can regulate extra cellular BDNF levels (Biffo, Offenhauser 
et al. 1995; Rubio 1997; Alderson, Curtis et al. 2000).   
TrkB-T1 has also been shown to be involved in cell morphology.  Over expression of full 
length TrkB receptors increases proximal dentritic branching, whereas TrkB-T1 promotes 
elongation of distal dendrites in cortical cells (Yacoubian and Lo 2000).  TrkBT-1 can also act 
in a ligand independent manner by altering cellular morphology in neuroblastoma lines; 
forming outgrowth of filopodia and processes in transfected neuroblastoma cell lines 
(Haapasalo, Saarelainen et al. 1999).  Interestingly, full length TrkB expression, suppresses 
the formation of filopodia and processes outgrowth in cells co-transfected with both full 
length and truncated TrkB.  The inhibitory effects from full length TrkB were inhibited upon 
k252a treatment. Therefore, depending on levels of full length and truncated TrkB receptor 
expression, their signalling functions can be counteracted. 
Overexpression of TrkB-T1 can also form filopodia in hippocampal neurones; this TrkB-T1 
signalling cascade involves p75NTR but is independent from ligand binding.  Importantly, the 
co-expression of TrkB-T1 and full length TrkB hinders dendritic filopodia formation.   
Notwithstanding, heterodimerization of full length and truncated TrkB which can inhibit 
autophosphorylation of the tyrosine kinase domain (Haapasalo, Koponen et al. 2001).  Co-
expression of truncated and full-length TrkB cDNAs in sympathetic neurons reduces the 
ability of full length TrkB to induce particular BDNF-dependent events such as neuronal 
survival (Ninkina, Adu et al. 1996).  Xenopus oocyte transfected with full length and 
truncated TrkB can form non-functional heterodimers, inhibiting the full length TrkB 
response upon BDNF stimulation (Eide, Vining et al. 1996).   
Another truncated TrkB receptor, that contains an Shc-binding site in the juxtamembrane 
domain, but lacks the kinase domain and has a unique truncated C terminus is known as 
TrkB T-Shc.  Co-immunoprecipitation experiments from human brain tissue show that TrkB-
T-Shc is not autophosphorylated by full length TrkB, indicating that it could also be a 
negative regulator of TrkB signalling in the brain (Stoilov, Castren et al. 2002). 
Taken together, the truncated TrkB receptors may therefore act as naturally occurring 
dominant negative modulators in cells co-expressing full length and truncated TrkB.  On the 
other hand TrkB-T1 may support and even promote full length TrkB signalling.   
It is known that BDNF and TrkB play an important role in modulating the plasticity of the 
adult hippocampus.  TrkB-T1 receptors have been postulated to prolong the availability of 
neurotrophin by acting as depots for BDNF.  Since BDNF can occur as a homodimer it can be 
speculated that these dimers contain two binding sites, one interacting with a full length 
receptor such as that on glial cells, and the other with a truncated receptor present on a 
growing axon, thereby promoting cell-cell interactions (Schneider and Schweiger 1991). 
The specific functions of full length and truncated TrkB receptors in Burkitt’s lymphoma are 
unknown.  However based on the literature it can be presumed that full length and 
truncated TrkB receptors within latency III Burkitt’s lymphoma B cells lines may work 
together promoting cell survival and proliferation.  In this case, cells would be control 
treated since latency III lines express TrkB and their receptors.  However when treated with 
the tyrosine kinase signalling inhibitor K252a, full length TrkB is inhibited whereas truncated 
TrkB (negative for the tyrosine kinase domain), should remain active.  K252a inhibits cell 
growth and proliferation therefore it is possible that truncated TrkB-1 expression is not 
involved in cell survival within Mutu latency III clone J8 lines. 
EBV negative and latency I Burkitt’s lymphoma cells on the other hand, express glycosylated 
truncated TrkB-T1.  Functional signalling via TrkB and BDNF pathways in these cell lines were 
not investigated due lack of glycosylated full length TrkB protein expression.  To test the 
hypothesis whether there are differences in full length TrkB and TrkB-T1 signalling 
compared to truncated TrkB-T1 signalling alone, the experiments conducted within this 
investigation TrkB and BDNF signalling would need to be applied using EBV negative and 
latency I Burkitt’s lymphoma Mutu cell lines.  It would also be highly beneficial to compare 
any results from these tests by using TrkB negative cell lines transfected with either TrkB-T1 
or full length TrkB cDNA.  Including these transfected lines would eliminate any signalling 
differences observed between the Burkitt’s lymphoma lines, influenced by EBV latency 
phenotype. 
Ways in which EBV influences its host cell are still being discovered.  Previously a publication 
by Eggers S.D.Z. and Windebank A.J. demonstrated that peripheral resting human B cells 
have undetectable levels of TrkB mRNA expression through the use of TrkB RT-PCR primers 
which recognise all variants (Scott D. Z. Eggers and Anthony J. Windebank 1996). Epstein-
Barr Virus Transformation Induces Expression of TrkB mRNA in Human B Lymphocytes).  By 
transforming B cells obtained from the same doner with EBV, enables the detection of Pan-
TrkB mRNA expression.   
EBV transformed B cells have also been seen to translate functional TrkB receptors that are 
phoshorylated upon BDNF treatment (Schenone, Gill et al. 1996).  Conversely, B cell 
transformation by EBV did not upregulate p75NTR expression or TrkA and TrkC mRNA 
expression, therefore TrkB expression seems to be linked EBV gene expression.          
 
From RT-PCR and western blotting, data not shown, it was concluded that LMP1 transfected 
BJAB cells express strong LMP1 protein, strong TrkB protein but weak levels of TrkB mRNA.  
LMP1 transfected DG75 lines on the other hand show weaker LMP1 protein levels, weaker 
TrkB protein expression and yet stronger TrkB mRNA levels.  Although the mRNA data did 
not match the TrkB protein levels detected by western blotting methods, it was speculated 
that these differences may have been due to the sensitivity for each method.   
For each RT-PCR experiment, 40ng/ml of cell sample RNA was loaded per PCR reaction, 
whereas 20ug/ml of protein was loaded per well within an SDS-PAGE gel for western 
blotting.  Since protein and RNA concentrations were considered for each method as 
opposed to cell numbers, the two methods cannot e directly compared in terms of 
expression levels.   
The differences in TrkB expression between the two methods are also possibly due to TrkB 
protein influencing its gene expression.  The high expression level of TrkB protein in LMP1 
transfected BJAB cells may have a negative feedback loop which could down regulate TrkB 
mRNA within the cell.  Whereas, low expression of TrkB protein in LMP1 transfected DG75 
cells may induce a positive feedback loop that may increase TrkB mRNA expression. 
Other reasons for the difference in mRNA and protein expression may include TrkB specific 
microRNAs (miRNAs) which act by binding to target mRNA and either cleave or reduce 
translation efficiency of that mRNA sequence.  The miRNAs  9, 125a, and 125b have been 
shown to bind truncated TrkC receptors in neuroblastoma tumors, decreasing cell growth 
(2007: 104,  7957).  TrkB specific miRNAs however have yet been discovered, however it is 
probable that EBV encoded miRNAs may influence TrkB expression.   
The possibility that LMP1 may upregulate TrkB protein expression was also tested in Mutu 
latency III clone J8 and IARC-171 cells transfected with an LMP1 specific siRNA (data not 
shown).  Unfortunately the LMP1 expression levels within siRNA transfected Mutu and IARC-
171 cells were not lessened compared to the control transfected samples.   
 
4.3.2  TrkB and p75NTR autocrine signalling discussion 
Autocrine signalling within Mutu latency III was scrutinized by use of various receptor and 
ligand inhibitors.  Although informative results were obtained from the use of tyrosine 
kinase inhibitor, K252a, it was worth comparing this inhibitors’ effect with the more specific 
inhibitor TrkBd5.  This was beneficial for comparing the resulting data since these TrkB 
inhibitors act by inhibiting differing sites within the receptor structure.   
K252a is considered to be a less specific Trk signalling inhibitor.  As well as inhibiting tyrosine 
kinase signalling, K252a can also induce cell cycle arrest and apoptosis in TrkA and TrkB 
expressing glioma cells, by inhibiting cyclin-dependent kinases (Chin, Murray et al. 1999).  
K252a is now regarded to be an inhibitor of varying kinases and neurotrophic factor 
signalling.  These varying kinases include calmodulin-dependent protein kinase (McGinnis, 
Wang et al. 2001), protein kinase C (Yamada, Iwahashi et al. 1987) and other 
serine/threonine protein kinases including MAPKs (Pan, Zhang et al. 2005).   
To strengthen data obtained from TrkB signalling experiments by the use of K252a inhibitor 
in Mutu latency III clone J8 cells, TrkBd5 was directly applied to the experiment as the more 
specific inhibitor.  As mentioned previously within the chapter, TrkBd5 is an analogue for the 
5th domain on the TrkB receptor structure, known to be the binding site for BDNF.  However 
it is also worth noting that BDNF can bind to a site spanning the third leucine-rich domain 
and the second cystein cluster domain (please refer back to the TrkB receptor structure 
shown in illustration 1.2.) (Haniu, Montestruque et al. 1997).   
It has also been shown that peptides corresponding to the leucine rich motif sequence, can 
effectively bind and block BDNF, NT-4 and NT-3 binding to the extracellular domain of TrkB 
(Windisch, Auer et al. 1995).  Therefore it is possible that Mutu latency III clone J8 cells 
treated with TrkBd5, secreting BDNF, may still be able to signal via the third leucine-rich 
domain and the second cystein cluster domain on TrkB, however the proliferation and cell 
survival were efficiently inhibited upon TrkBd5 treatment and there is currently no literature 
on the signalling outcomes of BDNF binding with the third leucine-rich domain and the 
second cystein cluster domain on TrkB.       
If TrkB and BDNF autocrine signalling was to be investigated further in Burkitt’s lymphoma B 
cell lines, the use of a large variety of TrkB signalling inhibitors, possessing differing  
inhibition mechanisms would be highly beneficial.  An example includes the novel tyrosine 
kinase inhibitor CEP-751 (KT-6587), which is  an indolocarbazole derivative (Hu, Sun et al. 
2008).  Nonetheless, its mode of action against Trk signalling receptors has not yet been 
documented.  
As for the mature neurotrophic factor low affinity receptor p75NTR, its expression was 
observed within all Burkitt’s lymphoma lines analysed.  Within Trk and p75NTR positive cells, 
the expression level balance between the two receptors could influence signalling for cell 
survival or cell death.  Cell survival can be signalled via Trk pathways whereas p75NTR can 
signal for cell death.  Scenarios where disruptions in this balance, favouring p75NTR signalling 
to induce cell death include diseases such as Alzheimer’s. 
The catalytic activity -secretase is dependent on its prestilin subunit, a multi-
transmenbrane aspartyl protease.  Mutations in presenilin-1 gene are known to induce 
familial Alzheimer’s disease (Citron, Westaway et al. 1997).  Mutations arise from the effects 
-secreatase-dependent processes of amyloid precursor protein and the subsequent 
formation of amyloid.  As documented by Hatchet C.S. et al., familial Alzheimer’s mutations, 
namely M146V mutations, induce p75NTR cleavage, releasing the ICD promoting cholinergic 
neuronal cell death (Hatchett, Tyler et al. 2007).  
p75NTR is synthesized as ~59-60kDa precursor which is subsequently glycosylated to produce 
a full length, 75kDa receptor.  p75NTR cleavage was observed upon inhibition of TrkB 
signalling in Mutu latency III clone J8 cells compared to control treated Mutu cells (data not 
shown).  This therefore indicates that p75NTR cleavage is either at a low levels or absent 
within Mutu latency III clone J8 cells.  This may be due to full length TrkB signalling, 
inhibiting p75NTR cleavage by co-localising with p75NTR forming heretodimers.  In this case 
the balance is shifted in the favour of TrkB signalling for cell survival. 
On the other hand, inhibiting TrkB kinase domain signalling by K252a enhanced p75NTR 
cleavage, tipping the balance in favour of p75NTR dependent cell death in Mutu latency III 
clone J8 cells.  p75NTR cleavage is also heightened by its high affinity receptor ProBDNF 
compared to BDNF protein in cells treated with K252a.  The ~35kDa ProBDNF monomers 
were detected within all Burkitt’s lymphoma lines indicating endogenous ProBDNF which 
may be secreted by Mutu latency III clone J8 cells.  Inhibiting TrkB signalling by K252a 
addition alone had a slight increase in p75NTR cleavage whereas the addition of K252a and 
exogenous ProBDNF increased p75NTR cleavage further showing biologically active ProBDNF 
within Mutu latency III clone J8.  On the other hand, if these experiments were to be 
repeated, the addition of another Trk signalling inhibitor could help verify the results 
obtained.  Novel inhibitors such as AZ-23 which acts as a potent and selective Trk kinase 
inhibitor could be used as a treatment for cancer (Thress, Macintyre et al. 2009). 
 
Neurotrophin signalling via TrkB:p75NTR and their ligands may therefore aid B cell survival 
and proliferation in EBV transformed Burkitt’s lymphoma B cells providing a possible novel 
axis as a tumour prophylaxis.  Burkitt’s lymphoma B cells also express detectable TrkA 
mRNA, however lack detectable NGF transcripts, therefore TrkA and NGF signalling 
pathways within EBV negative and EBV latency I cell lines were to be investigated within the 
next results chapter.            
 
5. Results 
 
Investigating possible NGF and TrkA signalling via 
paracrine interactions between Burkitt’s lymphoma B 
cell lines and Follicular Dendritic Cells and possible 
autocrine signalling effects within Burkitt’s lymphoma 
B cells 
 
5.1 Introduction 
In line with the previous chapter on TrkB signalling, TrkA expression and signalling was 
investigated in Burkitt’s lymphoma B cell lines.  This chapter is split into two sections.  The 
main focus for the first section was to study novel bi-directional neurotrophic factor 
communication between FDCs and Burkitt’s lymphoma B cells and to question possible FDC 
roles in lymphomagenesis.  As concluded from chapter 3, TrkA mRNA transcripts were 
detected in all Burkitt’s lymphoma cell lines analysed, yet, transcripts of its’ specific ligand, 
NGF were not observed, hence the hypothesis for a  paracrine signalling effect.      
The results gained from this first section of the chapter where used to drew the second 
hypothesis, asking whether TrkA and NGF autocrine signalling takes place in Burkitt’s 
lymphoma B cell lines.    
Possible source of NGF within the germinal centre (GC) microenvironment has been shown 
to be provided from T cells (Lambiase, Bracci-Laudiero et al. 1997); however there is 
currently no data on NGF secretion by follicular dendritic cells (FDCs).  FDCs were therefore 
questioned as possible sources of NGF within a GC.  
5.1.1 The function of FDCs within a germinal centre micro-environment 
First described as “a non-lymphoid population of embryonic non-phagocytic reticulum cells” 
by A. Maximow, FDCs are CD45 negative, multi-nucleated cells which form dense three-
dimentional structures within the light zone of germinal centre follicles (Gerdes, Stein et al. 
1983; Schriever, Freedman et al. 1989).      
FDCs within the GC assist B cell maturation by taking up antigen attached to antibodies or by 
presenting antigen complement complexes for centroblasts (Klaus, Humphrey et al. 1980).  
High affinity B cell selection then occurs by inducing class switch recombination, forming 
centrocytes within the light zone (Liu, Joshua et al. 1989).  Many centrocytes die of 
apoptosis and yet cells with higher affinity for antigens receive signals for survival by 
interacting with FDCs (Fliedner, Kesse et al. 1964).   
As summarised in illustration 5.1, FDC and B-cell interactions involve varying receptors and 
ligands for specific functions including cell proliferation, survival and adhesion, as well as 
upregulating CD19, CD154 and IL15 binding.  Germinal centres are also known to play a 
central role in the formation of memory B cell (Klaus, Humphrey et al. 1980; Kunkl and Klaus 
1981; MacLennan and Gray 1986).      
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 It was proposed by Babcock G. J. et al., that upon entry, EBV infects B cells within the 
submucosal membrane, and that these B cells enter the germinal centre to differentiate into 
EBV positive, sIgD negative memory B cells released within peripheral blood (Babcock, 
Decker et al. 1998).  There are indications of EBV positive cells to be of GC origin.  For 
example, the expression of GCET1 (Germinal Centre B cell Expressed Transcript-1) gene 
which codes for a serpin (Frazer, Jackson et al. 2000) is expressed in EBV positive B cells.   
Normally expressed in germinal B cells, GCET1 is also expressed within Burkitt’s lymphoma 
cell lines (Paterson, Horvath et al. 2007).  Other examples of GC B cell markers observed in 
Burkitt’s lymphoma lines include CD10, CD38 and CD77  (Gregory, Tursz et al. 1987; 
Mangeney, Richard et al. 1991; Mangeney, Lingwood et al. 1993).  Again, like GC B cells, 
Burkitt’s lymphoma B cells lack markers such CD39, CD23, CD25 and CD71 (Gregory, Tursz et 
al. 1987).  Drawn from these observations it seems that Burkitt’s lymphoma B cells undergo 
B cell maturation through GCs by interacting with T cells and FDCs.  The main focus within 
the first section of this chapter was to ask if neurotrophic factors and their receptors signal 
between Burkitt’s lymphoma B cells and FDCs.  One possible link between FDCs and B cells 
via neurotrophic factors may involve p75NTR.  FDCs have been shown to express p75NTR 
protein within paraffin embedded histological sections (Maeda, Matsuda et al. 2002).  
Hence, Mutu latency III clone J8 cells which secrete BDNF, may bind and signal to FDCs.   
To question these, two FDC cell lines were utilized.  The first being, FDC1 cell line, provided 
by Clark E.A. which was compared with the HK cell line provided by Choi Y.S.   
The FDC1 cell line was generated by shearing human tonsils and digesting them with DNase 
and collegenase (Schriever, Freedman et al. 1989; Clark, Grabstein et al. 1992).  When 
cultured, the large adherent cells with elongated extensions were isolated and grown in 
culture.  Initially, these cells were used to investigate CD40 signalling within the germinal 
centre.  Like true FDCs, the FDC1 cell line express CD11b, CD14, CD29, CD40, CD54. CD73, 
CD74 and VCAM-1.  The cells lack CD11c, CD22, CD18, CD25, CD45 and T-cell markers.  
Human B cells and B cell lines have been shown to bind to FDC1 lines and in the presence of 
anti IgM and/ or agonistic CD40 mAb, can induce B cell proliferation.  Importantly, T cells do 
not bind to the FDC1 cell line and yet B cells bind via VLA-4 and VCAM-1.  
Another very similar FDC cell line, HK, was found to express CD21, CD23, DRC-1, CD40, 
VCAM-1, ICAM-1 and HJ2 (Kim, Zhang et al. 1994).  Anti CD3 Ab activates T cells that bind 
and stimulate HK cells showing T cells stimulate resting B cells and support B cell maturation 
by stimulating FDC development.   
Both FDC cell lines are considered to be useful tools in studying surface molecular markers 
and cytokines expressed by FDCs.  Within this section of the thesis, FDC1 and HK cell lines 
were initially characterised for known FDC markers and screened for the expression of NGF 
mRNA transcripts and protein.   
 
 
 
 
  
 
5.1.2 TrkA phosphorylation and downstream signalling 
The functional effects upon NGF treatment were also analysed in Burkitt’s lymphoma B 
cells.  NGF has been shown to induce an array of biological effects in B cells such as cell 
survival, cell proliferation and cell migration.  B cells and B cell lines have been shown to 
express p75NTR and TrkA which is phosphorylated upon exogenous NGF addition (Melamed, 
Kelleher et al. 1996; D'Onofrio, de Grazia et al. 2000).  
NGF and IL2 stimulation increases the mitogenic effect of the T-independent B cell mitogen, 
Staphylococcus aureus Cowan I strain in tonsillar and peripheral human B cells (Brodie and 
Gelfand 1992).  NGF has also been shown to induce a dose-dependent increase in human B-
cell DNA synthesis (Otten, Ehrhard et al. 1989), enhances IgG4 production in cultures of 
human tonsillar B cells (Kimata, Yoshida et al. 1991), increases F-actin content, 
microfilament assembly and phosphorylation of paxillin in human B cells (Melamed, Turner 
et al. 1995).   
Upon TrkA phosphorylation, NGF, induces the tyrosine phosphorylation and activation of 
MAP-kinase (Franklin, Brodie et al. 1995), tyrosine phosphorylation of Shc and its 
association with Grb2 as well as inducing Vav phosphorylation and the activation of Ras 
downstream signalling (Melamed, Patel et al. 1999). 
In terms of cell survival, NGF is said to rescue B cell lines from apoptosis induced by anti-IgM 
(Kronfeld, Kazimirsky et al. 2002).  NGF may also act in an autocrine manner by signalling for 
cell survival within memory B cells and Hodgkin lymphoma derived, Hodgkin-Reed Sternberg 
cells (Torcia, Bracci-Laudiero et al. 1996; Renne, Minner et al. 2008).   
An additional signalling outcome upon NGF stimulation includes cell migration which has 
been demonstrated in primary melanoma cells (Shonukan, Bagayogo et al. 2003), mast cells 
(Sawada, Itakura et al. 2000), macrophages (Kobayashi and Mizisin 2001), microglial cells 
(De Simone, Ambrosini et al. 2007) and Schwann cells (Anton, Weskamp et al. 1994). 
 
 
5.1.3 Inhibitions for TrkA signalling 
The second part of this chapter will be to ask possible autocrine NGF signalling via TrkB 
within Burkitt’s lymphoma B cells.  These signalling effects were investigated in EBV 
negative Burkitt’s lymphoma cell lines by using TrkA signalling inhibitors.  Reagents used to 
observed TrkA protein and inhibit TrkA signalling at illustrated in illustration 5.2.  K252a 
signalling inhibition effects were compared to the specific TrkA inhibitors TrkAd5 and 
GW441756. 
TrkA-domain 5 (TrkAd5) is a receptor analogue that acts by binding to NGF which in turn out 
competes with any extracellular NGF binding to TrkA.  
 
Add Ill 5.2 here 
  
 
 
 
TrkAd5 was the first of the analogues to be designed and constructed after the discovery of 
NGFs’ specific binding site on the TrkA receptor structure.  This binding site lies within the 
extracellular part of TrkA known as the immunoglobulin-like domain 5 (Please refer to Trk 
receptor structure – illustration 1.3) (Holden, Asopa et al. 1997; Watson, Fahey et al. 2006).  
The TrkAd5 receptor analogue acts by binding to NGF which in turn out competes with any 
extracellular NGF.  This 5th domain structure was cloned, purified and tested in vitro and in 
vivo for its inhibitory effects on TrkA signalling.   
TrkAd5 inhibits NGF dependent neurite outgrowth and cell survival in PC12 cells (Watson, 
Fahey et al. 2006).  As shown by De Vries A. et al., 20ng/ml of NGF induces hyper-
responsiveness of isolated guinea pig tracheal rings following application of histamine (de 
Vries, van Rijnsoever et al. 2001).  Treatment with TrkAd5 prior to the addition of NGF was 
able to inhibit hyper-responsiveness to histamine.  Importantly, TrkAd5 shows no significant 
binding to BDNF, providing further evidence that domain 5 regions on TrkA and TrkB 
regulate specificity for cognate ligand binding (Ultsch, Wiesmann et al. 1999; Robertson, 
Banfield et al. 2001).  
 
Within this investigation, TrkAd5 was compared a potent, selective TrkA kinase inhibitor 
known as GW441756 that is able to inhibit TrkA-induced cell death in cell lines over 
expressing TrkA (Wood, Kuyper et al. 2004; Jung and Kim 2008).  GW441756 has also been 
shown to inhibit DNA damage due to the accumulation of H2AX leading to apoptosis in SK-
N-MC and U2OS cells over expressing TrkA (Jung, Kim et al. 2008; Jung and Kim 2008).  
 
 5.2 Results Part I : Investigating possible NGF and TrkA 
signalling via paracrine interactions between Burkitt’s 
lymphoma B cell lines and Follicular Dendritic Cells 
 
5.2.1   The characterisation of FDC-like lines, FDC1 and HK 
To question possible FDC-B-cell interactions via neurotrophic factors, HK and FDC1 cells 
were initially characterised for known published FDC markers.  These antibodies are known 
to react with normal FDCs by human tonsil histological staining (communication with Dr. D 
Hardie, University of Birmingham, UK).  The FDC-like cell lines were then screened for 
neurotrophic factor mRNA and NGF protein expression. 
The antibodies used for flow cytometry analysis on FDC1 and HK cell surface markers are 
shown in table 5.1 below. 
Table 5.1:  FDC markers used to characterise FDC lines 
FDC Markers Information Reference 
BU10  “Birmingham University” 
FDC marker 
(Johnson et al., 1986) 
FD6 – 88.6  FDC marker  
8D6 - FDC-SM-8D6  
aka CD320  
8D6 increases plasma cell 
generation in the GC and IgG 
secretion.  
(Li, Zhang et al. 2000) 
CD106 – VCAM-1  CD106 contributes to 
leukocyte adhesion.  
(Freedman et al., 1990) 
3C8  3C8 protein is a prostacyclin 
synthase.  
 (Li et al., 2000) 
 
These antibodies were used to stain HK and FDC1 cells for flow cytometry analysis.  It is 
proposed that CD19 is expressed by FDCs isolated from human tonsils therefore an anti-
CD19 antibody was also included within these experiments as shown in figure 5.1.  Very low 
levels of FDC marker surface expression was detected when cells live cells were stained 
(data not shown), therefore HK and FDC1 cells were permeabilized within each experiment.  
HK cells reveal low but detectable levels of CD19, FD6, 8D6 and CD106.  As for BU10 and 3C8 
and HK cells reveal high levels of protein.  As for the FDC1 line, low levels of BU10 and 3C8 
were observed.  Undetectable to weak levels of CD19, FD6, 8D6 and CD106 were observed.  
Representatives from three independent experiments are shown.  HK cells therefore 
revealed higher levels of characteristic FDC marker expression patterns compared to FDC1 
cell line.  
Other FDC marker antibodies such as CD21 and CD23 were also included to screen for FDC1 
and HK cells (data not shown), however due to time constraints these antibodies were not 
fully optimised for use.  It is also worth noting that cells were only used until they reached 
pass number 7.  It was observed that cells kept in culture after 7 passages had diminished 
levels of BU10 and 3C8 expression (data not shown).   
Fig 5.1 add here 
 
 
 
 
cDNA was then extracted from both FDC- like lines to test for -actin to ensure equal levels 
of cell sample cDNA within each PCR experiment (figure 5.2.1).  FDC-1 like cell samples were 
then tested for BAFF mRNA, also known to be expressed in FDCs.  Both HK and FDC-1 show 
detectable levels in figure 5.2.2, IARC-171 cell line was used as a positive control.  p75NTR 
expression had also been reported in FDCs, HK and FDC-1 cell lines show detectable levels of 
p75NTR mRNA transcripts  within figure 5.2.3, although, HK cells seem to reveal a stronger 
level of p75NTR transcripts compared to the FDC-1 line, as well as the positive control line, 
Kelly.   
Overall, both FDC like lines expressed detectable BAFF and p75NTR mRNA transcripts.  To test 
further, the expression of p75NTR, MLR2 antibody for p75NTR was used to stain permeabilized 
HK and FDC-1 cells for flow cytometry analysis (figure 5.3).  Representatives from three 
independent experiments are shown.  Kelly cell line was used as the positive control line.  
Both FDC-1 and HK cells show detectable levels of p75NTR protein by flow cytometry analysis 
compared to the control like Kelly cells. 
Therefore, as expected HK and FDC1 lines express BAFF mRNA transcripts and p75NTR 
transcripts and protein, as well as known FDC markers, namely BU10 and 3C8. 
 
Fig 5.2 and 5.3 add here 
 
 
 
 
5.2.2   The expression of Neurotrophic factors and their receptors in FDC-like 
lines, FDC1 and HK 
So far it has been shown that FDCs express p75NTR protein.  Hence Mutu latency III clone J8 
cells which secrete BDNF, may bind and signal to FDCs.  To question further the possibility 
that FDCs may interact with B cells within the germinal centre via neurotrophic signalling 
pathways, cDNA extracted from FDC-1 and HK cells was tested for neurotrophic factor and 
receptor mRNA transcripts by RT-PCR (figure 5.4).     
 
To ensure equal levels of cDNA was present between the FDC-1 like lines -actin primers 
were used (figure 5.4.1).  These samples were then test for TrkA and TrkB mRNA transcripts.  
Although HK cells show stronger levels of TrkA mRNA, FDC-1 cells also reveal detectable 
transcripts.  TrkB variants A and C transcripts were not detected in either FDC-like line.   But 
HK cells show detectable transcripts corresponding to Pan-TrkB variants which may include 
truncated TrkB mRNA.  FDC-1 lines on the other hand, lacked any detectable Pan-TrkB 
variants. 
As for NGF and BDNF, transcripts were detected within both HK and FDC-1 lines (figure 
5.4.2).  HK cells show stronger levels of NT-3 transcripts compared to FDC-1, however both 
lines also show detectable NT-3 transcripts within RT positive lines compared to RT negative 
lines.  NT-4 primers on the other hand reveal detectable transcripts within the RT positive 
and negative samples, therefore these results were rendered inconclusive. 
Add fig 5.4 here 
 
Overall, it is probable that FDCs can signal in an autocrine manner via TrkA and NGF and/ or 
NT-3.  As for possible TrkB signals, HK lines may signal via truncated TrkB and BDNF and/ or 
NT-3.  These results, together with the data on FDC markers, are summarised in table 5.1.   
It is however also possible that FDCs may communicate with B cells via BDNF in a paracrine 
manner via truncated TrkB expressed by Mutu negative clone 3 cell lines that show 
undetectable levels of BDNF secretion compared to their latency III equivalent line, Mutu 
clone J8. 
 
Add Table 5.1 here 
 
 
 
 
 
 
 
 
 
 
 5.2.3   The expression of NGF protein in FDC-like cell line, HK 
Based on the characterisation of FDC-likeness, HK cells seem to show stronger levels of FDC 
markers compared to FDC-1 lines.  Therefore HK cells are characteristically more FDC-like in 
terms of their expression for known FDC markers; hence HK cells were then carried forward 
within the investigation.  In terms of possible paracrine signalling, FDCs were hypothesised 
to provide NGF to B cells such as Burkitt’s lymphoma B cells which lack detectable NGF 
mRNA transcripts.  To test this it was first essential to further question NGF expression in HK 
cells.  
 
HK cells and the NGF control line, NT-2, were initially permeabilized then stained for NGF 
protein for flow cytometry analysis (figure 5.5).  Both NT-2 control cells and HK cell show 
detectable NGF protein.  Also, HK cells seem to have higher levels of NGF protein compared 
to NT-2 cells. 
NGF protein expression was also analysed by confocal microscopy (figure 5.6).  HK cells were 
grown on coverslips pre-coated with 5% poly L-Lysine, until 70 to 80% confluent.  Cell were 
then permeabilized and stained for NGF using two different NGF antibodies from separate 
companies.  Permeabilized cells stained with NGF (AF256NA) antibody show strong NGF 
stain which is considered specific by comparing the isotype control stain (figure 5.6.1).  Cells 
stained using NGF (N3279) also show strong NGF expression (figure 5.6.2).  The isotype 
control for this NGF antibody was also negative for any staining. 
Next NGF protein expression was then compared to p75NTR expression in HK cells.  NGF 
primary antibodies were detected using a green fluorescence secondary antibody for 
confocal microscopy, whereas the p75NTR antibody was detected using a red florescence 
secondary antibody (figure 5.6.3).  Both primary antibodies were added at the same time 
and excess antibody was washed off.  Specifically bound primary antibody was detected 
using the two secondary antibodies, also added at the same time.  This was completed to 
question possible co-localised staining of p75NTR protein and NGF.  A representative of three 
independent experiments is shown.     
 
Add fig 5.5 and 5.6 here 
 
 
 
 
 
 
 
 
 
 
  
Based on the confocal images shown in figure 5.6.1 to figure 5.6.3, NGF staining in HK cells is 
spread throughout the cellular cytoplasm.  As for p75NTR, the stain pattern seems to be 
localised around the cell nucleus.  However this pattern of staining may be due to the anti-
NGF antibody being more sensitive compared to the p75NTR antibody.   
Since FDCs produce NGF protein observed within the cytoplasm, the next question to ask 
whether FDCs secrete NGF for possible paracrine signalling to germinal centre B cells.  To do 
this, cell lysates obtained from HK and NT-2 cells were applied to measure the amount of 
NGF by an ELISA kit.   
Initially, a standard curve was drawn from a serial dilution of human recombinant NGF 
protein.  NGF dilutions ranging from 15pg/ml to 1000pg/ml were measured and OD readings 
were obtained. Raw OD readings for the NGF positive control cell line, NT-2 and four 
separate HK cell lysates were compared with the background standard.   
These OD readings were carried forward to measure picograme concentrations of NGF 
protein based on the linear regression equation.  The OD reading from the background 
control (used to dilute the NGF standards) was subtracted from each cell sample’s OD 
reading.  NGF concentrations were then calculated and plotted within figure 5.7. 
Add fig 5.7 
 
 
The NGF positive control line, NT-2, produced the highest detectable levels of intracellular 
NGF protein (451pg/ml), whereas, secreted the lowest levels of NGF protein within the 
supernatant (49pg/ml).  As for HK cells, similar levels of secreted NGF were detected 
(128pg/ml to 113pg/ml) compared to intracellular NGF levels (159pg/ml to 123pg/ml).  In 
all, NGF can be secreted by FDC-like cell line, HK.  However, it is worth noting that this level 
of NGF secretion was not able to induce neurite outgrowth in PC12 cells (data not shown).  
The possible reason for a lack in biological activity maybe due to low levels of NGF protein 
concentration secreted by the FDC line.   
 
To answer whether FDCs express could provide NGF paracrine signalling to TrkA expressing 
Burkitt’s lymphoma B cells, the next part of the investigation was to further investigate the 
expression of TrkA protein in Burkitt’s lymphoma B cell lines.   
 
 
 
 
 
 
 
 
  
 
5.2.4   The expression of TrkA protein in Burkitt’s lymphoma B cell lines  
 For TrkA and NGF paracrine signalling to occur between B cells and NGF producing FDCs, 
functional TrkA receptors will need to be expressed in B cells.  As concluded within chapter 
3, Burkitt’s lymphoma B cell lines displaying varying EBV latency phenotypes, show 
detectable levels of TrkA mRNA. 
The great advantage of confocal imaging is that it can show heterogeneity in the amount of 
protein within a cell line culture, while western blotting can only show the average amount 
for the whole cell population.  Therefore Burkitt’s lymphoma lines with varying EBV latency 
phenotypes were permeabilized and stained for TrkA protein using a primary TrkA antibody 
(figure 5.8).  Specifically bound TrkA antibodies were detected using FITC conjugated 
secondary antibodies which were then examined by confocal microscopy.   
 
Mutu negative clone 3 and Mutu latency I clone 59 cells express TrkA protein.  Mutu 
negative cells reveal strong peripheral staining, whereas the majority of Mutu latency I cells 
show weaker cytoplasmic staining with few cells in suspension showing stronger staining 
levels.   
Mutu latency III clone J8 cells and IARC-171 cells also stain for TrkA protein.  Like Mutu 
latency I cells, Mutu latency III cells show cytoplasmic staining patterns with few cells in 
suspension with stronger staining patterns.  IARC-171 cells on the other hand, like Mutu 
negative cells, show peripheral TrkA staining. 
Add fig 5.8 here 
 
Interestingly, all Burkitt’s lymphoma lines reveal heterogeneous patterns of TrkA staining.  
This is observed particularly in latency III cells Mutu clone J8 and IARC-171 with some live 
cells in suspension showing clear DAPI nuclear staining but lack any TrkA staining.  This 
staining pattern was observed within all three independent repeats for TrkA staining. 
In all, Burkitt’s lymphoma B cell lines express TrkA mRNA and protein but lack detectable 
NGF mRNA, whereas FDC-like cell lines express NGF mRNA and protein.  It has been noted 
that exogenous NGF includes a variety of downstream function effects in various cell types 
including B cells.  The next section of this chapter will investigate NGF signalling in Burkitt’s 
lymphoma cell lines.      
 
 
 
 
 
 
 
  
 
 
 5.2.5   Biological activity assessment for human recombinant NGF in PC12 cells 
The , human recombinant NGF used to question cells survival, proliferation as well as cell 
migration in EBV negative Burkitt’s lymphoma B cells was initially tested to ensure  it was 
biologically active.  To investigate this, PC12 cells were cultured on plates, pre-coated within 
Poly-D-lysine and rat tail collagen (figure 5.9).  Cells were left in control media or cultured 
with 100ng/ml NGF within media for 7 days.  Differences in cellular morphology were 
analysed by confocal microscopy and phase contrast microscopy.      
 
100ng/ml of human recombinant NGF induced neurite outgrowth in PC12 cell cultures 
within 7 days hence the NGF used is biologically active at this concentration.  This 
recombinant NGF then used to assess downstream signalling effects in Burkitt’s lymphoma 
B cell lines.    
 
Add fig 5.9 here 
 
 
  
 
5.2.6   The downstream signalling effects upon exogenous NGF treatment 
within Mutu negative clone 3 cells 
NGF is able to induce varying signalling outcomes in a variety of cells.  It has been shown by 
Melamed I. et al., that F-actin rearrangement and assembly can be observed upon NGF 
addition in human B cells (Melamed, Turner et al. 1995).  Changes in the cell cytoskeletal 
arrangement may be involved in the actual transduction of signals from the surface 
receptor, leading to cell activation and proliferation. Since this cytoskeletal re-arrangement 
is time dependent, Mutu negative clone 3 cells were exposed to 100ng/ml NGF for 1 
minute, 2 minutes, 5 minutes and 10 minutes (5.10.1).  Cell were then stained for F-actin 
and viewed under confocal microscopy. 
 
Without treatment (control media) F-actin levels remain low with weak phalloidin stain 
throughout the cell cytoplasm and the cellular periphery.  However within a minute of NGF 
addition, cells show strong levels of phalloidin staining at the cell membrane.  After two 
minutes of NGF exposure, Mutu cells reveal a more uniform spread of F-actin staining, with 
some cells in culture showing brighter staining than other cells.  However, at 5 and 10 
minutes of NGF treatments the phalloidin stain is weak and closely resembles the staining 
observed in control treated cells.  Hence NGF induces rapid F-actin rearrangement in Mutu 
negative clone 3 cells.      
 
Add fig 5.10 here 
It is also known that NGF can signal via TrkA causing receptor dimerization and 
phosphorylation.  Downstream signalling pathways involve adaptor proteins such as Erk and 
Akt signalling for cell survival, differentiation and/ or proliferation.   
Akt phosphorylation was then investigated in Mutu negative clone 3 cells treated with 
100ng/ml NGF for 2 minutes, 5 minutes and 10 minutes.  Cells were then washed and lysed.  
Protein lysates were then extracted and run through a 4 to 12% polyacrylamide with SDS 
gradient gel (Bis-Tris buffer) under reducing conditions, samples were transferred onto 
PVDF.  Samples were probed using either an Akt antibody or a Phospho-Akt antibody (figure 
5.10.2).    
Erk phosphorylation was also examined within NGF treated Mutu negative lines.  This time 
cells were treated at varying time points then fixed and stained for Phospho-Erk protein for 
confocal microscopy analysis (figure 5.10.3).     
To test whether Erk Phosphorylation induced by NGF is TrkA phosphorylation dependent, 
Trk signalling inhibitor K252a, as well as TrkA inhibitors GW441756 and TrkAd5, were 
compared to control treated cells (Figure 5.10.4).   
 
Akt phosphorylation was detected in control treated Mutu negative cells hence background 
signalling in Mutu negative clone 3 cells produces some Akt phosohorylation howver, within 
2 minutes of NGF treatment, Akt phosphorylation is observed (figure 5.10.2).  This level of 
phosphorylation is maintained 10 minutes post NGF addition.   
 
Peripheral Erk Phospho-protein staining was detected within control treated Mutu cells but 
at low levels (figure 5.10.3).  By treating cells with NGF, Erk Phosphorylation staining steadily 
increased from 30 seconds and peaked at 10 minutes.  Levels of Phospho-Erk protein started 
to diminish 15 minutes and at 30 minutes post NGF addition, levels of detectable protein 
had reduced to similar levels observed in control treated Mutu cells.  Erk signalling inhibitor 
PD98059, inhibited NGF induced Erk phosphorylation 10 minutes post NGF addition in Mutu 
negative cells.       
However to ensure NGF induced Erk Phosphorylation was dependent on TrkA 
phosphorylation, Trk inhibitors K252a, GW441756 and TrkAd5 were used to pre-treat the 
Mutu cells before addition of NGF for 10 minutes (figure 5.10.4).  Erk phosphorylation was 
inhibited when TrkA signalling was also withdrawn, hence Erk Phosphorylation, induced by 
NGF in Mutu negative clone 3 cells, is TrkA dependent.   
 
 
 
 
  
 
 
 
5.2.7   The effects of exogenous NGF in Burkitt’s lymphoma B cell lines treated 
in Anti-IgM 
To question the possibility that NGF may act in B cells by signalling for cell survival, an 
experiment published by Kronfeld et al., where anti-IgM induced cell death was inhibited 
upon NGF treatment within Ramos cells (Kronfeld, Kazimirsky et al. 2002).  The Ramos cell 
line was derived from an EBV negative Burkitt’s lymphoma tumour biopsy and shares many 
phenotypic characteristics of the original tumour (Klein, Giovanella et al. 1975).  These 
Ramos cells were treated in 10g/ml anti-IgM which induced cell death but addition of 
100ng/ml NGF lowered the percentage of non-viable cells by ~50%.  Importantly, a pre-
incubation with 50ng/ml K252a inhibits the anti-cell death effect observed by NGF.  This 
experiment was repeated using Ramos cells and L23055 cells.  L3055 cells are also EBV 
Burkitt’s lymphoma B cell lines used to compare Ramos cells (figure 5.11.1).      
The addition of 100ng/ml human recombinant NGF had little effect in comparison to control 
treated Ramos cells, however NGF seems to slightly decrease the percentage of live (PI low) 
L3055 cells compared to those in control media (figure 5.11.1).  2g/ml anti-IgM efficiently 
induced cell death; however 100ng/ml NGF was unable rescue both cell lines analysed.  The 
reasons for this lack of rescue was initially presumed to be limited NGF within culture 
therefore a dose response experiment was conducted using 50ng/ml, 100ng/ml and 
200ng/ml of human recombinant NGF in Ramos cells (figure 5.11.2) and another EBV 
negative line, BL41 cells (figure 5.11.3). 
 
Add fig 5.11 here 
As previously shown, anti-IgM induces cell death in Ramos cells treated for 24 hours 
however no rescue effect was observed in Ramos cells treated in either 50ng/ml, 100ng/ml 
or  200ng/ml NGF concentrations (figure 5.11.2).   
BL41 cells were also tested to question if NGF can rescue cells from cell death (figure 
5.11.3).  Unfortunately, like Ramos cells, 50ng/ml, 100ng/ml or 200ng/ml NGF is unable to 
rescue BL41 cells treated in 2g/ml anti-IgM.    
A summary showing four independent apoptosis experiments in BL41 and L3055 cells are 
shown within figure 5.11.4.   
 
Mean PI low cells and standard error bars from four independent experiments using L3055 
cells are shown on figure 5.11.4a and those for BL41 cells are shown in figure 5.11.4b.  All 
together, these results shown that human recombinant NGF is unable to rescue Ramos, 
L3055 and BL41 Burkitt’s lymphoma cells from apoptosis induced by anti-IgM.  It is also with 
noting that NGF alone does not increase the numbers of live cells in either Ramos, L3055 or 
BL41 lines compared to control treated cells.     
  
 
 
 
 
5.2.8   The effects of exogenous NGF in Burkitt’s lymphoma B cell proliferation 
Since NGF does not seem to induce cell survival in EBV negative Burkitt’s lymphoma B cells 
lines, and it seemed to not induce cell proliferation when added alone in culture, this was 
worth further testing the effects of NGF treatment on cell proliferation.  This time EBV 
negative Mutu clone 3 cells were initially treated in CFSE dye and cultured with varying 
concentrations of NGF for 24 hours (5.12.1).     
According to the mean CFSE dye levels from three independent experiments, shown in 
figure 5.12.1b, there seems to be a difference in CFSE dye levels between control cells and 
those treated in 50ng/ml NGF.  However this is a slight difference as clearly seen within the 
histograms displayed in figure 5.12.1a.  On the other hand, there does not seem to be any 
effect upon treatment with 100ng/ml or 200ng/ml NGF treatment.      
Cell proliferation rates were also measured by the assessment of DNA synthesis.  Mutu 
negative cells were treated in 2g/ml Anti-IgM, as a proliferation inhibition control, 1g/ml 
CD40-L, as a proliferation promoter control and compared to 100ng/ml NGF (figure 5.12.2).    
  
Add fig 5.12 here 
 
 
 
As expected, anti-IgM inhibited cell proliferation in Mutu negative clone 3 cells; whereas 
CD40-L stimulation promoted a slight increase in cell proliferation when compared to 
control treated cells (figure 5.12.2).  100mg/ml NGF on the other hand, seems to inhibit 
rather than promote cell proliferation, but of a lesser extent than anti-IgM treatment.  This 
is a discrepancy compared to the previous results obtained from the CFSE stain in Mutu 
negative cells treated with 100ng/ml NGF, where proliferation levels were similar to control 
treated cells (Figure 5.12.1).  This disparity may be due to the differences in methods used.  
CFSE dye is diminished over time as cells proliferate, whereas thymidine is incorporated into 
dividing cells, hence the thymidine method could also be used to observe any changes in cell 
viability upon treatment considering live cell uptake thymidine, whereas static, no-dividing 
viable cells would still maintain high levels of CFSE dye.  Hence the thymidine incorporation 
assay may indicate cell death in Mutu negative clone 3 lines upon treatment with 100ng/ml 
NGF over 24 hours which is not as clearly defined in the CFSE assay.  For this set of 
experiments to be repeated, Mutu negative clone 3 cells lines could be analysed for PI 
absorbance when treated for 24 hours in 100ng/ml NGF.     
 On the other hand, Ramos, L3055, BL41 or Mutu negative clone 3 cells do not show any 
signs of cell proliferation upon treatment with 50ng/ml, 100ng/ml or 500ng/ml human 
recombinant NGF. 
 
 
 
5.2.9   The effects of exogenous NGF in Burkitt’s lymphoma B cell migration 
The last set of experiments show that NGF does not seem to induce cell proliferation or 
rescue from cell death, thus the signalling outcome by exogenous NGF were still unknown.  
Next, it was speculated that NGF may induce cell migration in Burkitt’s lymphoma cells.  To 
test this hypothesis, cells were placed within the top chamber of transwell membrane 
inserts.  Chemoattractants were added within the bottom chamber and cells were left to 
migrate for 6 hours.   
Stromal cell-Derived Factor-1 (SDF-1) also known as CXCL-12, was used as the positive 
control chemoattractant and compared to varying concentrations of NGF for Mutu negative 
clone 3 cell migration.  To ensure Mutu negative clone 3 cells respond to CXCL-12, cells were 
tested for the CXCL-12 receptor, CXCR4 by flow cytometry (5.13.1). 
Mutu negative cells were then placed within the top chamber on transwell membrane 
plates.  The chemokine in question, the CXCL-12 control or human recombinant NGF, were 
placed within the bottom well of the transwell membrane plate.  Plates were incubated for 
6 hours.  The numbers of cells within the top and bottom wells were counted using a flow 
cytometer.  Cell migration percentages were calculated and compared between Mutu cells 
exposed to low NGF concentrations (50ng/ml to 100pg/ml) shown in figure 5.13.2a, and 
high NGF concentrations (100ng/ml to 100g/ml) shown in figure 5.13.2b.          
 
Add figure 5.13 here 
 
Mutu negative cells express the CXCR4 receptor for CXCL-12.  CXCL-12 was then used as a 
control chemoattractant and compared to NGF.  Low NGF concentrations of NGF do not 
induce cell migration as shown in figure 5.13.2a.  Higher NGF concentrations also do not 
promote cell migration in Mutu negative cells (figure 5.13.2b).  It is however worth noting 
that the migration percentages observed are very low in number, even within those cells 
exposed to CXCL-12.   
CXCL-12 induced cell migration was then compared to Mutu negative cells exposed to 
culture supernatant from HK cells and the cell line used as a positive control for NGF 
expression, human neural precursor, NT-2 cells (figure 5.13.3).  Although, CXCL-12 induces 
cell migration in Mutu negative clone 3 cells, supernatant from HK cells had no effect on cell 
migration, whereas supernatant from NT-2 cells promoted cell migration.  Importantly, 
Mutu negative cells pre-treated with TrkA inhibitor, GW441756, then exposed to NT-4 
supernatant show reduced cell migration percentages.  Whereas, Mutu negative cells pre-
treated with TrkAd5 reveal slightly higher levels of inhibition in cell migration. 
Therefore a chemokine expressed in NT-2 cells induced cell migration.  This chemokine is 
speculated to be, or involves NGF since pre-treating Mutu cells with TrkA inhibitors, greatly 
reduces cell migration numbers in Mutu negative cells.  However NGF alone did not induce 
such an effect in migration.   
 
 
 
 
Part I discussion 
The human recombinant NGF used in the experiments within this part of the results chapter 
was previously shown to induce neurite outgrowth in PC12 cell cultures within 7 days, 
therefore the lack of biological function within EBV negative cell lines, treated with NGF, are 
genuine results.   
It is possible that NGF and another unknown secreted protein may induce B cell migration as 
observed in figure 5.13.3, where Mutu negative clone 3 cells migrated towards media 
obtained from NT-2 cells.  Firstly, this result was unexpected since HK cells showed higher 
levels of secreted NGF compared to NT-2 cells within the ELISA assay (figure 5.7.3).  And yet 
media obtained from NT-2 cells induced cell migration which was NGF:TrkA signalling 
pathway specific due to the inhibition in migration when Mutu negative cells were pre-
treated with TrkA signalling inhibitors.  The unknown protein that may act with NGF or may 
be controlled by NGF and TrkA signalling to induce cell migration is possibly not expressed in 
HK cells.   
Notwithstanding, that basal Erk and Akt phosphorylation was detected in Mutu negative 
clone 3 lines, NGF induce a further increase in phosphorylation.  Also, Erk phosphorylation 
was blocked upon NGF stimulation in Mutu negative cells treated with varying TrkA 
signalling inhibitors.  Therefore, exogenous NGF activates Mutu cells by signalling through 
TrkA for Erk and Akt dependent activity, however the outcomes for this signalling cascade 
are currently known.   
 
 
Due to the observation of basal Erk and Akt phosphorylation in Mutu negative cells, and the 
lack of a survival or cell growth signalling outcome upon exogenous NGF addition, the 
hypothesis within this part of the thesis was altered to question possible NGF and TrkA 
autocrine signalling in Mutu negative cells.  
 
 
 
 
 
 
  
 
 
 
 
 
 
5.2 Results PartII : Investigating possible autocrine signalling 
effects within Burkitt’s lymphoma B cells 
 
5.2.10   The production of NGF protein in Burkitt’s lymphoma B cell lines 
To examine possible NGF protein expression in Burkitt’s lymphoma B cells lines, Mutu 
negative, latency I and latency III cells were permeabilized and stained for NGF protein for 
flow cytometry analysis (figure 5.14.1).  All Burkitt’s lymphoma B cell lines were also 
screened for NGF protein expression by western blotting methods (figure 5.14.2).     
 
Interestingly, NGF protein was detected within Mutu negative clone 3 cells, Mutu latency I 
clone 179 and Mutu latency III clone J8 cells (figure 5.14.1).   
NGF expression was also analysed by using western blotting methods.  Like HK cells, Mutu 
negative clone 3 cells expressed low levels of NGF protein compared to Mutu latency I, 
Mutu latency III and IARC-171 cells which show higher levels of detectable protein (figure 
5.14.2).  ~25kDa and ~32kDa proteins were detected buy the NGF antibody, presumed to be 
proNGF proteins.  Both ~25kDa and ~32kDa bands were observed at equal levels within all 
Mutu and HK cells analysed.      
 
Add fig 5.14 here 
In all, Burkitt’s lymphoma B cells express NGF protein.  EBV negative Mutu lines reveal 
similar levels of NGF expression to HK cells, whereas latency I and latency III cell lines show 
higher levels of NGF protein by ELISA and western blotting methods.   
In turn, Burkitt’s lymphoma B cells express NGF protein and its receptors TrkA and p75NTR.  
The focus for this part of the investigation was then altered to investigate the possible 
TrkA:p75NTR and NGF autocrine signalling pathways in Mutu negative clone 3 cells. 
 
 
 
 
 
 
  
 
 
 
 
 
5.2.11   The effect on cell death upon TrkA autocrine signalling inhibition in 
Mutu negative clone 3 Burkitt’s lymphoma B cell line 
To investigate TrkA and NGF autocrine signalling in Mutu negative clone 3 cells, the 
induction of cell death was analysed within cells treated with various TrkA:p75NTR and NGF 
signalling inhibitors.  24 hours post treatment cells were stained for PhiPhiLux and 
propidium iodide.  Cells were then measured by flow cytometry for the induction of 
apoptosis or necrosis (figure 5.15).    
Dose response assays using TrkA inhibitors were initially completed using TrkAd5.  Cells 
were treated in 1M to 25M TrkAd5 inhibitor for 24 hours (figure 5.15.1).  Caspase-3 
activity was measured by phiphilux staining and cell necrosis was measured by PI 
absorption.  As seen in the cell proliferation assay, TrkAd5 had no effect on cell survival in 
Mutu negative clone 3 cells.   
The TrkA inhibitor GW441756 was also used in a dose response assay for cell apoptosis in 
Mutu negative clone 3 cells (figure 5.15.2).  GW441756 concentrations ranging from 0.1nM 
to 100M were added to cells treated in culture for 24 hours.  Dot plots shown in figure 
5.15.2a show the majority of Mutu negative cells are live (81.8%) within control media.  
Between 0.1nM and 1M GW441756, majority of Mutu negative cells remain within the 
same quadrant within the dot plot, displaying live cells.  From a concentration of 5M to 
50M GW441756, majority of Mutu negative cells displayed early apoptotic staining 
patterns.  Finally, at a concentration of 100M GW441756, the majority of cells (90.2%) 
were late apoptotic.        
Looking at the same data plotted within a graph (figure 5.15.2b), it is clear that there is a big 
shift in live cells to early apoptotic cells between 1M and 5M GW441756.  This clear gap 
was also observed within the following figure (figure 5.15.3). 
The GW441756 dose response experiment was repeated.  Mean live, early, late apoptotic 
and necrotic cell percentages within each dot plot were calculated from three independent 
experiments.  This data, displayed in figure 5.15.3, also displays the standard deviation error 
bars form each experiment.  
Between concentrations of 0.1nM and 1M, the GW441756 inhibitor had no effect on Mutu 
negative cell survival.  However between 5M and 50M concentrations, GW441756 
induced early apoptosis in Mutu cells.  In turn, increasing the GW441756 concentration to 
100M induced late apoptosis in Mutu cells.  
 
Add figure 5.15.1 to 5.15.3 here 
 To pin point the concentration at which GW441756 shifts cells from live to early apoptotic 
cells, the dose response experiment was repeated to focus on concentrations between 1M 
and 5M GW441756 (figure 5.15.4a).   
GW441756 inhibitor has no effect on Mutu cell lines at 500nm and 1M concentrations.  
However from 2M to 10M, GW441756 induced early apoptosis in Mutu negative cells.  A 
further increase in GW441756 concentration from 50M to 100M increase the number of 
late apoptotic cells. 
GW441756 induced early, then late apoptosis in Mutu negative cells by inhibiting TrkA 
phosphorylation as shown in figure 5.15.4b.  Although TrkA phosphorylation was still 
detectable at a GW441756 concentration of 50M, phosphorylation levels were diminished 
compared to control treated Mutu cells.  Importantly, TrkA levels remained the same within 
all cell samples.    
The induction of apoptosis by GW441756 was then compared to K252a.  Concentrations 
ranging from 50nM to10M were analysed within a dose response experiment for cell 
survival (figure 5.15.5).  K252a treated cells were compared to control media treated cells 
and those treated with the K252a vehicle control, DMSO.  DMSO added was at an equivalent 
level to the 10M K252a concentration.  Mean cell percentages for live, early, late apoptotic 
and necrotic cells are displayed with their standard error bars from three independent 
experiments.      
At low K252a concentrations ranging from 50nM to 100nM, no changes in the levels of live 
Mutu cells were observed.  As the K252a concentration was increased from 500nM to 
10M, the proportion of live cells was diminished, with a steady increase in late apoptotic 
cells (5.15.5).  At a concentration of 10mM, K252a induced late apoptosis in Mutu negative 
cells. 
Unlike GW441756, K252a induced late apoptosis in Mutu negative cells by inhibiting TrkA 
phosphorylation as shown in figure 5.15.6.  Although TrkA phosphorylation was still 
detectable at a K252a concentration of 0.5M, phosphorylation levels were undetectable at 
a concentration of 1M, compared to control treated Mutu negative cells.  Importantly, full 
TrkA levels remained the same within all cell samples.    
Add fig 5.15.4 to 5.15.6 here 
A dose response experiment was also completed using Akt inhibitor, LY294002 and Erk 
inhibitor PD98059 (5.15.7).  By increasing the concentration of LY294002 from 1M to 
200M, increased the proportion of late apoptotic Mutu negative cells.  Hence the 
induction of apoptosis in Mutu negative clone 3 cells by TrkA inhibition may involve Akt 
signalling. 
As for Erk inhibition, PD98059 had no effect on cell survival.  A concentration of 1mM to 
200mM was used.  Erk signalling inhibition therefore may not be involved in the cell survival 
of Mutu negative clone 3 cells. 
Add fig 5.15.7 here 
 
 
 
  
 
 
 
 
 
 
In all, based on these dose response experiments, the working concentrations of the 
inhibitors were determined.  GW441756 was used at a concentration of 5M, K252a was 
used at 1M, TrkAd5 (like TrkBd5) used at 4.5M, p75NTR neutralising antibodies (MLR2 and 
MLR3) used at 100g/ml and Akt inhibitor (LY294002) and Erk inhibitor (PD98059) used at 
50M/ml.   
 
 
 
 
 
 
  
 
 
 
 
      
 
5.2.12   The effect on cell proliferation upon TrkA:p75NTR autocrine signalling 
inhibition in Mutu negative clone 3 Burkitt’s lymphoma B cell line 
To study autocrine signalling pathways within the EBV negative Mutu clone 3 line, TrkA and 
p75NTR signalling inhibitors and neutralising NGF antibodies were added within the culture 
to question their effects on cell proliferation.  Mutu negative cells were initially dyed with 
CFSE and treated with varying TrkA or NGF inhibitors for 48 hours.  The differences in CFSE 
dye levels were measured by flow cytometry analysis (figure 5.16).          
 
The negative controls, Anti-IgM (2g/ml) and Mitomycin C (40g/ml), were used as 
inhibitors for cell proliferation (Figure 5.16.1).  Proliferation was inhibited by Anti-IgM and 
Mitomycin C in Mutu negative clone 3 cells.  Interestingly, the Akt inhibitor, LY94002 
(50M/ml), slows cell proliferation in Mutu negative cells; however Erk inhibitor, PD98059 
(50M/ml), had no effect on cell proliferation.  Therefore Akt signalling seems to be 
involved in cell proliferation within Mutu negative clone 3 lines.  
Three TrkA inhibitors were added within this experiment.  Tyrosine kinase signalling 
inhibitor K252a (1M/ml), TrkA receptor domain 5 analogue TrkAd5 (4.5M/ml) and the 
selective aza-oxindole, GW441756 (5M/ml), were compared in their abilities to inhibit cell 
proliferation.  K252a inhibited cell proliferation compared to control treated cells and those 
treated with the K252a vehicle control, DMSO.   
 
Add figure 5.16 here 
 
The TrkA domain 5 inhibitor, TrkAd5 had no effect on cell proliferation inhibition, whereas 
GW441756 abridged cell proliferation but to a lesser extent compared to K525a.  The 
neutralising antibody for p75NTR signalling on the other hand, had no effect on cell 
proliferation in Mutu negative clone 3 cells. 
Unexpectedly, the NGF neutralising antibody (20 g/ml) also had no effect on Mutu 
negative clone 3 cell proliferation.    
 
Considering the possibility that TrkA may for heterodimers with p75NTR, it is possible that 
TrkA signalling alone in Mutu negative cells is required for cell proliferation since inhibiting 
p75NTR shows no effect in growth inhibition.  However TrkA and NGF may signal for cell 
proliferation since inhibiting TrkA signalling via K252a or GW441756 slows cell proliferation.  
Signalling for cell proliferation also involves Akt signalling however based on these results, it 
is known of Akt signalling occurs due to TrkA phosphorylation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
 
 
 
 
  
 
 
 
  
  
  
  
 
  
 5.3 Discussion 
Based on the initial hypothesis, the main conclusions drawn are that FDCs express NGF 
protein.  Exogenous NGF activates Akt and Erk signalling in EBV negative Burkitt’s lymphoma 
B cell lines; however NGF alone does not rescue cells from Anti-IgM induced apoptosis, cell 
proliferation or cell migration.  On the other hand it is possible that NGF may act with 
another chemokine to induce EBV negative, Burkitt’s lymphoma B cell migration.    
However, NGF protein was detected within all Burkitt’s lymphoma lines analysed, therefore, 
the main conclusions drawn from the second hypothesis are that endogenous NGF signalling 
in EBV negative Burkitt’s lymphoma B cells induces cell proliferation and cell survival, 
possibly via Akt signalling and not Erk. 
FDC interactions with B cells via neurotrophic factors were postulated within this part of the 
investigation.  By immunohistochemisty staining on Human palatine tonsil tissue, it is known 
that lymphocytes and FDCs express the neurotrophic receptor p75NTR however its functions 
within FDCs are unknown (Hannestad, Levanti et al. 1995; Maeda, Matsuda et al. 2002).  The 
expression of TrkA and TrkC protein was also observed within lymphocytes and FDCs.  TrkA 
and TrkC expression was noted within paracortical interdigitating cells and endothelial 
venule cells.  As for TrkB expression it was presumed that certain macrophage cell types 
expressed TrkB. 
Within this investigation, HK cells were found to express varying FDC markers, particularly 
BU10 and 3C8.  BU10 is a well documentd FDC marker which provided clear, string staining 
in FDC-like cells.  3C8 is prostacyclin synthase that inhibits proliferation of T cells.  FDCs 
expressing prostacyclin synthase within a germinal centre may explain why T cells constitute 
only a minor population compared with B cells within the light zone (Li et al., 2000).  Studies 
by I.Y. Lee et al, used the monoclonal antibody, 3C8 to study HK cells, the advantage of this 
antibody is that it does not display cross-reactivity with other cells such as those derived 
from bone-marrow (Lee et al., 2005). 
All the FDC markers analysed initiate signalling cascades in vivo for the interaction of FDCs 
with B cells.  These receptors are important for the regulation of B-cell development and 
prevention of apoptotic.  However either low levels or the lack of these markers were 
observed within the cultured FDC-like lines, with the exception of BU10 and 3C8.  As shown 
by Clark, et al., freshly isolated FDC-like cells extracted from human tonsil were directly 
compared to long term, in vitro cultured FDC-like cells.  Those cultured for long periods of 
time were observed to have a reduction in FDC, cell surface marker expression levels 
compared to those freshly isolated (Clark et al., 1992).  R. Tsunoda et al. initially found that 
fresh FDC-like lines which expressed CD21, CD23 and CD35 ceased to express these markers 
6 days post isolation (Tsunoda et al., 1990).  A reduction in FDC specific markers when FDC1 
lines were cultured by E.A. Clark et al, was also observed (Clark et al., 1992).  Similar 
observations were also found in HK lines (Kim et al., 1994).  It is therefore worth considering 
that removing FDCs from their germinal centre microenvironment drastically changes their 
behaviour and expression patterns.  In turn the results obtained from these FDC-like lines 
are speculations that need to be further investigated using in vivo models.  Hence NGF 
expression is best studies using immunohistochemical staining of human tonsils.          
Coincidently, NGF protein expression was detected in Burkitt’s lymphoma B cell lines.  This 
was an unexpected result due to the previous RT-PCR experiment results within chapter 3, 
revealing undetectable NGF mRNA transcripts in all Burkitt’s lymphoma B cells.  The reason 
for this is possibly due to low levels of mRNA transcripts expressed by the cell lines that 
were too low to be detected using RT-PCR methods; hence this method of choice was too 
insensitive for NGF transcript detection.   
Although, NGF expression in B cells, has been shown to be expressed in B cells within the 
literature.  Autocrine NGF signalling was documented by Torcia M., et al., where they 
observe TrkA:p75NTR and NGF autocrine signalling for cell survival in memory B cells (Torcia, 
Bracci-Laudiero et al. 1996).  
Exogenous NGF however does not rescue B cells from Anti-IgM induced apoptosis.  
Experiments documented by Kronfeld I. et at., where Ramos cells were rescued from 
10g/ml Anti-IgM induced apoptosis by 100ng/ml NGF, could not be replicated (Kronfeld, 
Kazimirsky et al. 2002).  In this thesis, lower concentrations of Anti-IgM were used to induce 
apoptosis in Ramos cells, BL41 and Mutu negative clone 3 cells.  Variations in time points (6 
hours to 48 hours), NGF concentrations (50g/ml to 500g/ml), serum percentages (0% to 
20% ) and cell densities (1x105 cells/ml to 1x106 cells /ml) were attempted to replicate the 
rescue effect from NGF treatment (not all data is shown).  Unfortunately all experiments 
were unsuccessful. 
Possible explanations for the discrepancy in results from those published may be due to the 
cell passage number (Briske-Anderson, Finley et al. 1997; Yu, Cook et al. 1997; Wenger, 
Senft et al. 2004).  The Ramos line used within this investigation may have a higher or lower 
passage history compared to that used in the study by Kronfeld I. et at.  It is possible that 
cell lines at high passage numbers may have alterations in cell morphology, response to 
stimuli, growth rates, protein expression, transfection and signalling, compared to lower 
passage cells.  As experienced with the use of FDC like lines in this thesis, within 10 
passages, cells lose FDC-like surface markers, therefore Ramos cells used by Kronfeld I. et 
at., may have been cells at low passage number,  and responsive to NGF stimuli, on the 
other hand, other EBV negative Burkitt’s lines within this results chapter, were also analysed 
for a possible rescue effect from Anti-IgM induced cell death by NGF and yet similar results 
were observed.   
Other possible reasons for the lack of an NGF rescue effect in all lines analysed may be due 
the type of foetal calf serum used within the media.  In house experience using the EBV 
negative Burkitt’s lymphoma cells line, L3055, has revealed that cells respond to exogenous 
treatment depending on the serum they are cultured in.  Serum in general, is considered to 
be an ill-defined component in culture media due to varying unknown peptides and 
chemicals that may alter signalling pathways in cells (Gstraunthaler 2003).  L3055s for 
example, are more resistant to apoptosis if grown in serum obtained from Cambrex 
Bioscience Wokingham Ltd. (Berkshire, UK – Cat. Nos. 14-4926) compared to serum from 
First Link (Birmingham, UK – Cat. Nos. 0205850).  According to the publication by Kronfeld I. 
et at., 10% heat inactivated FCS was supplemented within RPMI 1640 tissue culture media.  
Within this investigation, RPMI 1640 and heat inactivated FCS was also used, however it is 
unknown whether the same type of FCS was used which may have affect the NGF rescue 
effect.      
Work by Melamed I. et al., was also replicated to question the increase in F-actin content, 
upon NGF stimulation.  Equal numbers of Mutu negative clone 3 cells were treated in either 
50g/ml, 100g/ml, 250g/ml and 500g/ml human recombinant NGF for 1 minute, 2 
minutes, 3 minutes 4 minutes and 5 minutes.  Equal volumes of cell lyates were loaded into 
a 4 to 12% polyacrylamide with SDS gradient gel (Bis-Tris buffer) under reducing conditions, 
samples were transferred onto PVDF.  Samples were then probed using an actin antibody 
(data not shown).  The experiment was repeated three times and was unsuccessful each 
time.  The levels of actin remained the same in all NGF concentrations and at all time points.  
By western blotting methods, NGF does not increase actin levels in Mutu negative clone 3 
cells.  On the other hand, F-actin levels were increased by confocal analysis of NGF treated 
Mutu negative cells stained for by phalloidin dye.  This lack in detecting an increase in actin 
protein concentration may also be due to the type of FCS used within the culture media, 
affecting the cellular response to stimli.   
 
Autocrine NGF and TrkA signalling induced TrkA phosphorylation as seen in control treated 
Mutu negative cell lysates probed for phospho-TrkA protein observed in western blots 
(figures 5.15.4b and 5.15.6b).  Autocrine signalling also induces basal Erk and Akt 
phosphorylation, however exogenous NGF increases the level of Erk and Akt 
phosphorylation in Mutu negative lines (figure 5.10).  However Akt inhibition was observed 
to diminish cell proliferation and cell survival, whereas Erk inhibition had no effect on cell 
survival or growth (figures 5.15 and 5.16).  In mice, is has been shown that TrkA and NGf 
signalling influences B cell signalling.   
Transgenic mice developed to have inactive TrkA in non-neuronal tissues were viable and 
grossly normal however an accumulation of B1 cells with aging and the deregulation of 
immunoglobulin production was observed (Coppola, Barrick et al. 2004).  TrkA signalling was 
thought to modulate B cell receptor signalling, hence, NGF may modulate B cell 
development via TrkA.           
Although to a lesser extent compared to mature NGF, ProNGF has also been shown to 
activate TrkA phosphorylation, Erk and Akt signalling as well as inducing neurite outgrowth 
in PC12 cells (Boutilier, Ceni et al. 2008).  It is probable that mature NGF and proNGF may 
signal via TrkA in Mutu negative cells for cell survival and proliferation (figure 5.14.2).  This 
may explain the possible reason why adding neutralising NGF antibody or TrkAd5 to Mutu 
negative clone 3 cells does not affect their viability or rate of proliferation (figure 5.16.2).  
Inhibiting extracellular mature NGF may therefore enable ProNGF to bind and signal via 
TrkA.   
To ensure whether ProNGF signalling takes over on Mutu cells treated with extracellular 
NGF inhibitors, a neutralising antibody for ProNGF could also be added to question the 
effect on cell survival and proliferation.  It would also be important to ensure that TrkA 
phosphorylation is maintained due to ProNGF signalling in Mutu negative clone 3 cells 
treated with mature NGF inhibitors.  
As previously noted within the last chapter, p75NTR can be cleaved in the middle of the 
transmembrane domain.  Like TrkB, TrkA can form a heterodimer co-receptor complex with 
p75NTR.  Studies by Jung K.M. et al., show that -secretase cleaved p75NTR receptors are 
unable to co- immunoprecipitate with TrkA receptors, therefore p75NTR cleavage plays a role 
in controlling TrkA:p75NTR heterodimerization (Jung, Tan et al. 2003).   
As reviewed by Bredesena, D. E. and Rabizadeha, S., TrkA and p75NTR co-receptor ratios 
determine whether the signal is Trk or p75NTR dominant upon neurotrophin binding.  At low 
ratios such as 1 to 10, TrkA to p75NTR dimers, TrkA signalling is thought to be the dominant 
signalling pathway.  Whereas, neuroblastomal cell lines that express 1 to 100, TrkA to p75NTR 
rations show anti-apoptotic effects mediated by p75NTR signalling, hence higher p75NTR ratios 
are thought to be the dominant signalling pathway upon neurotrophin binding (Cortazzo, 
Kassis et al. 1996).  This may explain the lack in cell proliferation inhibition in Mutu negative 
clone 3 cells treated with the neutralising p75NTR antibody (MLR2).  Since these cells express 
both receptor types, there may be low TrkA:p75NTR ratios enabling TrkA to be the dominant 
signalling pathway, therefore inhibiting p75NTR signalling would not have had any effect on 
cell growth.                 
Overall, EBV infection in B cells may up regulate NGF expression in B cells to signal mainly 
via TrkA receptors in an autocrine manner involving Akt signalling for cell survival and cell 
proliferation.  However, with the discovery that FDC-like cells express NGF, the next part of 
the investigation was to question TrkA and NGF signalling between B cells and FDCs within 
tonsillar germinal centres. 
6. Results 
 
Investigating signalling effects of NGF in Germinal 
centre B cells and questioning possible NGF and TrkA 
paracrine signalling with Follicular Dendritic Cells 
 
6.1 Introduction 
The final part of this thesis is to investigation further, possible NGF and TrkA signalling 
within the germinal centre environment.  From the previous chapter it is known that 
malignant EBV negative B cells can express and signal via TrkA and NGF in an autocrine 
manner and that exogenous NGF can induce F-actin re-arrangement, Erk and Akt 
phosphorylation.  This final chapter questions the expression of this neurotrophic factors 
and its receptor in normal germinal centre B cells as well as considering possible paracrine 
signalling between germinal centre B cells and FDCs via NGF and TrkA.      
 6.1.1 B cell development within the germinal centre 
As mentioned within the thesis introduction, naive B cells entre the germinal centre for 
expansion, somatic mutation of surface immunoglobulin, affinity maturation and selection, 
isotype switching, and differentiation into memory B cells and plasma cells.  Cell surface 
expression patterns are changed depending on the site at which the B cell is within and 
around the germinal centre.  These transcriptional changes observed during B cell transit    
through the germinal centre are displayed in illustration 6.1.  These B cell markers were 
obtained by purifying naive B cells, centroblasts, centrocytes and memory B cells from 
human tonsillar mononuclear cells by magnetic cell separation (Pascual, Liu et al. 1994; 
Agematsu, Hokibara et al. 2000; Klein, Tu et al. 2003).   
As discussed within a compilation of reviews, prior to germinal centre entry, B cells are 
characterised by the expression of cell cycle arrest and anti-apoptotic gene expression.  
Once within the germinal centre, naive B cells become centroblasts which lack c-Myc 
expression and proliferation at a fast rate.  The cells are pro-apoptotic and have decreased 
levels of cytokine, chemokine and adhesion receptors.  Cell cycle arrest is observed in 
centrocytes which encounter T cell and FDCs by the upregulation of cytokines, chemokines 
and adhesion receptors (Berek and Ziegner 1993; Kelsoe 1995; Rajewsky 1996). 
As cells leave the germinal centre their phenotype then resembles that of naive B cells.  
Long-lived, high affinity memory B cells then differentiate into plasma cells upon the 
encounter of antigen during the secondary immune response) (Stein, Gerdes et al. 1982; 
Wagner and Neuberger 1996; McHeyzer-Williams and Ahmed 1999) 
Add illustration 6.1 here 
 
 
 
 
6.1.2 The extraction of centrocytes from the tonsillar germinal centres 
Tonsillar germinal centre B-cell subsets were initially documented by G. Siegel, who 
separated cells by density gradient then performed quantitative cytological analysis, as well 
as morphological analysis (Siegel 1978).  From cytological analysis, the Kiel classification was 
applied to depict the B cell subsets from germinal centres.  Centrocytes, centroblasts, 
lymphocytes and plasma cells were described. 
The germinal centre cells of interest within this part of the investigation are IgD- CD38+ 
CD23- CD77+.  These cells are found in the dark zone and known as centrocytes.  It is at this 
stage of B cell differentiation that the initiation of somatic hypermutation occurs within 
CD38+ CD23- CD77+ cells (Pascual, Liu et al. 1994).   
For these cells to be purified from tonsil tissue, density gradient centrifugation was applied 
to purity cells at each stage.  Initially, tonsils were sheered into FCS negative RPMI media.  
All cells were spun down in ficoll to separate lymphocytes from other tonsil cells such as red 
blood cells.  Sheep red blood cells pre-treated in 2% AET solution (pH8) were added to the 
tonsil cells (Kaplan and Clark 1974).  This method enables T cells, which express CD2, to bind 
glycoproteins on sheep red blood cell membranes, forming E-rosettes (Smith and Barker 
1973; Bernard, Gay-Bellile et al. 1984).    B cells and T cells bound to sheep red blood cells 
are separated by density gradient centrifugation, enabling T cells to sink to the bottom of 
the tube.  Cells at the interface are obtained, however there is still the possibility that some 
T cells, macrophages and dentritic cells would remain.  To purity germinal centre 
centroblasts, these cells are incubated in a cocktail of primary mouse monoclonal IgG 
antibodies.   
The four antibodies used include an anti-IgD mouse monoclonal antibody, an anti-CD39, anti 
CD14 and an anti CD3 antibody.  Surface IgD is expressed on naive and peripheral B cells 
(Mudde, van Dam et al. 1986; Briere, Servet-Delprat et al. 1994). Anti-CD39 monoclonal 
antibody AC-2 was also included which binds activated B cells, subsets of T cells, 
macrophages and dendritic cells (Rowe, Hildreth et al. 1982; Kansas, Wood et al. 1991; 
Maliszewski, Delespesse et al. 1994).  CD14 is expressed by macrophages and dendritic cells 
(Zhou and Tedder 1996) and CD3 is part of the T cell receptor complex on a mature T 
lymphocytes (van den Elsen, Shepley et al. 1984; Alexander, Goris et al. 1989).   
These antibodies bind to IgD, CD39, CD14 and CD3 positive cells of the germinal centre.  
These cells are depleted by the addition of dynabeads coated with pan mouse IgG antibody 
which recognises and binds all classes of IgG mouse subclasses and is Fc specific.  Cells with 
surface IgD, CD39, CD14 and CD3 are depleted by magnetic attachment at the side of the 
universal.  The supernatant is collected and presumed to contain germinal centre 
centroblasts.   
These centroblasts were carried forward to question neurotrophic factor expression in 
germinal centre B cells and possible paracrine neurotrophic communication with FDCs.  This 
part of the study was with taken to question novel B-cell and FDC interactions within a 
normal germinal centre microenvironment.  
 
 
6.2 Results 
6.2.1   Phenotyping freshly isolated germinal centre B cells 
To question possible FDC-B-cell interactions via neurotrophic factors within the germinal 
centre, germinal centre B cells were initially isolated from human tonsils, then phenotyped 
for their expression of known germinal centre B cell markers by flow cytometry (figure 6.1).   
Cells co-stained for CD38 and IgD were compared to the antibody isotype control as 
illustrated in figure 6.1a.  Whereas, CD3 and CD19 stained cells were compared to the 
isotype control shown in figure 6.1b.  Based on these dotplots, the purified cells isolated 
from tonsils are mainly CD19+, CD38+, IgD- and CD3- which coincides with the surface 
expression patterns observed in centroblasts.  
 
Add fig 6.1 here 
 
 
 
 
 
 
 
6.2.2   Neurotrophic factor and receptor mRNA expression in germinal centre B 
cells 
Once germinal centre B cells were obtained from human tonsils, RNA was extracted and 
amplified to cDNA for the analysis of neurotrophic factor and receptor mRNA transcripts by 
RT-PCR analysis (figure 6.2).    
In total, eight human tonsils were analysed for the expression of neurotrophic factors and 
their receptors by RT-PCR.  Initially -actin was used to ensure equal levels of mRNA 
transcripts between the tonsil samples (figure 6.2.1).  Although comparable -actin 
transcripts were detected within all tonsil samples, RT negative cDNA from Tonsil 6 
contained residual genomic DNA.        
For NGF mRNA transcript analysis, RT negative samples were also included within the PCR 
reaction since the primers used to recognise NGF transcripts lie within one exon.  NGF 
transcripts within RT positive and negative samples were not detected in any of the 
germinal centre B cell samples analysed, however all samples, excluding tonsil 3 and tonsil 
8, expressed NGF’s receptor, TrkA mRNA transcripts (6.2.2).   
When tonsil samples 1 and 2 were extracted, their RNA samples were not considered for 
analysing BDNF and TrkB RT-PCR expression since these tonsil samples were extracted at 
different stages of the investigation.  As for tonsil samples 3 to 8, possible BDNF and TrkB 
expression was questioned below.    
BDNF primers also lie within one exon (6.2.3).  By comparing RT positive and negative 
samples, the expression of BDNF transcripts in RT positive samples and the lack of 
detectable transcripts in RT negative samples was only observed in tonsil 5, hence positive 
BDNF mRNA expression was only detected in tonsil sample 5.  As for tonsil samples 4, 6,7 
and 8, BDNF transcripts were observed in RT negative samples which also may represent 
genomic DNA.  Although the RT positive samples show BDNF transcripts, the true expression 
of BDNF transcripts within these tonsil samples were not determined.  Tonsil sample 3 on 
the other hand did not display detectable transcripts within the RT positive or negative 
samples, hence rendered BDNF negative. 
As for the BDNF receptor, TrkB, Tonsil samples 4, 5, 6 and 7 show measurable levels of TrkB 
transcripts specific for all TrkB variants which were not detected within their RT negative 
equivalents.  However mRNA corresponding to TrkB variant A and C were not detected in 
any tonsil samples.  The lack of TrkB mRNA expression from both Pan-TrkB and TrkB variants 
A and C primers was concluded in Tonsil samples 3 and 8. 
RT-PCR transcripts recognising the low affinity receptor p75NTR, were also detected in tonsil 
samples 1, 2, 4, 5, 6, and 7.  However tonsils 3 and 8 reveal undetectable levels of p75NTR 
mRNA expression. 
 A summary of the RT-PCR results are displayed in table 6.1.  It can be concluded that tonsil 
3 and tonsil 8 lack the expression of all neurotrophic factors and receptors whereas all other 
tonsil samples express the receptors TrkA and p75NTR.  Germinal centre B cell samples 4 to 7 
expressed TrkB mRNA corresponding to all TrkB variants however these  cells reveal 
undetectable levels of TrkB variants A and C transcripts. This therefore reveals that germinal 
centre B cells may express truncated TrkB but not full length TrkB transcripts.   As for the 
neurotrophic factors, the lack of NGF transcripts were observed and only one tonsil sample 
was concluded to be a true positive for BDNF expression. 
Add Fig 6.2 to 6.3 here 
Table 6.1 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
In, all tonsil samples tested, excluding tonsil 3 and 8 expressed mRNA for both NGF 
receptors p75NTR and TrkA.  On the other hand, NGF mRNA was not detected within these 
germinal centre B cells.  To enquire whether these cells expressed TrkA or/ and p75NTR 
protein, cells were analysed by confocal microscopy and flow cytometry. 
 
6.2.3   The expression of CD19, TrkA and p75NTR protein in germinal centre B 
cells compared to the Mutu negative clone 3 Burkitt’s lymphoma B cell lines 
 
To question the expression of CD19 and TrkA protein in germinal centre B cells, freshly 
isolated cells from tonsils 4, 5 and 6 were permeabilized and stained for CD19 or TrkA 
(figure 6.3).  Cells were then analysed for the expression by confocal imaging.    
Mutu negative clone 3 cells express CD19.  The tonsillar B cells also express comparable 
levels of CD19 protein to Mutu clone 3 cells.  As for TrkA expression, Mutu negative cells 
express stronger staining levels compared to germinal centre B cells.  Germinal centre B 
cells obtained from tonsils 4 and 5 reveal detectable but very weak staining; however cells 
from tonsil 3 are negative for TrkA protein.    
The expression of p75NTR in tonsil samples 4, 5 and 6 were analysed by flow cytometry.  Cells 
were permeabilized then stained using the Anti-p75NTR, MLR2 antibody (6.3.3).  These 
germinal centre B cells were compared to Mutu negative clone 3 cells for their expression of 
p75NTR protein.    
Like Mutu negative cells, germinal centre B cells extracted from three separate tonsils 
expressed p75NTR protein at high levels.  In all, germinal centre B cells obtained from tonsils 
generally expressed the neurotrophin receptors p75NTR and TrkA protein.   
Based on previous experience from the last chapter, to analyse NGF mRNA and protein in 
Burkitt’s lymphoma B cell lines, the NGF primers were too sensitive to detect NGF 
transcripts and yet NGF protein was observed within all Burkitt’s lines analysed.  With these 
results in consideration it was still worth asking weather germinal centre B cells express NGF 
protein. 
 
 
 
 
 
 
 
 
 
 
6.2.4   NGF protein expression in germinal centre B cells compared to Mutu 
negative clone 3 Burkitt’s lymphoma B cell lines 
Initially, NGF expression was considered using confocal imaging methods (figure 6.4.1).  
Germinal centre B cells and Mutu clone 3 cells were permeabilized and stained for NGF 
expression using the Anti-NGF (N3279) antibody.   
Mutu negative clone 3 cells express NGF protein as previously shown within chapter 5.  As 
shown in figure 6.4.1, some Mutu cells in culture display larger levels of NGF protein staining 
compared to the majority of cells which have lower levels and weaker NGF stain.  As for the 
germinal centre B cells obtained from tonsil 4, 5 and 6, very weak to negative levels of NGF 
staining was observed.  The low expression levels are true NGF staining considering the 
isotype control displayed undetectable staining within the same tonsil samples. 
The expression of NGF protein was also scrutinized using flow cytometry analysis (figure 
6.4.2).  Cells were permeabilized and stained for expression using the Anti-NGF (N3279) 
antibody.   
NT-2 cells, the positive control line for NGF expression, Mutu clone 3 cells and samples from 
tonsil 4, 5 and 6 were permeabilized then stained.  As expected NT-2 show the expression of 
NGF protein.  The expression of NGF in Mutu clone 3 cells is much higher that that observed 
in germinal centre B cell samples extracted from three separate tonsil samples.   
Finally, NGF expression was also investigated by western blotting analysis (figure 6.4.3).  Cell 
lysates were obtained from Mutu clone 3 and germinal centre B cells obtained from tonsils 
3, 4, 5, 6, 7 and 8.  20ug of protein was loaded per well within a 4% to 12% polyacrylamide 
with SDS gradient gel (Bis-Tris buffer) under reducing conditions, samples were transferred 
onto PVDF.  Samples were then probed using an NGF antibody (AF256NA). 
Varying levels of NGF expression were detected when comparing germinal centre B cells 
obtained from six different tonsil preparations. The highest level s of NGF protein detected 
were within tonsil samples 5 and 7, on the other hand, very low protein levels were 
observed in tonsil samples 3 and 4.  However, the expression of NGF protein in Mutu 
negative clone 3 cells is very strong compared to all germinal centre B cell samples.  
Add fig 6.4 here 
  
 
 
 
 
 
 
 
 
 
In all, Mutu negative clone 3 cell lines express higher levels of TrkA and NGF protein 
compared to germinal centre B cells obtained from human tonsils.  Previously it has been 
shown that biologically active exogenous NGF added alone does not induce cell survival cell 
proliferation or cell migration in Mutu negative clone 3 cells and yet induced F-actin re-
arrangement and Erk and Akt phosphorylation.  Therefore the effects of exogenous NGF 
were also applied in germinal centre B cells to question NGF signalling functions in normal B 
cells. 
 
6.2.5   Exogenous CD40-L and NGF treatment on cell proliferation in freshly 
isolated germinal centre B cells 
It is known that freshly isolated centrocytes degenerate rapidly by apoptosis when cultured, 
however with the addition of CD40-L, cells are rescued from apoptosis (Liu, Joshua et al. 
1989; Holder, Wang et al. 1993).  To test this, germinal centre B cells obtained from tonsil 
samples 1, 2, 3, 4 and 5 were either cultured in control media, in varying concentrations of 
CD40-L or varying exogenous human recombinant NGF protein, then analysed for thymidine 
incorporation (figure 6.5).  
 
Control treated germinal centre B cells did not synthesis DNA when cultured for 48 hours.  
As expected, a gradual increase in DNA synthesis was observed in CD40 treated germinal 
centre cells, although, tonsil 1 and 4 show very high thymidine counts when treated in 
1g/ml CD40-L.  NGF treatment on the other hand, had no effect on DNA synthesis within 
germinal centre B cells from all five tonsil samples.  NGF alone therefore, cannot rescue 
germinal centre centroblasts from apoptosis.              
To have a closer look at other possible NGF induced functions in B cells, RNA samples from 
three tonsils were used within a microarray study to analyse genes that are turned on and 
off upon the addition of NGF.    
 
 
 
  
 
 
 
 
 
 
 
 
 
6.2.6   The changes in gene expression upon NGF treated germinal centre B 
cells 
Three further germinal centre B cell extractions were performed (tonsil 9, 10 and 11).  Once 
phenotyped, cells were screened for the expression of NGF receptors TrkA and p75NTR 
mRNA (figure 6.6.1).  Cells were then exposed to either control media or media containing 
100ng/ml human recombinant NGF, tested for bioactivity prior to the experiment.  Cells 
were treated for 6 hours; RNA was then extracted and used for microarray analysis.  The 
levels of expression were measured using the Robist multichip average method.  Readings 
were analysed using the Linear Models for Microarray Data software package (Limma).  To 
comparing levels of gene expression changes upon NGF treatment, paired test analysis were 
competed using significance analysis of microarrays software.        
195 genes showed significant changes at p-values less than 0.01 whereas 71 genes showed 
an average gene expression fold change of 1.5 or more.  25 genes that met both this criteria 
are displayed in figure 6.6.2. 
13 genes were found to be down regulated upon NGF treatment; the known functions of 
these genes are displayed in table 6.2.  12 genes on the other hand were up regulated and 
their functions are shown in table 6.3.       
 
 
 
 
 
As displayed in figure 6.6.1, all there tonsil samples (tonsils 9, 10 and 11) used for micro 
array analysis expressed NGF receptors, p75NTR and TrkA mRNA.  When cultured in 
100ng/ml NGF, varying genes were observed to be up regulated and downregulated. 
In all, based on tables 6.2 and 6.3, NGF stimulation in GC tonsil B cells could affect RNA 
processing, induce cytoskeletal re-arrangement, inhibit cell cycle arrest, promote calcium 
influx, chromosomal organisation re-arrangement and regulate cell proliferation in germinal 
centre B cells.  Although, cell proliferation upon the addition of NGF alone, had no effect in 
GC tonsil B cells.  On the other hand, germinal centre B cells expressed lower levels of NGF 
protein compared an EBV negative Mutu line (figure 6.4.1) therefore NGF available within 
its microenvironment may induce the genes expression alterations observed.  To identify 
possibly sources for this NGF within normal germinal centres NGF staining was completed 
within human tonsil tissue sections.            
 
 
 
 
 
 
 
6.2.7   Immunohistochemical staining for CD19, p75NTR, BU10 and NGF within 
tonsillar germinal centres 
As previously shown in chapter 5, FDC-like cell lines obtained from human tonsils show the 
expression of NGF mRNA and protein.  Within this chapter is has been shown that germinal 
centre B cells can express TrkA and p75NTR mRNA and protein and yet low levels of NGF.  
Exogenous NGF has also been shown to induce changes in germinal centre B cell gene 
expression.  It was therefore worth testing the possibilities of TrkA and NGF paracrine 
between normal germinal centre B cells and cells within the germinal centre.   
Freshly excised human tonsil tissue was sliced in 5mm thickness.  Cryogenically frozen tissue 
was sectioned onto glass slides at -20oC.  Sections were then acetone fixed then stained.  
Initially cells were stained for known germinal centre markers BU10, p75NTR and CD19 
(figure 6.7).    
B cells and FDCs are CD19 and p75NTR positive, therefore cells within the light zone, dark 
zone and follicular mantel stain were detected by adding the secondary antibodies specific 
for CD19 and p75NTR.  On the other hand, BU10 is an FDC specific antibody which detected 
staining within the light zone of the germinal centre.  The overlay image for all three primary 
antibodies and the Hoechst nuclear stain is compared with the overlay image taken from 
the isotope control.      
To test the expression of NGF in human germinal centres a serial dilution of the anti-NGF 
(N3279) antibody was completed and tested in tonsil sections.  An optimal concentration 
was determined which revealed staining within the light zone of the germinal centre (figure 
6.8).  The concentration of primary antibody used was compared to the same isotype 
concentration displayed within an overlay image also showing nuclear staining.        
To ensure this staining was legitimate FDC staining, cells were co-stained for NGF and BU10 
(figure 6.9).  Three separate images of stained germinal centres obtained from the same 
tonsil are displayed within figures 6.9.1, 6.9.2 and 6.9.3. These three figures were compared 
to their isotype control images; one of which is represented within figure 6.9.4.   All three 
germinal centre images reveal NGF and BU10 co-staining patterns within the light zone of 
the germinal centre.  The different germinal centre zones are illustrated within figure 6.9.5 
which is an overlay image obtained from figure 6.9.1.   
Cells co-staining for BU10 and NGF were viewed at a higher magnification (figure 6.9.6).  The 
staining pattern observed is that of FDCs (communication with Dr D.L. Hardie, University of 
Birmingham).  Interestingly, some FDCs stain for NGF alone (green), some for BU10 alone 
(Red) whereas some co-stain for both (yellow) revealing possible heterogeneity of FDC cells 
within the light zone.             
 
 
 
 
 
 
 
Add fig 6.7 and 6.8 and 6.9 here 
 
 
 
 
Overall, it can be concluded from this data that germinal centre B cells express high levels of 
the low affinity NGF receptor p75NTR and lower levels of the high affinity receptor, TrkA 
protein.  Exogenous NGF induces the up regulation and down regulation of genes with 
varying function in germinal centre B cells and FDCs have been observed to express NGF 
within a germinal centre environment.  NGF and TrkA may therefore signal in a paracrine 
manner between B cells and FDCs; however the specific functions of this interaction are 
currently unknown. 
For this to be investigated further, questions on more functional outcomes in germinal 
centre B cells, upon NGF treatment would need to be analysed using varying NGF 
concentrations of NGF as well as other known germinal centre cytokines.  By investigating 
TrkA and NGF signalling further, within normal germinal microenvironments, more 
knowledge would be gained on how normal germinal centre B cells interact and the reasons 
for the  upreguation of these neurotrophic factors and receptors in Burkitt’s lymphoma B 
cells.   
These important findings could then be applied for better understanding in Burkitt’s 
lymphoma pathogenesis, EBV interaction with B cells, B cell signalling within a germinal 
centre and provide novel and yet specific, affective therapeutics in the fight against Burkitt’s 
lymphoma.  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.2:  Down regulated genes in germinal centre tonsil B cells treated with NGF 
compared to those treated in control media   
Gene 
Symbol 
Gene Description Gene function Reference 
SNORA20 Small nucleolar RNA 
20 
Both SNORA20 and SNORA22 are members 
of the H/ACA class of small nuclear RNA 
which guide the sites for Uridines 
modification to Pseudouridines. 
(Kiss, Jady et 
al. 2004) 
SNORA22 Small nucleolar RNA 
22 
SNORD82 Small nucleolar RNA 
82 
SNORA82, SNORA94, SNRPN  // 
SNORD116-1 and SNRPN  // SNORD116-8 
contain the conserved sequence motifs 
known as the C box and the D box. Most of 
the members of the box C/D family 
function in directing site-specific 2'-O-
methylation of substrate RNAs 
(Galardi, 
Fatica et al. 
2002) SNORD94 Small nucleolar RNA 
94 
SNRPN  // 
SNORD116-
1 
Small nuclear 
ribonucleoprotein 
polypeptide N  // 
small nucleolar RNA 
116-1 
SNRPN  // 
SNORD116-
8 
Small nuclear 
ribonucleoprotein 
polypeptide N  // 
small nucleolar RNA 
116-8 
RNU5B-1 RNA, U5B small 
nuclear 1 
U5 RNA is a non-coding RNA that is a 
component of both types of known 
spliceosome. The precise function of this 
molecule is unknown. 
(Hinz, Moore 
et al. 1996) 
CEP170L Centrosomal protein 
170kDa-like 
The product of the CEP170 gene is a 
170kDa component of the centrosome and 
a non-membraneous organelle that 
functions as the major microtubule-
organizing center in animal cells.  The 
protein interacts with the intraflagellar 
transport protein 81 (IFT81) and is 
phosphorylated by cyclin dependent kinase 
1 (CDK1) and polo-like kinase 1 (PLK1), and 
functions in maintaining microtubule 
organization, cell morphology and cilium 
stability. 
(Strausberg, 
Feingold et al. 
2002) 
ANKRD20B Ankyrin repeat 
domain 20B 
The ankyrin repeat is a 33-residue motif in 
proteins consisting of two alpha helices 
separated by loops.  Ankyrin repeats 
mediate protein-protein interactions and 
are among the most common structural 
motifs in known proteins.  The repeat has 
been found in proteins of diverse function 
such as transcriptional initiators, cell cycle 
regulators, cytoskeletal, ion transporters 
and signal transducers. 
(Sedgwick and 
Smerdon 
1999) 
ZNF443 Zinc finger protein 443 A zinc finger protein is a DNA-binding 
protein domain consisting of zinc fingers.  
They occur in nature as the part of 
transcription factors conferring DNA 
sequence specificity as the DNA-binding 
domain. 
(Katoh, Oguri 
et al. 1998) 
ZNF724P Zinc finger protein 724 
pseudogene 
 
DPY19L2P1 Dpy-19-like 2 
pseudogene 1 (C. 
elegans) 
DYP19L1 and DYP19L2 genes belong to a 
transmembrane gene family.  The 
functions for these genes are unknown.  
(Carson, 
Cheung et al. 
2006) 
LOC644714 Hypothetical protein 
LOC644714 
Function Unknown.  
 
Table 6.3:  Up regulated genes in germinal centre tonsil B cells treated with NGF compared 
to those treated in control media   
Gene 
Symbol 
Gene 
Description 
Gene function Reference 
CD177 CD177 molecule CD177 is a glycol-phsosphatidylinositol (GPI) 
linked N-glycosylated cell surface glycoprotein 
first described in a case of neonatal alloimmune 
neuropenia.   CD177 is also known as neutrophil 
specific antigen-1.  Its function is unknown.   
(Lalezari, 
Murphy et al. 
1971) 
HBG1 Hemoglobin 
subunit gamma-1 
(gamma A) 
 
 
 
Hemoglobin subunit gamma-1 is a protein that 
in humans is encoded by the HBG1 gene. 
 
The gamma globin genes (HBG1 and HBG2) are 
normally expressed in the fetal liver, spleen and 
bone marrow. Two gamma chains together with 
two alpha chains constitute fetal hemoglobin 
(HbF) which is normally replaced by adult 
hemoglobin (HbA) at birth. In some beta-
thalassemias and related conditions, gamma 
chain production continues into adulthood. 
 
Hemoglobin subunit gamma-2 is a protein that 
in humans is encoded by the HBG2 gene. 
(Higgs, Vickers 
et al. 1989) 
HBG2 Hemoglobin 
subunit gamma-2 
(gamma G) 
SPINK5 Serine peptidase 
inhibitor, Kazal 
type 5 
Serine protease inhibitor Kazal-type 5 is an 
enzyme that in humans is encoded by the 
SPINK5 gene. 
 
This gene encodes a multidomain serine 
protease inhibitor that contains 15 potential 
inhibitory domains. The inhibitor may play a 
role in skin and hair morphogenesis and anti-
inflammatory and/or antimicrobial protection 
of mucous epithelia 
(Magert, 
Standker et al. 
1999) 
S100A8 S100 calcium 
binding protein A8  
The protein encoded by this gene is a member 
of the S100 family of proteins containing 2 EF-
(Schafer, 
Wicki et al. 
hand calcium-binding motifs. 
 
S100 proteins are localized in the cytoplasm 
and/or nucleus of a wide range of cells, and 
involved in the regulation of a number of 
cellular processes such as cell cycle progression 
and differentiation 
1995)  
LOC554201 Hypothetical 
LOC554201 
Function unknown  
GPM6A Glycoprotein M6A Neuronal membrane glycoprotein M6-a is a 
protein that in humans is encoded by the 
GPM6A gene. 
(Renne, 
Minner et al. 
2008) 
DPPA2 Developmental 
pluripotency 
associated 2 
One of the genes recently identified to be 
expressed specifically in pluripotent cells.  
Reduced expression of Dppa2 is observed in 
differentiated mouse ES cells, which also show 
repressed cell proliferation activity. 
 
RBMY1A1 RNA binding motif 
protein, Y-linked, 
family 1, member 
A1 
RNA-binding motif protein, Y chromosome, 
family 1 member A1/C protein is encoded 
(Chai, Zhou et 
al. 1998) 
RSPO3 R-spondin 3 
homolog 
(Xenopus laevis) 
This gene encodes a member of the 
thrombospondin type 1 repeat supergene 
family.   The protein contains a furin-like 
cysteine-rich region. Furin-like repeat domains 
have been found in a variety of eukaryotic 
proteins involved in the mechanism of signal 
transduction by receptor tyrosine kinases 
(Kazanskaya, 
Glinka et al. 
2004) 
OR6B2 Olfactory 
receptor, family 6, 
subfamily B, 
member 2 
Encodes Olfactory receptor 6B2.  Olfactory 
receptors interact with odorant molecules in 
the nose, to initiate a neuronal response that 
triggers the perception of a smell. 
(Miwa, 
Moriizumi et 
al. 2002) 
NCBP2L Nuclear cap 
binding protein 
subunit 2-like 
Function unknown  
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
6. Discussion 
From the array data, amongst the genes that were down regulated upon NGF treatment in 
germinal centre B cells, six small nucleolar RNA genes were determined, two of which are also 
known as small nuclear ribonucleoproteins (snRNPs).  snRNPs guide nucleotide modifications within 
ribosomal RNAs or spliceosomal RNAs and are involved in RNA processing which associate with 
coiled bodies within neuronal cells (Raska, Ochs et al. 1990; Huttenhofer, Brosius et al. 2002).  Coiled 
bodies are components within nuclear bodies which frequently associate with the nucleous in 
neuronal cells (Andrade, Tan et al. 1993).  Using PC12s as a model for neuronal cell differentiation, 
snRNPs remained associated with the coiled bodies during NGF induced differentiation in neurones 
(Janevski, Park et al. 1997).  The association between coiled bodies and nucleoli appears to be a 
feature common to neuronal cells and may represent a nuclear organization associated with 
neuronal differentiation.  The effects on snRNPs in B cells treated with NGF however are unknown. 
As for the centrosomal protein, which is a component of the centrosome has been associated with 
cell shape.  By down regulating gene expression of Cep170 by siRNA duplex oligonucleotide, 
transfected HeLa cells changed from a typical epithelial shape, to a more fibroblastic, 
elongated appearance whereas, U2OS cells depleted of Cep170 showed an apparent 
increase in size (Guarguaglini, Duncan et al. 2005).  As discussed in chapter 5, NGF induced 
F-actin rearrangement in EBV negative Burkitt’s lymphoma B cells; therefore NGF may alter 
cytoskeletal arrangements in B cells which may involve the down regulation of Cep170.   
Zinc finger protein 443 and the Zinc finger protein 724 pseudogene are also down regulated upon 
NGF addition in germinal centre B cells.  The Schwann factor cell-1 protein (SC-1) belongs to the 
retinoblastoma interacting zinc finger family of transcription factors, which contains six zinc finger 
domains  and interacts with the cytoplasmic domain on p75NTR (Chittka and Chao 1999).     
Nuclear translocation from the cell cytoplasm is observed in cells expressing both SC-1 and p75NTR 
upon NGF treatment, however the co-expression of TrkA inhibits this translocation (Chittka and 
Chao 1999).  SC-1 also behaves as a transcriptional repressor upon NGF treatment within cells 
transfected with both SC-1 and either p75NTR or TrkA.  
The expression of p75NTR has previously been linked to cell cycle arrest in sympathoadrenal cells 
(Verdi, Birren et al. 1994).  Since TrkA expression can regulate cellular transformation or promote 
mitogenesis, restricting nuclear localisation of SC-1 may prevent growth arrest signalling from p75NTR 
(Chittka, Arevalo et al. 2004).  
High p75NTR expression levels in germinal centre B cell treated with NGF may down regulate zinc 
finger proteins to inhibit the transcriptional repression by SC-1 and may inhibit cell cycle arrest via 
p75NTR.  The down regulation of SC-1 may be important in these germinal centre B cells considering 
low to undetectable levels are TrkA protein are observed.  
 
Human recombinant NGF has also been observed to induce gene up regulation in germinal 
centre B cells.  One of which includes the Hemoglobin subunit gamma-1.  NGF is able to 
induce angiogenesis, increase hemoglobin concentration in a dose-dependent manner and 
promote wound healing via TrkA and p75NTR (Calza, Giardino et al. 2001; Emanueli, Salis et 
al. 2002; Graiani, Emanueli et al. 2004; Park, Kwak et al. 2007).  However the reason why 
HBG1 and HBG2 are up regulated in NGF treated germinal centre B cells is unknown.     
NGF is also liked to the pathogenesis of various skin conditions such as psoriasis by 
influencing inflammatory responses within the subcutaneous tissue (Raychaudhuri and 
Raychaudhuri 2009).  Mutating the SPINK6 gene can result in Netherton syndrome, a 
genetic skin disorder characterised by the appearance of dry, thickened, scaly or flaky skin 
(Chavanas, Bodemer et al. 2000).  However the implications as to why NGF up regulates 
SPIUNK5 in germinal centre b cells is currently unknown. 
The S100 proteins are characterized by the presence of two Calcium binding sites of the EF-
hand type and have been implicated in several roles which include interacting with effector 
proteins within cells, and in turn regulate enzyme activities (Donato 1986; Donato 1999).  
Examples of these activities include, cytoskeletal arrangement, cell growth, differentiation 
and Calcium homeostasis (Donato 2001; Donato 2003).   
Seven days after the addition of NGF to PC12 cells, neurite projections are observed, 
however the withdrawal of NGF within the media initiates cellular apoptosis, which is 
exacerbated upon the treatment of S100 protein (Fulle, Mariggio et al. 1997).  These 
apoptotic effects can be blocked by the readmission of NGF.  The S100 genes, S100A1, 
S100B, and S100A4 have been reported in lymphocytes but their role has not been studied 
(Singh and Cheng 1996).   
As for the S100A8 gene, its expression is up regulated in germinal centre B cells treated with 
NGF which may regulate certain enzymatic, calcium dependent pathways however these 
signalling outcomes are unknown.      
Originally, glycoprotein M6a was thought to be expressed exclusively by neurons in the 
central nervous system and the non-neuronal peripheral tissues such as the apical 
membranes of polarized epithelial cells within the choroid plexus and proximal renal tubules 
(Yan, Lagenaur et al. 1993; Yan, Narayanan et al. 1996).   
Interestingly, PC12 cells transfected with rat M6a cDNA show an increase in calcium influx 
via protein kinase C upon NGF treatment enabling neuronal differentiation (Mukobata, 
Hibino et al. 2002).  The up regulation of GPM6A gene in NGF treated germinal centre B cells 
may increase intracellular calcium for B cell differentiation; however there is currently no 
literature on these signalling effects.  
The DPPA2 gene, on the other hand, encodes for the developmental pluripotency 
associated-2 protein which has a SAP putative DNA binding motif often found in proteins 
involved in chromosomal organization and various aspects of RNA biology (Aravind and 
Koonin 2000).  Its gene expression is thought to be restricted in pluripotent cells and the 
developing germ line, however germinal centre B cells treated with NGF show an up 
regulation of DPPA2 (Maldonado-Saldivia, van den Bergen et al. 2007).      
The R-spondin genes (Rspo1, Rspo2, Rspo3 and Rspo4) encode a novel family of secreted 
proteins in vertebrates that activate Wnt/β-catenin signalling and interact with LDL 
receptor-related protein 6 (Kazanskaya, Glinka et al. 2004). It is known that NGF can 
promote axonal branching and target innervation in developing sympathetic targets by 
regulating the neuronal expression of Wnt5a.  Wnt/β-catenin signalling promotes B cell 
proliferation via the lymphocyte enhancer factor-1, hence NGF may induce cell proliferation 
by the up regulation of RSPO3 gene in germinal centre B cells. 
Other genes that were observed to be either up regulated or down regulated upon NGF 
stimulation within germinal centre B cells are either uncharacterised for their function or 
currently unknown to have any links with B cells and or NGF stimulation.  However based on 
the microarray data analysis NGF stimulation may affect RNA processing, induce 
cytoskeletal re-arrangement, inhibit cell cycle arrest, promote calcium influx, chromosomal 
organisation re-arrangement and regulate cell proliferation in germinal centre B cells. 7. 
Thesis discussion 
Based on the results obtained from this thesis it can be concluded that Burkitt’s lymphoma B cell 
lines displaying varying EBV latency phenotypes do express functional neurotrophic factors and their 
receptors that can signal for either cell survival and or cell proliferation.  Hence, inhibiting 
neurotrophic factors signalling can be considered as a novel axis in suppressing tumour growth in 
Burkitt’s lymphoma.   
The EBV latency III phenotype has been observed in lymphoid tissue during infectious 
mononucleosis primary infection (Anagnostopoulos, Hummel et al. 1995; Joseph, Babcock et al. 
2000; Kurth, Hansmann et al. 2003).  Hence, since the latency III phenotype is rarely seen in vivo due 
to immune recognition, to discover new therapeutics against Burkitt’s lymphoma, focus should be 
based in targeting B cells displaying a latency I EBV phenotype. 
Neurotrophins are classically defined at trophic factors for neuronal cells.  With increasing evidence 
in the expression of functional neurotrophins acting as trophic factors within cells of the immune 
system, neurotrophic factors can be re-defined as immunotrophic factors.  However specific roles of 
immunotrophins in the development of haematopoietic cells are still a mystery.     
 
Neurotrophins have previously been applied as therapeutics for treatment of varying conditions 
such as Alzheimer's disease, depression, asthma and Charcot-Marie-Tooth disease. 
 
Both NGF and BDNF levels were shown to be reduced in Alzheimer's disease hippocampus and 
temporal cortex (Goedert, Fine et al. 1989; Connor, Young et al. 1997).  Phase I clinical trial reported 
by Tuszynski M.H. et al, were reported to have successfully stimulated cholinergic function by 
implanting autologous fibroblasts that secreted NGF within the forebrain (Tuszynski, Thal et al. 
2005). 
Lower serum BDNF protein levels have been reported in patients with depressive disorders, whereas 
increased serum BDNF concentrations have been observed after treatment with an antidepressant 
(Karege, Perret et al. 2002; Shimizu, Hashimoto et al. 2003).  Antidepressants such as Mirtazapine, 
which antagonises the alpha-2 adrenergic receptor was found to increase BDNF mRNA levels in rat 
hippocampus and cerebral cortex compared to the well known and widely used antidepressant, 
imipramine (Rogoz, Skuza et al. 2005) 
Patients suffering from allergic diseases, in particular asthma, show increased levels of NGF in their 
serum (Bonini, Lambiase et al. 1996).  As shown by Braun et al. nasal application of anti-NGF to 
ovalbumin-sensitized mice reduces IL-4 levels and prevents  development of airway hyperreactivity 
induced by a specific allergen challenge (Braun, Appel et al. 1998). 
As for Charcot-Marie-Tooth disease patients, NT-3 therapy can enhance nerve regeneration and in 
other genetic diseases involving peripheral myelin protein-22 (Pleasure and Chance 2005). 
As for currently available Burkitt’s lymphoma therapeutics, chemotherapy is still the main type of 
treatment used.  However the cytotoxic drugs applied, which include cyclophosphamide, vincristine 
and doxorubicin, produce many side effects are not cost effective.  Rituximab is an anti-CD20 
monoclonal antibody, when combined with cyclophosphamide, doxorubicin, vincristine and 
prednisolone cytotixic drugs is used as treatment for diffuse large B-cell lymphoma and Burkitt’s 
lymphoma (Golay, Zaffaroni et al. 2000).  The down side of these therapeutics are the side effects 
and the cost of manufacture. Since Burkitt’s lymphoma prevalence is the highest in equatorial Africa, 
many individuals are unable to pay for and access these prophylaxes.  However, with increasing 
neurotrophic factor research, it is possible that reducing Burkitt’s lymphoma tumour growth can be 
achieved with the use of neurotrophic factors associated prophylaxes.    
 
Despite the achievements gained from this thesis, there is still much work to be completed to gain 
better understanding of EBV and its relationship with B lymphocytes and how to compact 
neurotrophic factor exploitation in B cell lymphomas.    
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